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NOVEL α-MSH PEPTIDE ANALOGS FOR MELANOMA TARGETING 
By 
 
Adam Michael Flook 
Bachelor of Science, Biology, University of Redlands, 2009 
Ph.D; Biomedical Sciences, University of New Mexico, 2014 
 
ABSTRACT 
Skin cancer is the one of the most diagnosed cancers in the United States 
with increasing incidence over the past two decades. There are three major 
forms of skin cancer but melanoma is the deadliest. It is estimated that 76,690 
new diagnoses of melanoma and 9,480 deaths will occur in 2013.  Melanoma 
accounts for approximately 1.6% of all cancer related deaths and is the 5th 
leading diagnosed cancer in the United States. The mean survival rate of 
patients diagnosed with metastatic melanoma is six months, with five year 
survival rates of less than 5%. In this project, we describe the design and 
characterization of novel melanoma-targeting peptide analogs for use in 
diagnostic imaging of both primary and metastatic melanoma lesions. 
Novel α-MSH peptide conjugates were designed to target the 
melanocortin-1 receptor present and over-expressed on melanoma cells. These 
peptides were synthesized and their in-vitro melanocortin-1 receptor binding 
affinities were established in murine melanoma cells. Once binding affinities were 
determined, the peptides were radiolabeled with 99mTc utilizing a novel direct 
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radiolabeling technique developed in our laboratory. The peptides were purified 
via reverse-phase high performance liquid chromatography and in-vivo 
melanoma targeting and pharmacokinetic properties were determined in B16/F1 
melanoma-bearing female C57BL/6 mice. Biodistribution and SPECT/CT imaging 
studies were performed with the promising 99mTc-labeled peptide conjugates. 
All α-MSH peptide conjugates tested showed low nanomolar binding 
affinity for the melanocortin-1 receptor. All peptides were readily radiolabeld with 
99mTc with greater than 95% radiochemical purity.  All 99mTc-labeled peptides 
displayed high specific in-vivo melanoma tumor uptake while maintaining low 
normal organ accumulation, and were excreted through the urinary system in a 
timely fashion. In addition, all tested 99mTc-labeld α-MSH peptides demonstrated 
clear visualization of in-vivo tumor lesions with SPECT/CT. While all peptides 
exhibited high melanoma uptake, extremely high non-specific renal uptake was 
of concern. After synthesis of α-MSH peptide conjugates containing a different 
amino acid linker, renal uptake was drastically reduced and a lead compound 
had emerged, showing favorable in-vivo melanoma targeting and uptake 
properties with limited amounts of non-specific renal accumulation.  
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Chapter 1 
Introduction 
Carcinogenesis 
 Over the last half of a century, cancer research has spawned a vast and 
complex body of knowledge into the underlying mechanisms of cancerous cell 
development.  The research to date reveals cancer to be a complex disease 
involving dynamic alterations at both a genomic and proteomic level [1, 2].  
These alterations allow for the process of carcinogenesis to take place.  
Carcinogenesis is a highly complicated, multi-step mechanism of malignant 
transformation by genomic mutations producing both oncogenic and tumor 
suppressive genes capable of transforming normal cells into highly malignant 
cells [1, 2]. The combination of oncogenic gene activation and tumor suppressive 
capabilities allows for excessive, uncontrolled cellular proliferation and 
development of clinically diagnosed tumors.  These processes have been 
reiteratively studied and classified utilizing transgenic mouse models and 
cancerous cell lines (both human and animal) to determine the multi-step 
modality of which carcinogenesis takes place [1, 2]. 
Deemed the “Hallmarks of Cancer” by Hanahan and Weinberg in 2000, 
the acquired capabilities of cancerous cells necessary for cancer development 
and progression can be categorized into six functional traits: self-sufficiency in 
growth signals, insensitivity to anti-growth signals, limitless replicative potential, 
sustained angiogenesis, evasion of apoptosis, and tissue invasion and 
metastasis.  It is believed that all cancers acquire these traits during their 
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transformation from normal cells, albeit through a tremendous variety of 
molecular mechanisms and genetic mutations.  
 
Melanoma epidemiology and carcinogenesis 
Skin cancer is the one of the most diagnosed cancers in the United States 
with increasing incidence over the past two decades.  Different types of skin 
cancer include basal cell carcinoma, squamous cell carcinoma, and melanoma. 
Of these three types of skin cancer, melanoma is by far the deadliest. It is 
estimated that 76,690 new diagnoses of melanoma and 9,480 deaths will occur 
in 2013.  Melanoma accounts for approximately 1.6% of all cancer related deaths 
and is the 5th leading diagnosed cancer in the United States [3].  Metastatic 
melanoma is the leading cause of skin cancer related deaths with a poor 
prognosis.  The mean survival rate of patients diagnosed with metastatic 
melanoma is six months, with five year survival rates of less than 5% [4, 5]. The 
rise in incidence and diagnoses is due to both increased awareness of cutaneous 
lesions and lifestyle changes that have led to increased ultraviolet light exposure 
over the past few decades [6, 7].  Melanomas are derived from the malignant 
transformation of cutaneous melanocytes, the cells residing in the basal layer of 
the epidermis that are solely responsible for human pigmentation [8].  The 
majority of melanomas arise de novo although some may originate in existing 
nevi [8, 9].  
Exposure to ultraviolet light sources such as the sun and an ever 
increasing proclivity towards cosmetic enhancement of the skin through the use 
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of tanning beds have presented as important causative factors in melanoma 
carcinogenesis.  Intermittent UV exposure and sunburn history in melanoma 
development have been identified as major contributors in epidemiological 
studies [5, 7] . The pathogenic effects of UV exposure could involve genotoxic, 
mitogenic, or immunosuppressive responses to damage induced by both 
Ultraviolet A (UVA) and Ultraviolet B (UVB) radiation.  UVA, also known as long 
wave radiation, has a particle wavelength of 320-400 nM and can penetrate the 
skin past the epidermal layers and into the dermal tissue. UVA radiation indirectly 
damages DNA through reactive oxygen species (ROS) generation and formation 
of Guanine to Thymine transversion mutations. UVB, also known as short wave 
radiation, has a particle wavelength of 290-320 nM and is the chief cause of skin 
reddening and sun burning, damage occurring to the more superficial epidermal 
tissues of the skin. UVB radiation can directly damage DNA through mutagenesis 
at dipyrimidine sites, inducing apoptosis in normal keratinocytes [7, 10].   
 While the strong correlation between UV exposure and melanoma 
development exists, it is extremely difficult to accurately delineate the precise 
exposure patterns of individuals and entire populations to both UVA and UVB 
exposure.  Clinically cutaneous melanomas have been categorized into four 
distinct subtypes: superficial spreading melanoma on intermittently exposed skin 
such as the upper back, lentigo maligma melanoma in chronically exposed skin, 
acral lentiginous melanoma on the hairless skin of the palms and soles, and 
nodular melanoma with vertical growth, not associated with a macular 
component [7, 11]. The potential targets of UV-induced damage from a molecular 
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point of view include the signaling cascades of the melanocortin-1 receptor 
(MC1R) and BRAF genes.  The BRAF gene is an important molecule in the 
mitogen-activated protein kinase (MAPK) pathway, which regulates cell growth, 
survival, and invasion. MAPK signaling initiates at the cell membrane through 
receptor tyrosine kinases binding their respective ligand or via RAS-GTPase 
activation upon adhesion of integrin molecules to extracellular matrices [7, 12].  
BRAF, a serine-threonine kinase, can become constitutively activated upon 
mutation of a single amino acid substitution of valine with glutamic acid at 
position 600 (known as the V600E mutation).  This BRAF mutation, which 
activates a 500-fold induction of BRAF, constitutively activates downstream 
MAPK/ERK signaling in cells without upstream activation of RAS, in a growth 
factor-independent manner [13].  Constitutive MAPK/ERK activity stimulates 
proliferation, survival, and can induce the expression of the microphthalmia-
associated transcription factor (MITF) gene in cutaneous melanocytes. The MITF 
gene has been shown to be the master regulator of melanocytes with induced 
activation resulting in increased pigmentation, survival, and proliferation through 
a mechanism that triggers cell cycle exit [6, 7, 14-17].  While the discovery of the 
BRAF mutations elicit the potential for therapeutic intervention, due to the 
extensive heterogeneity of this disease, BRAF mutations have only been 
identified in approximately 50-60% of all cutaneous melanomas [6, 13, 18].   
 Current diagnostic procedures for detecting both melanoma and non-
melanoma related skin cancers remain fickle to this day, even with clinical 
knowledge that detection of any form of skin cancer in the early treatable phases 
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is critical for favorable prognosis.  The American Cancer Society recommends 
“careful skin check by a clinician as part of a routine cancer-related checkup”, 
however, many clinicians do not perform any routine skin screenings during 
regular checkups [19].  In order to diagnosis a melanocytic lesion on a patient, 
clinicians utilize the ABCDE rule to guide naked eye examinations: A= lesion 
asymmetry, B= border irregularity, C= color variability, D= diameter usually larger 
than 6mm, E= evolution or change in shape, color, size, elevation, or any 
emerging symptoms such as bleeding, itching or crusting [19, 20]. Once a 
melanoma diagnosis has been given, some clinicians will opt for the utilization of 
imaging modalities to rule out any clinically resectable distant disease. This is 
done to avoid potential surgery when curative resection is not a viable option, as 
well as ease patient anxiety by confirming the absence of distant disease [21]. 
Currently, the most commonly used imaging modalities for melanoma patients 
include chest x-ray, computed tomographic (CT) imaging, magnetic resonance 
imaging (MRI), ultrasonography, positron-emission tomographic (PET) imaging, 
and PET-CT [21]. While these imaging modalities are powerful tools to help aide 
clinicians in patient diagnosis, several studies have demonstrated that the 
detection rate of metastatic disease is lower than the rate of false positivity [21, 
22]. False positivity rates with staging x-ray studies range from 7-15% as 
compared to a 0.0-0.2% detection rate for metastatic disease.  Similar results 
have been obtained with current CT imaging, ultrasonography, and FDG-PET 
scans [21-24].  It is imperative that new diagnostic imaging procedures be 
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implemented in order to aide clinicians in successful diagnosis of both primary 
melanoma lesions and metastatic disease.      
 
Clinical treatment of metastatic melanoma 
 Melanoma is notoriously difficult to treat and has been considered as one 
of the most therapeutically challenging malignancies due to its genetic 
heterogeneity, dysregulation of cell cycle events allowing for evasion of apoptosis 
and constitutive proliferative potential, and increased drug resistance to current 
chemotherapeutic and immunotherapeutic agents [18, 25-28].  Through the years 
many novel systemic therapeutic approaches have been developed to treat 
metastatic melanoma but have proven largely ineffective.  Cytotoxic 
chemotherapeutic agents deployed as the “standard of care” for treatment of 
metastatic melanoma include Dacarbazine (DTIC), Temozolomide (TMZ), and 
taxanes such as paclitaxel or docetaxel [25, 29, 30]. Dacarbazine is the only FDA 
approved chemotherapy agent for metastatic melanoma and is closely related to 
its more bioavailable and orally tolerable derivative, TMZ [30-33].  Both 
chemotherapeutic agents are prodrugs that are transformed into 5-(3-
methyltriazen-1-yl)imidazole-4-carboximide (MITC), which can then methylate 
guanine residues in the DNA, forming O6-methylguanine adducts, repair of which 
is vital and necessary for cell integrity and survival.  These adducts work to 
generate single and double-strand DNA breaks when repair of adducts is 
attempted by cellular mismatch repair enzymes, causing activation of apoptotic 
pathways [31, 34].  Response from treatment with these chemotherapeutic 
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agents on malignant metastatic melanoma have been less than promising since 
their development, with overall response rates ranging between 15-20%, and a 
median survival of approximately 7 months [31, 32, 35, 36].  Paclitaxel and 
docetaxel are both mitotic inhibitors that can stabilize microtubules, interfering 
with the normal breakdown of microtubules during cellular division.  Both drugs 
have not shown significant activity in melanoma with response rates in metastatic 
melanoma not exceeding 15%, and a median survival of 5 months [32, 33, 37, 
38].  Multidrug combination therapy of these agents combined with tamoxifen and 
cisplatin showed no significant benefit to overall survival and increased toxicity 
when compared to DTIC alone [32, 33, 39, 40].   
Treatments of metastatic melanoma with systemic immunotherapeutic or 
biochemotherapeutic treatment regimens have not encountered much more 
success than chemotherapeutic agents alone [32, 33].  Interferon as a single 
agent, has shown modest activity against metastatic melanoma with an average 
response rate ranging from 10-15%, while high dose interleukin-2 (IL-2), which 
has recently garnished FDA approval for late stage metastatic melanoma, 
showed an overall response rate of 16%, but can achieve durable complete 
remissions in a small percentage of patients [32, 33, 41-43].  
Biochemotherapeutic regimens, utilizing both chemotherapeutic and 
immunotherapeutic agents, with combined DTIC, cisplatin,IL-2, and IFN have 
shown promise in Phase III clinical trials with response rates ranging from 30-
60% with some durable complete remissions in patients [32, 33, 44].  Targeted 
therapies such as Sorafenib or Vemurafenib, FDA approved oral multikinase 
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inhibitors targeting the MAPK pathway and oncogenic B-raf V600E mutation, 
when added to conventional treatments with paclitaxel and/or carboplatin have 
shown a high partial response rate of 40% and median survival of 13.6 months, 
but antitumor activity was independent of BRAF mutational status [43, 45-51].  
 
Metastatic melanoma chemo and immunoresistance 
Melanoma resistance to exogenous drug and immunotherapies is a 
multifaceted and complex problem involving a multitude of molecular 
mechanisms.  Chemotherapeutic efficacy is often impaired by intrinsic or 
acquired tumor resistance, known as multi-drug resistance (MDR).  MDR can be 
the result of varying mechanistic alterations to cancer cells including changes in 
tumor cell cycle checkpoints, impairment of apoptotic pathways, increased repair 
of damaged cellular targets, and a vast reduction in drug accumulation within the 
tumor cells [25, 30].  The mechanism encountered in the vast majority of 
laboratory research has been that of the enhanced efflux of hydrophobic 
cytotoxic drugs mediated by one of a family of transporters, known as the ATP-
binding cassette (ABC) transporters [25].  The ABC transporters are an energy-
dependent family of proteins that typically efflux exogenous hydrophobic solutes 
and structurally diverse molecules out of the cytoplasm of the cell and back into 
the extracellular environment [25, 26, 30, 52-55].  In human melanoma, the 
transport proteins with elevated mRNA expression in both primary and metastatic 
melanoma cells contributing to increased MDR are ABCA5, ABCB2, ABCB6, 
ABCD3, ABCD4, ABCF1, ABCF2 and ABCF3 [52, 55].  Expression of the most 
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common and extensively studied ABC transport proteins, ABCB1 and ABCC1, 
remain controversial and may be induced by chemotherapy treatment itself, but 
their role in the high chemoresistance of human melanoma may be limited [52, 
56, 57].  The ABCB5 transport protein, which shares high homology with its 
structural analog ABCB1, has demonstrated high expression in both clinical 
melanomas and specifically within cells of melanocytic origin, and may represent 
an novel chemoresistance mediator in human melanoma [52, 58, 59].   
Resistance of human melanoma to chemo and immunotherapeutic 
regimens may also be conferred by an increased expression and activation of 
DNA repair enzymes.  Increasing evidence indicates that damage to highly 
proliferating cells, such as melanoma, induced by the use of cytostatic drugs can 
be counteracted and compensated for by modulation of DNA-repair mechanisms 
[30, 60].  Decreased efficacy of cytostatic drugs such as TMZ and other 
therapeutic agents can be conferred by the inhibition of the DNA-mismatch repair 
pathway (MMR) and over expression of O6-methylguanine-DNA 
methyltransferase (MGMT) [30, 54].  DNA-mismatch repair deficiency imparts 
drug resistance by enervating the ability of cells to repair DNA damage 
generated from alkylating agents and activate cellular apoptosis [30, 60].  In 
particular, O6-methylguanine adducts invoked by the use of TMZ or DTIC, are not 
properly reconstituted due to the up-regulation of MGMT in melanoma cells.  
MGMT encodes the DNA-repair protein O6-alkylguanine DNA alkyltransferase 
(AGT) and is a singular protein pathway that recognizes and repairs DNA 
through its specificity for O6-substituted purines without the use of any other 
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multi-enzyme complexes such as the nucleotide excision repair (NER) pathway 
[61, 62].  Specifically, AGT recognizes the O6-guanine base lesion induced by 
alkylating agents and transfers the aberrant methyl group to a cysteine residue in 
its active site, thus repairing the guanine base.  Removal of the methylation on 
the guanine residue prevents cytotoxicity by regenerating intact DNA.  Regular 
cellular replication and transcription is allowed to proceed, while the AGT 
molecule is ubiquitinated and eventually degraded [54, 61, 63, 64].  Loss of MMR 
protein expression in melanoma cell lines confers resistance to apoptotic stimuli 
and causes destabilization of the melanotic genome, resulting in high mutation 
rates, increased proliferation, invasion, and survival [30, 60, 65]. 
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Melanoma targeting via alpha-melanocyte stimulating hormone (α-MSH) ligand 
biding to the melanocortin-1 receptor 
 
Melanocortin-1 receptor  
The melanocortin-1 receptor (MC1R) is part of a superfamily of G-protein 
coupled receptors (GPCR’s) expressed in melanocytes and melanoma cells, 
initially authenticated by ligand-binding studies [66-68].  At the present time, five 
melanocortin receptors have been identified, namely the MC1R-MC5R. The 
MC1R is expressed largely in melanocytes and leukocytes and involved in skin 
pigmentation and animal coat coloration [69]. Expression levels of functional 
MC1R are 100-fold higher in melanocytes than immune derived lymphoblastoid 
cells with an estimated number of MC1R transcripts of 20-200 receptors per cell 
for normal melanocytes and 1-10 receptors per cell for normal keratinocytes [70]. 
The MC2R is expressed in the adrenal glands and regulates 
glucocorticoneogenesis [71]. The MC3R and MC4R are expressed in brain 
tissues and are found to regulate feeding behavior and energy homeostasis [72].  
The MC5R is widely expressed throughout peripheral tissues and may participate 
in the mediation of exocrine gland function [73].  
The MC1R is an integral membrane protein consisting of 317 amino acids 
and harboring all the structural hallmarks of classical GPCR’s; an extra cellular 
N-terminus, seven transmembrane (TM) fragments, and an intracellular C-
terminus [68, 74]. According to several 3-D ligand-receptor models and site 
directed mutagenesis, the ligand binding site of the MC1R forms a pocket located 
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below the plasma membrane-extracellular matrix interface [74, 75].  The 3-D 
models developed suggest a highly charged region containing a Glu residue from 
TM2 and two Asp residues from TM3 interact with an Arg residue on the 
pharmacophore binding sequence of the native MCR agonists, the family of 
peptide hormone derivatives known as the melanocortins.  In addition, a network 
of aromatic residues on the extracellular side of TM4, TM5, and TM6 may also 
play an important role in agonist binding by interacting with other aromatic 
residues of the pharmacophore sequence of the melanocortins (Fig. 1.1) [68, 
76].   
 
Fig. 1.1- Schematic structure of the human melanocortin-1 receptor. (Adapted from 
Yang, 1997). 
 
The MC1R is a significant contributor to skin phenotype and sensitivity to 
UV light induced DNA damage and photocarcinogenesis through regulation and 
production of the amount and type of pigments produced in the skin [68, 77-80].  
The total amount of melanin content present and relative contributions of 
Extracellular
Intracellular
TM1
TM2
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TM4
TM5
TM6
TM7
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pheomelanin (a red/ yellow pigment) and eumelanin (a brown/ black pigment) 
synthesized by human epidermal melanocytes are a key contributor of epidermal 
pigmentation and UV protection [68, 81].  Epidermal pigmentation is directly 
correlated with eumelanin content, which is more abundant in dark pigmented 
skin than lighter pigmented skin.  Eumelanin is considered to be the primary 
photo-protective mechanism as it reduces the penetration of UV radiation (UVR) 
through the epidermal layers and into the underlying dermis; known as the 
tanning response.  Eumelanin is superior to pheomelanin in its photoprotection 
properties as it is less resistant to degradation from UVR exposure and boasts 
the ability to quench reactive oxygen species generated during UVR that can 
cause cellular lipid peroxidation and protein/ DNA damage [77, 78, 81, 82].   
Activation of eumelanin production within wild type melanocytes upon 
UVR exposure occurs through a cascade of autocrine and paracrine signaling 
within the skin.  Upon exposure of the human epidermis to UVR, a variety of 
factors will be released by keratinocytes, including the native MC1R ligand, α-
MSH.  Binding of α-MSH to the MC1R on melanocytes activates the cAMP/PKA 
signaling cascade and production of cAMP through adenylyl cyclase.  cAMP 
accumulation in the cytoplasm activates the MAPK and ERK1/2 kinases leading 
to phosphorylation of cAMP responsive-element-binding protein (CREB) 
transcription factor family members.  CREB phosphorylation transcriptionally 
activates the microphthalmia transcription factor (MITF), which is used to activate 
production of tyrosinase and tyrosinase related protein-1 (TRP-1) and TRP-2 as 
well as promote survival and proliferation of melanocytes.  Cooperatively in a 
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storage organelle called the melanosome, tyrosinase, TRP-1, and TRP-2 
enzymatically convert the precursor molecule, tyrosine, into eumelanin.  
Eumelanin will stay deposited in the melanosome to exert its biological effects of 
UV protection and skin pigmentation [68, 77-79, 81-84].   
 In addition to the important biological role of the MC1R in reducing UV 
induced damage in the epidermis, the process of ligand binding induces several 
other important molecular mechanisms including cell survival through evasion of 
apoptosis and cellular internalization of the ligand-receptor complex.  Upon 
binding of α-MSH, the MC1R also activates the inositol triphosphate (IP3) kinase 
survival pathway, an important survival pathway in many different cell types [77, 
85].  Induction of this pathway ultimately leads to the activation of protein kinase 
B (Akt/PKB).  Activated Akt inhibits apoptosis by phosphorylating and inactivating 
pro-apoptotic proteins Bad and caspase 9.  This evasion of apoptosis was seen 
independent of α-MSH melanogenic or mitogenic effects [77, 85, 86].     
Agonist binding to the MC1R triggers an important cellular process of 
internalization of the ligand-receptor complex.  The process of agonist dependent 
internalization is initiated upon MC1R binding of its native agonist, α-MSH.  
Binding of the receptor initiates a phosphorylation of the MC1R by the GRK 
family of kinases.  This phosphorylation targets the receptor, with bound ligand, 
for internalization into an endocytic vesicle.  This process has been determined 
for the MCR4 and can be speculated with the MC1R due to the presence of 
melanocortins in melanoma cells following their addition to external medium and 
time-dependent appearance of acid-resistant binding [87].  The fate of the 
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MC1R-ligand complex remains unclear upon endocytosis into the cell but 
evidence has been presented that radiolabeled α-MSH agonists are rapidly 
internalized into the cell and translocated to the lysosome, where they remain 
within cellular cytoplasm for a prolonged period of time [68, 88, 89]. 
MC1R expression on both human and murine melanoma cells makes this 
receptor system an attractive molecular target for melanoma specific targeting.  
Radioligand binding studies have demonstrated functional MC1 receptor 
populations ranging from 1,000-6,000 receptor sites per cell on human melanotic 
and amelonotic melanoma cells and between 5,000-8,000 receptors sites per cell 
for murine melanoma cells [90, 91].  The relatively low number of receptor sites 
per cell necessitates the need for high affinity ligand molecules for successful 
molecular targeting of the MC1R.   
 
Wild type α-MSH ligand for MC1R 
 α-melanocyte stimulating hormone (α-MSH) is a tridecapeptide derived 
from the posttranslational processing of proopiomelanocortin (POMC) produced 
in the pituitary gland [92, 93].  Wild type α-MSH (Ac-Ser1-Tyr2-Ser3-Met4-Glu5-
His6-Phe7-Arg8-Trp9-Gly10-Lys11-Pro12-Val13-NH2) is a potent MC1R agonist that 
exerts its biological effects in the regulation of eumelanin production, as 
previously stated.  Structure bio-activity analyses have demonstrated that the 
four peptide pharmacophore binding sequence of His6-Phe7-Arg8-Trp9, is solely 
responsible for binding the MC1R and exerting melanotropic activity [93, 94].  
With over 80% of all human melanoma tumor samples obtained from patients 
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with metastatic disease harboring receptors for α-MSH and the intrinsic 
nanomolar binding affinity of wild-type α-MSH for the MC1R, underscores the 
potential use of this ligand-receptor complex for selective delivery of either 
diagnostic or therapeutic radiopharmaceuticals for melanoma imaging or therapy 
[95].          
 
Radiolabeled α-MSH peptide analogs used in targeting of the MC1R 
Linear α-MSH tritium-labeled radiopharmaceuticals were first developed 
during the 1970’s and 1980’s for tissue distribution and melanoma detection but 
suffered with low specific activity, making tumor targeting inefficient.  In addition, 
the linear structure of these peptide analogs allowed for increased 
conformational freedom attributing to less potent MC1 receptor binding and 
decreased in-vivo stability.  Currently the “gold standard” in linear α-MSH peptide 
analogs is 125I-[Nle4,D-Phe7]-α-MSH (NDP-MSH), due to its sub-nanomolar 
binding affinity to the MC1 receptor [93, 96].  Utilization of this peptide analog 
was limited to in-vitro studies as dehalogenation of 125I-NDP-MSH occurs in-vivo.  
Radiolabeling linear α-MSH peptide analogs through conjugation of radionuclide 
chelators was another method employed to develop potent melanoma imaging 
probes.  1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and 
diethylene triamine pentaacetic acid (DTPA) metal chelators conjugated to the N-
terminus of the peptides are able to form stable complexes with a variety of 
radiometals and were demonstrated to increase melanoma imaging sensitivity, 
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tumor uptake, and decrease normal organ uptake compared to their linear 
peptide analog counterparts [93, 97, 98].  
In more recent years, new targeting peptide design methods have been 
employed with increasing promise.  Peptide cyclization strategies were employed 
to enhance in-vivo stability, receptor selectivity, and receptor binding affinity of 
the α-MSH peptides [99-102].  Cyclization of the α-MSH peptide allowed for 
decreased conformational freedom due to stabilization of peptide secondary 
structures, including beta turns, as compared to the linear peptide.  This 
decrease in conformational freedom allows for increased receptor binding affinity 
[100-102]. Cyclization strategies can be classified into four types: (1) backbone to 
backbone; (2) N-terminus to C-terminus; (3) side chain to C-terminus; (4) two 
side chains via disulfide, metal, or lactam bridges [4].  Unique lactam bridge 
cyclization occurs by an amide bridge formed between two amino acid side 
chains within the peptide such as a positively-charged Lysine and a negatively-
charged Aspartic acid [101-103].  Lactam bridge, disulfide bond, and metal 
cyclization strategies were employed to improve the stability of the α-MSH 
peptides against in-vivo proteolytic degradation as well as further enhance the 
binding affinity of the α-MSH peptides to the MC1 receptor [104, 105].  
 Research into the potential use of these cyclized α-MSH radiopeptides 
was thoroughly conducted over the last decade.  Through this research it was 
determined that the different cyclization strategies may have a profound effect on 
pharmacokinetic and biodistribution properties of radiopeptides with comparable 
in-vitro binding affinities.  A comparison of DOTA-conjugated Re-metal-cyclized 
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peptides with disulfide bridge-cyclized α-MSH analogs showed that metal 
cyclization results in increased receptor-mediated tumor uptake and decreased 
renal uptake values compared to disulfide bridge-cyclization, correlating to more 
favorable pharmacokinetic and biodistribution properties [106].   
Lactam cyclization and substitution of Phe7 with D-Phe7 in α-MSH peptides 
along with radiolabeling of 67Ga and 111In to form 67Ga-DOTA-GlyGlu-CycMSH 
and 111In-DOTA-GlyGlu-CycMSH, showed improved cellular internalization and 
retention in B16/F1 mouse melanoma cells as well as fast whole body clearance 
[100, 104].  In addition, visualization of in-vivo tumor formation in B16/F1 
melanoma-bearing C57 mice utilizing whole body SPECT/CT imaging of 111In-
DOTA-GlyGlu-CycMSH, demonstrated clear potential for diagnostic applications 
[104].  The data showed the significant improvement and utilization of the lactam 
bridge-cyclized α-MSH radiolabeled peptides as a melanoma specific imaging 
and therapeutic agent.   
Recent research has been focused on fine tuning the use of the lactam 
bridge-cyclized peptides by both adjusting the position of the DOTA metal 
chelator and reducing the ring size of the cyclized peptide.  DOTA position had 
previously been shown to have a profound effect on radiolabeled linear α-MSH 
peptide tumor and renal uptake whereas conjugation of the DOTA chelator to the 
C-terminus in the 111In-DOTA-NAPamide complex exhibited 75% greater 
melanoma uptake and 63% less renal uptake than the N-terminus conjugated 
111In-MSHoct [102].  Thus, alternate conjugation of the DOTA chelator to 
111In-
labeled lactam bridge-cyclized α-MSH was a logical next step.  Indeed 
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conjugation of the DOTA chelator to the α-amino group of Lys in the cyclic ring of 
Ac-GluGlu-CycMSH[DOTA]-111In exhibited increased MC1 receptor binding 
affinity of 0.6 nM, high tumor uptake (11.42 ± 2.20 % injected dose/gram (%ID/g) 
2 h post injection), increased cellular retention (9.42 ± 2.41 %ID/g 4 h post 
injection), and low non-target organ uptake values (<1.3 %ID/g) [102].  
  Reduction in the ring size of the cyclized α-MSH peptide from 12 amino 
acids to 6 amino acids in the 111In-DOTA-Nle-CycMSHhex complex exhibited 
increased tumor uptake values (24.94 ± 4.58 %ID/g 0.5 h post injection), rapid 
clearance of 82% of injected radioactivity through the urinary system by 2 h post 
Injection, and clear, defined whole body melanoma visualization through 
SPECT/CT imaging.  In addition, linker modifications have demonstrated 
profound effects on the melanoma-targeting and pharmacokinetic properties of 
the 111In-labeled lactam-bridge cyclized α-MSH peptides. Hydrocarbon, amino 
acid, and polyethylene glycol linkers were previously shown to have favorable 
pharmacokinetic and melanoma-targeting profiles on radiolabeled 
bombesin[107], RGD[108], and α-MSH peptides[100]. Introduction of the GluGlu 
linker in the 111In-DOTA-Nle-CycMSHhex peptides produced 
111In-DOTA-GGNle-
CycMSHhex, which demonstrated high melanoma uptake while reducing both 
kidney and liver uptake values by 28-42% and 61-68% respectively.    
In nuclear medicine, both 111In and 99mTc radionuclides are widely used as 
diagnostic imaging agents due to their unique imaging properties.  99mTc is an 
ideal imaging radionuclide due to its favorable nuclear decay properties and ease 
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of coordination with imaging probes, such as small peptides like the α-MSH 
peptides previously discussed.  
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99mTc-radiolabeling of α-MSH peptides 
 
Background of technetium  
Technetium, a second-row transition metal and element 43 on the Periodic 
Table, was discovered in 1937 by a pair of Italian scientists in a sample of 
molybdenum that had been irradiated by deuterons for some years in the U.C. 
Berkeley cyclotron [109-111].  Stemming from the Greek word technetos, 
meaning artificial, technetium was the first previously unknown element on earth 
to be artificially made by man.  Since its discovery, 21 isotopes of technetium 
have been produced ranging from Tc-90 to Tc-110. All technetium isotopes 
produced are radioactive with nuclear half-lives ranging from 0.86 sec (short-
lived 110Tc , T1/2= 0.86 sec) to 2.6 x10
6 years (long-lived 97Tc, T1/2= 2.6 x10
6 y) 
[110, 112].   
 Currently, 99mTc is the most commonly used radioisotope in diagnostic 
nuclear medicine.  99mTc can be produced through the use of the 99Mo/99mTc 
commercial generator first developed in 1957 at the Brookhaven National 
Laboratory (BNL) in Upton, New York [110, 112, 113].  Purification work on the 
132Te/ 132I generator at BNL in the late 1950’s turned up a contaminant which was 
discovered to be 99Tc after the presence of 99Mo was found in the chemical 
separation process [109, 114].  The 99Mo/99mTc generator uses the parent 
isotope (99Mo), obtained as a fission by-product of 235U or by bombardment of 
98Mo with neutrons, loaded onto an alumina column as molybdate, 99MoO4
2-.  
The positively-charged alumina absorbs the negatively-charged molybdate ions.  
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Through a β-decay process, 99mTc is produced as 99mTcO4
- pertechnetate (Fig. 
1.2) [112].  The 99mTcO4
- is then eluted off the column with sterile normal saline to 
generate the final product of Na99mTcO4
-, sodium pertechnetate, at high specific 
activity with only diminutive quantities of chemical contaminants such as carrier 
molybdate and 99Tc.   
  
γ decay 
β- decay 
γ decay 
β- decay 
 
Fig. 1.2- Generation and decay of 99mTc through the use of the 99Mo/99mTc generator. 
(Adapted from Bartholom , 2010). 
 
The 99Mo/99mTc generator can be eluted multiple times per day as 99Mo 
radioactivity remaining on the column continues to decay, yielding fresh 99mTc 
activity.  The worldwide use of this generator system in nuclear medicine is due 
to the ease of operation, high elution efficiency, extraordinary radionuclide purity, 
and remarkable specific activity [110-112] .  Other methods used for separating 
99mTc from 99Mo include: solvent extraction of “instant technetium” with 
methylethyl ketone, sublimation of technetium oxides from Mo complexes at 
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temperatures exceeding 850°C, and elution of 99mTc from zirconium molybdate 
gel columns [111].  
 Technetium-99m is an ideal SPECT (single photon emission computed 
tomography) imaging radionuclide due to its nuclear decay properties.  Decay of 
the metastable 99mTc to the ground state, and virtually stable, 99Tc element, 
releases three gamma photons of 2.2, 140, and 143 KeV, with the 
monochromatic 140 KeV photon in highest abundance with 89.1% of all nuclear 
transitions [110, 113].  The 140 KeV photon emission is strong enough to 
penetrate tissues in-vivo but can be readily collimated and absorbed by 
commercial gamma camera detectors to give images with superior spatial 
resolution.  In addition to the 140 KeV photon emission, the convenient physical 
half-life of 99mTc (T1/2= 6.03 hours) also renders the radionuclide an ideal SPECT 
imaging agent [109, 110, 112, 115].  The physical half-life of this isotope is long 
enough to synthesize 99mTc-labeled radiopharmaceuticals, perform quality 
controls, administer 99mTc-labeled compounds to a patient as well as allow 
compound accumulation in a target tissue and collection of imaging data, while 
minimizing the total radiation dose the patient.  The wide use of 99mTc for 
diagnostic radioimaging studies is demonstrated by the fact that 19 million 
injections of 99mTc radiopharmaceuticals were performed in the United States in 
2007 for cardiac, lung, kidney, bone, liver, and gall bladder studies, representing 
nearly 85% of radiopharmaceuticals used as nuclear medicine [112].       
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Coordination geometries of technetium 
As a transitional metal element, technetium displays some unique 
chemistry characteristics, including its rich and diverse redox chemistry, with 
compounds of technetium exhibiting all formal oxidation states between +7 and -
1 [115, 116].  Table 1.1 summarizes the oxidation states and coordination 
geometries of technetium.  The existence of technetium in these many oxidation 
states suggests an advantage in structural diversity for 99mTc-labeled 
radiopharmaceuticals.  However, the existence of the technetium in these diverse 
redox states also demonstrates the potential reactions for undesirable side 
products. 
Oxidation State Example 
Coordination 
Chemistry 
Coordination 
number 
+7 (d0) 
[TcH9]
2- 
TcO4
- 
trigonal prism 
tetrahedron 
9 
4 
+6 (d1) TcO4
2- tetrahedron 4 
+5 (d2) 
TcOCl4- 
[Tc(NCS)6]
- 
[Tc(Diars)2Cl4]
+ 
square pyramid 
octahedron 
dodecahedron 
5 
6 
8 
+4 (d3) [TcCl6]
2- octahedron 6 
+3 (d4) [Tc(diars)2Cl2]
+ octahedron 6 
+2 (d5) [TcCl2(PhP(Oet)2)4] octahedron 6 
+1 (d6) [Tc(CNC(CH3)3)6]
+ octahedron 6 
0 (d7) [Tc2(C0)10] octahedron 6 
-1 (d8) [Tc(CO)5]
- trigonal bipyramid 5 
 
Table 1.1- Oxidation states and coordination geometries of technetium. (Adapted from 
Liu, 1999). 
 
Technetium must be reduced to a lower oxidation state in order to produce 
stable and effective 99mTc-labled biomolecules.  The choice of reducing agents 
and reaction conditions play a pivotal role on determining the final redox state of 
the technetium complex.  These reducing agents will be discussed later in 99mTc 
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radiolabeling approaches.  The most stable oxidation states of technetium for use 
in radiopharmaceuticals can be characterized by chemically robust core 
structures depicted in Fig. 1.3 [115].  The most studied and utilized core moiety 
is that of [99mTcO]3+ (B), characteristic of the Tc(V) oxidation state. Complexes of 
this core generally yield a square pyramidal geometry and are stabilized via NxS4-
x tetradentate ligands.  The use of this technetium core produces 
99mTc-
complexes containing both syn- and anti- isomers [116].  These isomeric 
compounds generally contain different lipophilicity and biodistribution properties 
in biological systems, so it is critical to determine the species desired, and 
perform optimized radiosynthesis under specific conditions to obtain that single 
species.        
 
Fig. 1.3- Technetium cores used in 99mTc labeling of biomolecules. X= N or S, Y= N or S, 
L= neutral donor ligand. (Cited from Liu, 1999). 
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Design of 99mTc radiopharmaceuticals  
The early design of  99mTc radiopharmaceuticals in the 1970’s and 1980’s 
was directed toward investigating ligands that were able to stabilize technetium in 
lower oxidation states for localized direction of the radionuclide in-vivo, known as 
technetium-essential radiopharmaceuticals.  These compounds use technetium 
as the essential core atom around which other conjugating ligands are arranged.  
The first stable core structures were demonstrated by a group at MIT in which the 
Tc(V)O core could be stabilized utilizing bisdithiolate (S4) or diamidedithiolate 
(N2S2) ligands to form square pyramidal complexes [109, 117].  This initial finding 
permitted the development of newer generations of technetium-labeled, 
technetium-essential radiopharmaceuticals with differing core structures [115, 
117].  Many of these core structures are still in use today as the basis for 
diagnostic 99mTc radiopharmaceuticals [109, 115, 118]. 
Throughout the years various strategies have been employed for receptor-
based 99mTc radiopharmaceuticals targeting both intra- and extra-cellular 
receptors, also known as technetium-tagged receptor targeting 
radiopharmaceuticals.  As the basis of these compounds, technetium is 
conjugated to a receptor-targeting moiety for site specific localized targeting.  
Design strategies for these compounds fall into three categories: the integrated 
approach, the bifunctional approach, and the peptide-hybrid approach [109, 115, 
118].  The integrated approach for receptor-based 99mTc radiopharmaceuticals 
integrates or replaces part of a known receptor-binding ligand with the 99mTc 
chelate (Fig. 1.4) [115, 118].  In this approach the 99mTc metal chelate becomes 
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a pivotal component of the receptor-binding ligand and all parts are arranged in 
such a way that the whole metal complex becomes a high affinity receptor ligand.  
This approach often results in challenging synthetic synthesis of target molecules 
with low receptor binding affinity. Therefore, it is crucial to comprehensively 
consider the effects of the 99mTc chelator on a ligand’s size, charge, 
conformation, and lipophilicity during the structural design [118]. 
 
 
Fig. 1.4- Schematic representation of the integrated design strategy of receptor targeted 
radiopharmaceuticals. M=99mTc, X &Y= donor atoms. (Cited from Liu, 2004). 
 
   The second design strategy is the bifunctional approach.  In this 
approach, a receptor-binding ligand is used as the targeting biomolecule, a 
bifunctional coupling agent (BFCA) is used for 99mTc chelation, and a chemical 
linker is used to covalently attach the two components (Fig. 1.5) [118]. This 
design is a more popular approach for target-specific radiopharmaceutical 
development due to the likelihood of retaining high receptor binding affinity with 
the targeted tissue. The receptor-targeting biomolecule in this design serves as a 
vehicle to carry the radionuclide to the targeted disease tissue, which should be 
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known to harbor a substantial concentration of the target receptor. In this design, 
the biomolecule can be monoclonal antibodies, small peptides, or other non-
peptide small molecule receptor ligands.  The high specificity of receptor binding 
to the biomolecule is essential and will result in selective uptake and distribution 
of the radiolabeled receptor ligand in the disease tissue.  Many biomolecules 
including antibody fragments and small peptides have been studied as “carriers” 
for radionuclides and have been FDA approved for both diagnostic and 
therapeutic treatment of disease.  Examples of FDA approved target-specific 
radiopharmaceuticals include Octreoscan® (111In-pentetreotide) for imaging of 
neuroendocrine tumors and Zevalin® (90Y-Ibitumomab tiuxetan) for treatment of 
non-Hodgkin’s lymphoma [118].  
Different chemical linkers can be used to modify the binding affinity and 
pharmacokinetic properties of the radiolabeled biomolecule as well as structurally 
keep the radiometal chelate far enough away from the biomolecule to limit any 
possible interference it may have with the receptor binding motif of the 
biomolecule.  The choice of linker depends on the pharmacokinetic requirements 
for the radiopharmaceutical. The linker can range from a simple hydrocarbon 
chain to increase lipophilicity, to a poly amino acid sequence to increase 
hydrophilicity to facilitate renal clearance, to a long polyethylene glycol (PEG) 
molecule to slow extraction by hepatocytes.[115, 118, 119]. 
 The requirements for an ideal BFCA are the selective stability of an 
intermediate or lower oxidation state of technetium to minimize the redox 
reactions pertaining to the 99mTc complex, formation of a complex with the 
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minimum number of isomers possible, ease of attachment to the biomolecule, 
and high radiolabeling efficiency [115, 118, 119].  Attachment of the BFCA to the 
biomolecule in these complexes is performed by a reactive conjugation group.  
These reactive groups can be either intrinsic to the peptide (e.g. an amino group 
from lysine, phenol moiety from tyrosine, thiol group from cysteine, or carboxylate 
group from aspartic or glutamic acid) or can be chemically introduced into a 
peptide.  The attachment of the BFCA/ radiometal complex occurs through the 
following reactive groups: N-Hydroxysuccinimide (NHS) esters, isothiocyanates, 
or maleimide moieties (Fig 1.6) [113].  The NHS-esters can attach to a lysine 
amine or linker amino group through an amide bond and is very stable under 
physiological conditions.  Hence, the NHS-esters are the most widely used and 
powerful conjugation groups.  The isothiocyanates are amine reactive groups as 
well and can form thiourea bonds with primary amino acid amines.  The 
maleimide moiety is a thiol-reactive group that can selectively react with a thiol 
from a peptide to form a thioether bond [115].   
 
Fig. 1.5- Schematic representation of the bifunctional design strategy of receptor 
targeted radiopharmaceuticals. (Cited from Liu, 2004). 
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Fig. 1.6- Representative conjugation groups capable of attaching the BFCA to the 
targeting biomolecule. (Cited from Liu, 1999). 
 
 The third radiopharmaceutical design strategy is the peptide-hybrid 
approach.  In this approach, the 99mTc is chelated and conjugated by a tripeptide 
sequence (such as Gly-Gly-Gly, Cys-Gly-Gly, Cys-Gly-Cys, or Cys-Cys-Cys) 
within the targeting peptide which contain a N4, N3S, N2S2, or NS3 donor set 
respectively.  The radiometal can be conjugated to either a linear polypeptide or 
cyclic peptide backbone, incorporating it as a component of the macrocyclic 
peptide framework (Fig. 1.7) [117]. Coordination of the radiometal to a linear 
peptide increases receptor binding affinity by creating a constrained macrocyclic 
metallopeptide with less conformational freedom to its intended receptor [118, 
120].  The site-specific metal cyclization can also improve the stability of the 
radiolabeled peptide in-vivo [99, 101].    
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Fig. 1.7- Schematic representation of the peptide-hybrid design strategy of receptor 
targeted radiopharmaceuticals. M= 99mTc.  (Cited from Liu, 2004). 
 
 In addition to 99mTc-radiolabeling design on these pharmaceuticals, it is 
also important to consider the pharmacokinetics of each compound.  The 
pharmacokinetic considerations to include are absorption, distribution, 
metabolism, and excretion.  The main goal of any diagnostic radiopharmaceutical 
is to acquire the highest target-to-background ratio possible in the shortest 
amount of time.  In optimizing this ratio, the patient will receive the least amount 
of non-target radiation, as the radioactivity will be quickly excreted from the body 
through the urinary system.  When applied systematically and in most cases 
intravenously, radiopharmaceutical blood residence time should be short enough 
to quickly release the diagnostic agent into the target tissue, but long enough to 
adequately accumulate in target tissue as well.  For receptor-targeting 
radiopharmaceuticals, the receptor binding affinity should be extremely high, 
binding rate should be fast, and the radiopharmaceutical should have adequate 
cellular retention to eliminate the potential of non-targeted radiation doses to 
healthy tissue, as well as achieving optimal imaging characteristics in the 
targeted tissue [118, 119]. 
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Radiolabeling approaches of technetium 
 99mTc-radiolabeling techniques have advanced throughout the years, and 
labeling approaches depend on the type of biomolecules being used (e.g. 
antibodies or small peptides) and the purpose of the study being conducted (e.g. 
product development or proof of concept).  Many techniques have been 
established for 99mTc-radiolabeling of biomolecules such as antibodies, small 
peptides, and other non-peptide small molecules.  These radiolabeling 
approaches usually fall into three main categories: the pre-labeling approach, the 
post-labeling (or indirect labeling) approach, and the direct labeling approach.   
 The pre-labeling approach (also referred to as the pre-formed chelate 
approach) involves the chelation of 99mTc with the BFCA, activation of the BFCA, 
and conjugation of the 99mTc-BFCA complex to the biomolecule in a separate 
step (Fig. 1.8) [109, 119].  This approach has been more extensively researched 
and the chemistry involved is better defined than that of the direct labeling 
approach.  One advantage of this approach is that the peptide or protein being 
labeled is not exposed to the harsh environment that is sometimes necessary for 
the chelation step (e.g. pH extremes or high temperatures).  For research 
purposes this labeling approach is very useful for developing proof of concept 
studies, but the complex and time consuming radiosynthesis process is not 
suitable for routine clinical use or kit formulation.  This approach has been 
successfully used to 99mTc-radiolabel antibodies and small peptides in a variety of 
studies including the use in cyclic platelet glycoprotein GPIIb/IIIa receptor 
antagonists coordinated with HYNIC [109, 115, 119, 121].  
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Fig. 1.8- Schematic of the 99mTc pre-labeling approach. X & Y= donor atoms. (Cited from 
Liu, 2008). 
 
 The post-labeling approach (also known as the indirect labeling approach) 
involves attachment of the BFCA to the biomolecule, forming a BFCA-
biomolecule conjugate. In this instance the BFCA can be attached to either the 
C- or N-terminus of the peptide or protein, as well as to an amino acid side chain, 
or directly incorporated into the peptide backbone utilizing multi-step organic 
synthesis.  Once the BFCA-biomolecule conjugate is prepared, radiolabeling with 
99mTc can be accomplished through multiple mechanisms including direct 
reduction of 99mTcO4
- in the presence of the BFCA-biomolecule conjugate, ligand 
exchange with an intermediate 99mTc complex, or a reduction-substitution 
reaction (Fig. 1.9) [119].  This labeling approach utilizes the ease of direct 
radiolabeling and well-defined chemistry of the pre-labeling approach, making it 
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the most practical approach for development of target-specific 
radiopharmaceuticals [109, 115, 119].  
 
Fig. 1.9- Schematic of the 99mTc post-labeling (indirect labeling) approach. X & Y= donor 
atoms. (Cited from Liu, 2008). 
 
 99mTc radiolabeling of the BFCA-biomolecule complex through the direct 
reduction approach involves directly reducing 99mTcO4
- pertechnetate in one step 
by a variety of reducing agents (SnCl2, NaBH4, Na2S2O4, H3PO4, NH2NH2, 
ascorbic acid, and HCl, among many others), in the presence of adequate BFCA-
peptide conjugate.  This reaction generally produces mixed 99mTc reduction 
species, but can be controlled and prepared into a single 99mTc-BFCA-
biomolecule species through the use of a particular reducing agent and BFCA 
under well-controlled labeling conditions.  The most commonly used reducing 
agent is SnCl2 for its rapid reduction kinetics.  The use of Sn(II) however can lead 
to production of the Tc (VI) intermediate (99mTcO4
2-) and Tc [122] intermediate ( 
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99mTcO2); both of which form unstable complexes capable of undergoing 
hydrolysis and compromising the radiolabeling yield of the 99mTc-BFCA-
biomolecule complex [109, 115, 119]. 
    Another way of 99mTc radiolabeling the BFCA-biomolecule complex is 
through a two-step ligand exchange.  In this process, the pertechnetate ion is 
reduced by a reducing agent in the presence of a weak chelating agent to form a 
99mTc-chelate intermediate.  This intermediate is then allowed to react with the 
BFCA-biomolecule complex under milder conditions to form the final desired 
99mTc-BFCA-biomolecule complex.  This route is often used to limit the exposure 
of the BFCA-biomolecule conjugate to the sometimes harsh radiolabeling 
conditions.  One example of a ligand exchange process is the use of 
glucoheptonate (GH) as a weak chelating agent to aid in radiolabeling the α-MSH 
peptide with 99mTc.  In this process, a reducing agent such as SnCl2 is used to 
reduce the pertechnetate ion to the Tc(V) state containing the [99mTcO]3+ core in 
the presence of the glucoheptonate.  Once reduced, the glucoheptonate chelates 
and stabilizes the [99mTcO]3+ core and protects from redox reactions with the 
aqueous environment.  Once stabilized, the BFCA-biomolecule conjugate (α-
MSH in this case) is allowed to react and conjugate with [99mTcO]3+ to form the 
final radiolabeled product of 99mTc-(Arg11)CCMSH (Fig. 1.10)  [115, 119, 123-
125]. 
36 
 
 
Fig. 1.10- Schematic representation of ligand-exchange radiolabeling with 
glucoheptonate of 99mTc-(Arg11)CCMSH. (Adapted from Miao, 2007 and de Kieviet, 
1981). 
 
 The direct labeling approach uses a reducing agent to convert disulfide 
linkages into free thiols, which are then able to strongly bind technetium (Fig. 
1.11).  Many reducing agents can be used (e.g. NaBH4, Na2S2O4, H3PO4, 
NH2NH2, ascorbic acid, and HCl, among many others) but stannous chloride 
(SnCl2) is the most commonly used.  SnCl2 is used to break the disulfide linkage 
as well as reduce the 99mTcO4
-, Tc(VII), to a lower oxidation state such as Tc(V) 
[110].  This approach applies mainly to antibodies and antibody fragments as 
many small peptides do not have disulfide linkages, or if one exists, the linkage 
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may be critical for maintaining biological properties and therefore should not be 
reduced.  For this approach however there are some critical questions that must 
be addressed: the desired oxidation state of 99mTc, the number of 99mTc 
conjugations to the biomolecule, purity of the desired 99mTc-labeled species, and 
impact on the targeting molecules biological activity after 99mTc-radiolabeling.  
Examples of direct 99mTc-radiolabeling can be seen with many 99mTc-labeled 
monoclonal antibodies including those to aid in detection of colorectal and 
ovarian cancer.   
 
Fig. 1.11- Schematic of the 99mTc direct labeling approach. (Cited from Liu, 2008). 
 
Recently, our lab has developed a unique one-step radiolabeling 
procedure utilized for 99mTc-radiolabeling of hybrid peptides.  These hybrid 
peptides coordinate the technetium into the cyclic backbone of the peptide via 
three cysteine amino acid additions.  The sulfhydryl side chains of the cysteine 
residues strongly conjugate to the 99mTc(V)O core, stabilizing the technetium 
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within the cyclic peptide backbone via an NS3 coordination system.  
Radiolabeling of the peptide is performed through direct reduction of 99mTcO4
- 
with SnCl2.  Since the sulfhydryl side chains on the cysteine residues are already 
fully reduced, the 99mTc(V) core, [TcO]3+, is allowed to covalently conjugate 
directly to those residues without the need for attachment to a BFCA.  
Meanwhile, the hybrid peptide can be simultaneously cyclized during the 
radiolabeling of 99mTc, allowing for diminished conformational freedom of the 
peptide secondary structure and reduced in-vivo proteolytic degradation.  The 
cyclization process increases in-vivo stability as well as binding affinity of the 
peptide for its targeted receptor.  Radiolabeling synthesis is performed by 
incubation of the peptide, sodium pertechnetate, SnCl2, and buffer solutions 
(NH4OAc/ Na2 tartate•2H2O) for twenty minutes at room temperature.  Upon 
radiolabeling synthesis, collection of a single species of 99mTc-labeled peptide 
can be performed through RP-HPLC (Fig 1.12).  This labeling approach is well 
suited for use in clinical applications as it can be performed in a single step at 
room temperature.    
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Fig. 1.12- Structure of 99mTc-RGD-Lys-(Arg11)CCMSH peptide after direct reduction 
radiolabeling synthesis. (Adapted from Yang, 2010). 
 
 
99mTc-Labeled α-MSH analogs 
 Throughout the past two decades, novel 99mTc-labeled α-MSH peptide 
analogs have been employed for development of diagnostic or therapeutic 
targeting molecules for metastatic melanoma with varying success.  One of the 
first attempts at utilizing 99mTc-labeled α-MSH peptide analogs was the 
development of 99mTc-CGCG-NDP, which employed a tetrapeptide chelator of 
Cys-Gly-Cys-Gly on the amino terminus of the synthetic α-MSH analog NDP-
MSH.  99mTc-CGCG-NDP showed moderate melanoma uptake in B16/F1 
melanoma bearing C57 mice with a peak tumor uptake at 30 minutes post-
injection of 6.52 ± 1.11 %ID/g [97, 120].  A novel α-MSH peptide analog, 
[Cys3,4,10,D-Phe7]α-MSH3-13 (CCMSH), was created utilizing the peptide-hybrid 
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approach of chelation within the backbone of the α-MSH peptide via addition of 
three cysteine residues at amino acid positions 3, 4, and 10 [97, 98].  The metal 
cyclized portion of the peptide contained the potent α-MSH pharmacophore 
consensus sequence. 99mTc-CCMSH exhibited rapid and high tumor uptake as 
well as fast whole-body clearance in B16/F1 melanoma bearing mice.  The peak 
tumor uptake was seen at 30 min post-inject with an uptake value of 12.97 ± 2.38 
%ID/g [126].  In an effort to decrease non-specific renal uptake of the 99mTc-
CCMSH peptide, a substitution to the Lys11 for Arg11 was made to establish the 
novel peptide analog (Arg11)CCMSH.  99mTc-(Arg11)CCMSH exhibited a peak 
tumor uptake value of 14.03 ± 2.58 %ID/g at 1 h post-injection while 
demonstrating a 62% reduction in non-specific renal uptake at 4 h post-injection 
[97, 125, 126].   
 Newer generations of 99mTc-labeled α-MSH peptides generated in our lab 
emerged as dual receptor targeting molecules.  Arg-Gly-Asp-conjugated α-MSH 
hybrid peptides were developed to target both the MC1R and the αVβ3 integrin 
present on melanoma cells.  The cyclized Arg-Gly-Asp (RGD) αVβ3 integrin 
binding motif was attached to the hybrid α-MSH peptide containing the MC1R 
pharmacophore binding sequence via a Lys amino acid linker, forming a novel 
RGD-Lys-(Arg11)CCMSH hybrid peptide [127].  It was hypothesized that targeting 
of both the MC1R and αVβ3 integrin would provide for superior melanoma 
targeting as compared to MC1R targeting alone.  As a control, the cyclic RGD 
motif was also substituted into a cyclic RAD motif in order to ablate αVβ3 binding, 
producing the RAD-Lys-(Arg11)CCMSH peptide.  Receptor binding studies with 
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both peptides in human M21 melanoma cells demonstrated that indeed 
substitution of the Gly residue in the RGD motif for an Ala residue ablated αVβ3 
integrin binding, with IC50 values of 403 nM for RGD-Lys-(Arg
11)CCMSH 
compared with greater than 100,000 nM for RAD-Lys-(Arg11)CCMSH.   
Surprisingly, MC1R binding affinity of the RAD-Lys-(Arg11)CCMSH peptide 
was nearly 10-fold higher than the original RGD-Lys-(Arg11)CCMSH M21 human 
melanoma cells, with IC50 values of 0.3 nM and 2.0 nM, respectively [127]. This 
elevated MC1 receptor binding affinity resulted in enhanced melanoma tumor 
uptake of 99mTc-RAD-Lys-(Arg11)CCMSH as compared with 99mTc-RGD-Lys-
(Arg11)CCMSH (19.91± 4.02 vs 14.83 ± 2.93% ID/g at 2 h post-injection) in 
B16/F1 melanoma-bearing C57 mice as well [128]. The minor structural 
difference of the addition of one extra methyl group on the Ala residue as 
compared to the Gly residue, indicated that the existence of the methyl group 
enhanced the in-vivo melanoma tumor uptake of 99mTc-RAD-Lys-(Arg11)CCMSH. 
Therefore, it was of interest to determine how other minor structural differences 
to the 99mTc-RAD-Lys-(Arg11)CCMSH peptide could further enhance the MC1R 
binding affinity and in-vivo tumor targeting and pharmacokinetics, as well as 
determine the optimal structure for use as a melanoma SPECT imaging probe.  
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Purpose, hypothesis, and specific aims 
 
Currently, no curative treatment options exist for metastatic melanoma.  A 
patient’s best opportunity for a cure is early detection of melanocytic lesions and 
prompt surgical removal of cancerous tissues [3, 6, 27].  The development of 
novel targeting radiopharmaceuticals capable of both early detection and imaging 
of primary melanoma lesions and metastases represents a potential innovative 
tool suited for a patient’s best chance at survival.  At present, the work being 
conducted in the development of novel radiolabeled α-MSH peptide analogs is 
still in the pre-clinical stage.  Proper optimization and characterization of the 
newest generations of these peptides is of importance to ascertain the most 
promising compounds capable of utilization in a clinical setting. 
The research emphasis for this project entails combining the knowledge 
from different biomedical sciences in the fields of oncology, cellular and 
molecular biology, chemistry, and radiopharmacology to develop, optimize, and 
characterize novel radiolabeled α-MSH peptide analogs for targeting and 
radioimaging of melanoma lesions.  The development of which can potentially 
aide clinicians in determining the location and size of both primary melanoma 
lesions and their metastatic counterparts for prompt surgical removal and 
monitoring the growth and spread of disease over the periods of progression, 
remission, and recurrence. 
With the promising results seen by the modification of α-MSH analogs in 
respect to increased MC1 receptor binding affinity and increased in-vivo 
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melanoma targeting and uptake in B16/F1 melanoma-bearing C57 mice, it was 
the purpose of this study to determine the optimal α-MSH peptide structure 
necessary for development of an ideal melanoma targeting probe suitable for 
diagnostic imaging. 
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Central Hypothesis    
 Our central hypothesis states that structural modifications of novel α-MSH 
peptides targeting the melanocortin-1 receptor will enhance melanoma targeting 
and pharmacokinetic properties of 99mTc-labeled α-MSH peptide analogs for 
SPECT radioimaging and may provide a distinct non-invasive tool for early 
detection and diagnosis of melanocytic disease, both primary and disseminated.   
 
Figure 1.13- Schematic representation of the modifications made to the novel α-
MSH peptides in the RXD motif (1), linker (2), and XAD motif (3). 
  
(2)
(3)
(1)
99mTc=O
Ala, Ser, 
Thr, Val, 
Nle, Phe, 
DPhe
Glu, Nle
Lys, β-Ala
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Specific aims 
 I will attempt to examine our central hypothesis through the following 
specific aims: 
1. To determine the effect of single amino acid substitutions to the RXD 
motif on the targeting and biodistribution properties of RXD-Lys-
(Arg11)CCMSH peptides. 
 
In order to evaluate specific aim #1, α-MSH peptides will be designed and 
synthesized containing amino acid substitutions to the Ala residue on the RXD 
motif. The in-vitro MC1 receptor targeting properties of the RXD-Lys-
(Arg11)CCMSH peptides will be determined in the B16/F1 murine melanoma cell 
line. The in-vivo melanoma targeting and pharmacokinetic properties of the 
99mTc-RXD-Lys-(Arg11)CCMSH peptides will be evaluated in B16/F1 melanoma-
bearing C57 mice. 
 
2. To reduce in-vivo non-specific renal uptake of α-MSH peptide analogs 
via L-Lys co-injection and linker modification through substitution of the 
positively charged Lys linker with a neutral β-Ala linker, without 
disrupting melanoma  tumor uptake. 
 
In order to evaluate specific aim #2, as a proof of concept study, reduction 
of in-vivo non-specific renal uptake of the 99mTc-RXD-Lys-(Arg11)CCMSH 
peptides will be determined with the use of a purified L-Lys co-injection. Based 
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on the results of the L-Lys co-injection study, α-MSH peptides will then be 
designed and synthesized containing an amino acid substitution of the positively 
charged Lys linker with a neutral β-Ala linker. The in-vitro MC1 receptor targeting 
properties of the RXD-β-Ala-(Arg11)CCMSH peptides will be determined in the 
B16/F1 murine melanoma cell line. The in-vivo reduction of renal 
radiopharmaceutical uptake and pharmacokinetic properties of the 99mTc-RXD-β-
Ala-(Arg11)CCMSH peptides will be evaluated in B16/F1 melanoma-bearing C57 
mice. 
   
3. To further reduce in-vivo non-specific renal uptake of α-MSH peptides 
by amino acid substitutions to XAD motif on XAD-β-Ala-(Arg11)CCMSH 
peptides, without disrupting melanoma tumor uptake.  
 
In order to evaluate specific aim #3, α-MSH peptides will be designed and 
synthesized containing amino acid substitutions to reduce the overall net charge 
of the peptides by replacing the Arg residue in the RXD motif, creating the XAD-
β-Ala-(Arg11)CCMSH peptides. The in-vitro MC1 receptor targeting properties of 
the XAD-β-Ala-(Arg11)CCMSH peptides will be determined in the B16/F1 murine 
melanoma cell line. The further in-vivo reduction of renal radiopharmaceutical 
uptake and pharmacokinetic properties of the 99mTc-XAD-β-Ala-(Arg11)CCMSH 
peptides will be evaluated in B16/F1 melanoma-bearing C57 mice. 
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Chapter 2 
Evaluation of new Tc-99m-labeled Arg-X-Asp-conjugated α-melanocyte 
stimulating hormone peptides for melanoma imaging   
 
Introduction 
Malignant melanoma is the most lethal form of skin cancer with an 
increasing incidence [3].  Melanoma leads to greater than 75% of deaths from 
skin cancer although it only accounts for less than 5% of skin cancer cases. 
There is no curative treatment available for metastatic melanoma. Both 
melanocortin-1 (MC1) and αvβ3 integrin receptors have been utilized as targets 
for developing melanoma imaging probes [91, 100, 103, 105, 129-145].  The 
radiolabeled α-melanocyte stimulating hormone (α-MSH) peptides were used to 
target the MC1 receptors [91, 100, 103, 105, 129-137], whereas the radiolabeled 
Arg-Gly-Asp (RGD) peptides were reported to target the αvβ3 integrin receptors 
[138-145].  In our previous report, we developed a novel Arg-Gly-Asp (RGD)-
conjugated α-MSH hybrid peptide {RGD-Lys-(Arg11)CCMSH} to target both MC1 
and αvβ3 integrin receptors for M21 human melanoma imaging [127].  The dual 
receptor-targeting 99mTc-RGD-Lys-(Arg11)CCMSH exhibited significantly higher 
melanoma uptake than single receptor-targeting 99mTc-RAD-Lys-(Arg11)CCMSH 
or 99mTc-RGD-Lys-(Arg11)CCMSHscramble in M21 human melanoma-xenografted 
nude mice. Interestingly, the switch from RGD to Arg-Ala-Asp (RAD) in the hybrid 
peptide dramatically improved the MC1 receptor binding affinity of RAD-Lys-
(Arg11)CCMSH as compared to RGD-Lys-(Arg11)CCMSH (0.3 vs. 2.0 nM) in M21 
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melanoma cells [127].  The stronger MC1 receptor binding resulted in enhanced 
melanoma uptake of 99mTc-RAD-Lys-(Arg11)CCMSH as compared with 99mTc-
RGD-Lys-(Arg11)CCMSH (19.91 ± 4.02 vs. 14.83 ± 2.93% ID/g at 2 h post-
injection) in B16/F1 melanoma-bearing C57 mice [128]. 
The minor structural difference between 99mTc-RAD-Lys-(Arg11)CCMSH 
and 99mTc-RGD-Lys-(Arg11)CCMSH is Ala and Gly. The Ala has one more methyl 
group as compared with the Gly. The biodistribution results indicated that the 
existence of methyl group in Ala enhanced the melanoma uptake of 99mTc-RAD-
Lys-(Arg11)CCMSH [128].  Therefore, we were interested in whether the 
substitution of Gly with other amino acids could affect the melanoma targeting 
and pharmacokinetic properties of 99mTc-labeled peptides. In this study, we 
replaced the Gly with Thr and Val to generate RTD-Lys-(Arg11)CCMSH and RVD-
Lys-(Arg11)CCMSH peptides. The MC1 receptor binding affinities of RTD-Lys-
(Arg11)CCMSH and RVD-Lys-(Arg11)CCMSH were examined in B16/F1 
melanoma cells. Thereafter, we determined the biodistribution and imaging 
properties of 99mTc-RTD-Lys-(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH 
in B16/F1 melanoma-bearing C57 mice. 
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Experimental design and methods 
 
Chemicals and Reagents 
 
Amino acids and resin were purchased from Advanced ChemTech Inc. 
(Louisville, KY) and Novabiochem (San Diego, CA). 125I-Tyr2-[Nle4, DPhe7]-α-
MSH {125I-(Tyr2)-NDP-MSH} was obtained from PerkinElmer, Inc. (Waltham, MA) 
for receptor binding assay. 99mTcO4
- was purchased from Cardinal Health 
(Albuquerque, NM). L-lysine was purchased from Sigma-Aldrich (St. Louis, MO). 
All other chemicals used in this study were purchased from Thermo Fischer 
Scientific (Waltham, MA) and used without further purification. B16/F1 murine 
melanoma cells were obtained from American Type Culture Collection 
(Manassas, VA). 
 
Peptide Synthesis and In Vitro Competitive Binding Assay 
 
The RTD-Lys-(Arg11)CCMSH and RVD-Lys-(Arg11)CCMSH peptides were 
synthesized according to our previously published procedure [146] with slight 
modification on Sieber amide resin by an Advanced ChemTech multiple-peptide 
synthesizer (Louisville, KY). Briefly, 70 µmol of Sieber amide resin and 210 µmol 
of Fmoc-protected amino acids were used for the synthesis. Fmoc-Lys(Boc) was 
used to generate a Lys linker in the hybrid peptide. The RTD-Lys-(Arg11)CCMSH 
and RVD-Lys-(Arg11)CCMSH were purified by reverse phase-high performance 
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liquid chromatography (RP-HPLC) and characterized by liquid chromatography-
mass spectroscopy (LC-MS). 
The IC50 values RTD-Lys-(Arg
11)CCMSH and RVD-Lys-(Arg11)CCMSH for 
the MC1 receptor were determined in B16/F1 melanoma cells. The receptor 
binding assay was replicated in triplicate for each peptide. The B16/F1 cells were 
seeded into a 24-well cell culture plate at a density of 2.5 × 105 cells/well and 
incubated at 37° C overnight. After being washed with binding medium {modified 
Eagle’s medium with 25 mM N-(2-hydroxyethyl)-piperazine-N′-(2-ethanesulfonic 
acid) (HEPES), pH 7.4, 0.2% bovine serum albumin (BSA), 0.3 mM 1,10-
phenathroline}, the cells were incubated at 25 °C for 2 h with approximately 
30,000 counts per minute (cpm) of 125I-(Tyr2)-NDP-MSH in the presence of 
increasing concentrations (10-13 M to 10-6 M) of RTD-Lys-(Arg11)CCMSH or RVD-
Lys-(Arg11)CCMSH in 0.3 mL of binding medium. The reaction medium was 
aspirated after the incubation. The cells were rinsed twice with 0.5 mL of ice-cold 
pH 7.4, 0.2% BSA/0.01 M phosphate buffered saline (PBS) to remove any 
unbound radioactivity and lysed in 0.5 mL of 1 M NaOH for 5 min. The activities 
associated with the cells were measured in a Wallac 1480 automated gamma 
counter (PerkinElmer, NJ). The IC50 value for each peptide was calculated using 
Prism software (GraphPad Software, La Jolla, CA). 
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Peptide Radiolabeling 
 
RTD-Lys-(Arg11)CCMSH and RVD-Lys-(Arg11)CCMSH peptides were 
labeled with 99mTc via a direct reduction reaction with SnCl2. Briefly, 10 μL of 1 
mg/mL SnCl2 in 0.1 M HCl, 40 μL of 0.5 M NH4OAc (pH 5.2), 100 μL of 0.2 M 
Na2tartate (pH 9.2), 100 μL of fresh 
99mTcO4
- solution (37-74 MBq), and 10 μL of 
1 mg/mL RTD-Lys-(Arg11)CCMSH or RVD-Lys-(Arg11)CCMSH peptide in 
aqueous solution were added into a reaction vial and incubated at 25 °C for 20 
min to form 99mTc-labeled peptide. Each 99mTc-peptide was purified to a single 
species by Waters RP-HPLC (Milford, MA) on a Grace Vydac C-18 reverse 
phase analytic column (Deerfield, IL) using a 20-min gradient of 16-26% 
acetonitrile in 20 mM HCl aqueous solution at a flow rate of 1 mL/min. Each 
purified peptide was purged with N2 gas for 20 mins to remove the acetonitrile. 
The pH of final peptide solution was adjusted to 7.4 with 0.1 N NaOH and sterile 
normal saline for stability, biodistribution and imaging studies. The serum stability 
of 99mTc-RTD-Lys-(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH was 
determined by incubation in mouse serum at 37 C for 24 h and monitored for 
degradation by RP-HPLC. Briefly, 100 µL of HPLC-purified peptide solution (~7.4 
MBq) was added into 100 µL of mouse serum (Sigma-Aldrich Corp, St. Louis, 
MO) and incubated at 37 oC for 24 h. After the incubation, 200 µL of a mixture of 
ethanol and acetonitrile (V:V = 1:1) was added to precipitate the serum proteins. 
The resulting mixture was centrifuged at 16,000 g for 5 min to collect the 
supernatant. The supernatant was purged with N2 gas for 30 min to remove the 
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ethanol and acetonitrile. The resulting sample was mixed with 500 µL of water 
and injected into RP-HPLC for analysis using the gradient described above.   
 
Cellular Internalization and Efflux  
 
Cellular internalization and efflux of 99mTc-RTD-Lys-(Arg11)CCMSH and 
99mTc-RVD-Lys-(Arg11)CCMSH were evaluated in B16/F1 melanoma cells. The 
B16/F1 cells were seeded into a 24-well cell culture plate at a density of 2.5 × 105 
cells/well and incubated at 37° C overnight. After being washed twice with 
binding medium [modified Eagle's medium with 25 mM N-(2-hydroxyethyl)-
piperazine-N’-(2-ethanesulfonic acid), pH 7.4, 0.2% bovine serum albumin (BSA), 
0.3 mM 1,10-phenathroline], the B16/F1 cells were incubated at 25C for 20, 40, 
60, 90 and 120 min (n=3) in the presence of approximate 200,000 counts per 
minute (cpm) of HPLC-purified of 99mTc-RTD-Lys-(Arg11)CCMSH or 99mTc-RVD-
Lys-(Arg11)CCMSH. After incubation, the reaction medium was aspirated and the 
cells were rinsed with 2  0.5 mL of ice-cold pH 7.4, 0.2% BSA / 0.01 M PBS. 
Cellular internalization was assessed by washing the cells with acidic buffer [40 
mM sodium acetate (pH 4.5) containing 0.9% NaCl and 0.2% BSA] to remove the 
membrane-bound radioactivity. The remaining internalized radioactivity was 
obtained by lysing the cells with 0.5 mL of 1 N NaOH for 5 min. Membrane-bound 
and internalized activities were counted in a gamma counter. Cellular efflux was 
determined by incubating the B16/F1 cells with 99mTc-RTD-Lys-(Arg11)CCMSH or 
99mTc-RVD-Lys-(Arg11)CCMSH for 2 h at 25C, removing non-specific-bound 
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activity with 2  0.5 mL of ice-cold PBS rinse, and monitoring radioactivity 
released into cell culture medium. At time points of 20, 40, 60, 90 and 120 min, 
the radioactivities on the cell surface and inside the cells were separately 
collected and counted in a gamma counter. 
 
Biodistribution Studies  
 
All the animal studies were conducted in compliance with Institutional 
Animal Care and Use Committee approval. The biodistribution properties of 
99mTc-RTD-Lys-(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH were 
determined in B16/F1 melanoma-bearing C57 female mice (Harlan, Indianapolis, 
IN). Each C57 mouse was subcutaneously inoculated on the right flank with 
1106 B16/F1 cells. The weight of tumors reached approximately 0.2 g 10 days 
post cell inoculation. Each melanoma-bearing mouse was injected with 0.037 
MBq of 99mTc-RTD-Lys-(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH via 
the tail vein. Groups of 4 mice were sacrificed at 0.5, 2, 4 and 24 h post-injection, 
and tumors and organs of interest were harvested, weighed and counted. Blood 
values were taken as 6.5% of the body weight. The specificity of tumor uptake 
was determined by co-injecting 99mTc-RTD-Lys-(Arg11)CCMSH or 99mTc-RVD-
Lys-(Arg11)CCMSH with 10 g (6.1 nmol) of unlabeled NDP-MSH at 2 h post-
injection. 
L-lysine co-injection is effective in decreasing the renal uptake of 
radiolabeled α-MSH peptides. To determine the effect of L-lysine co-injection on 
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the renal uptake of 99mTc-RTD-Lys-(Arg11)CCMSH and 99mTc-RVD-Lys-
(Arg11)CCMSH, a group of 4 mice were injected with a mixture of 0.037 MBq of 
99mTc-RTD-Lys-(Arg11)CCMSH or 99mTc-RVD-Lys-(Arg11)CCMSH and 15 mg of 
L-lysine. The mice were sacrificed at 2 h post-injection, and tumors and organs of 
interest were harvested, weighed and counted in a gamma counter. 
 
Melanoma Imaging with 99mTc-RTD-Lys-(Arg11)CCMSH and 99mTc-RVD-Lys-
(Arg11)CCMSH  
 
To determine the melanoma imaging properties, approximately 7.4 MBq of 
99mTc-RTD-Lys-(Arg11)CCMSH or 99mTc-RVD-Lys-(Arg11)CCMSH was injected 
into two B16/F1 melanoma-bearing C57 mice via the tail vein, respectively. The 
mice were euthanized for small animal SPECT/CT (Nano-SPECT/CT®, Bioscan, 
Washington DC) imaging 2 h post-injection. The 9-min CT imaging was 
immediately followed by the SPECT imaging of whole-body. The SPECT scans 
of 24 projections were acquired. Reconstructed data from SPECT and CT were 
visualized and co-registered using InVivoScope (Bioscan, Washington DC). 
 
Urinary Metabolites of 99mTc-RTD-Lys-(Arg11)CCMSH and 99mTc-RVD-Lys-
(Arg11)CCMSH 
 
Approximately 3.7 MBq of 99mTc-RTD-Lys-(Arg11)CCMSH or 99mTc-RVD-
Lys-(Arg11)CCMSH was injected into two B16/F1 melanoma-bearing C57 mice 
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via the tail vein to determine the urinary metabolites. The mice were euthanized 
to collect urine at 2 h post-injection. The collected urine samples were 
centrifuged at 16,000 g for 5 min before the HPLC analysis. Thereafter, aliquots 
of the urine were injected into the HPLC. A 20-minute gradient of 16-26% 
acetonitrile / 20 mM HCl with a flow rate of 1 mL/min was used for urine analysis. 
 
Statistical Analysis 
 
Statistical analysis was performed using the Student’s t-test for unpaired 
data to determine the significance of differences in tumor and kidney uptake 
with/without peptide blockade or with/without L-lysine co-injection in 
biodistribution studies described above. Differences at the 95% confidence level 
(p<0.05) were considered significant. 
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Results 
The schematic structures of RTD-Lys-(Arg11)CCMSH and RVD-Lys-
(Arg11)CCMSH are presented in Figure 2.1. RTD-Lys-(Arg11)CCMSH and RVD-
Lys-(Arg11)CCMSH were synthesized and purified by RP-HPLC. The overall 
synthetic yields were 30% for RTD-Lys-(Arg11)CCMSH and RVD-Lys-
(Arg11)CCMSH. The chemical purities of RTD-Lys-(Arg11)CCMSH and RVD-Lys-
(Arg11)CCMSH were greater than 95% after the HPLC purification. The peptide 
identities were confirmed by electrospray mass spectrometry. The measured 
molecular weights for RTD-Lys-(Arg11)CCMSH and RVD-Lys-(Arg11)CCMSH 
were 2194 and 2192. The competitive binding curves of the peptides are shown 
in Figure 2.2. The IC50 values of RTD-Lys-(Arg
11)CCMSH and RVD-Lys-
(Arg11)CCMSH were 0.7 ± 0.07 and 1.0 ± 0.3 nM in B16/F1 melanoma cells. 
RTD-Lys-(Arg11)CCMSH and RVD-Lys-(Arg11)CCMSH were readily 
radiolabeled with 99mTc with greater than 95% radiolabeling yields. The 99mTc-
RTD-Lys-(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH peptides were 
purified and separated from their excess non-labeled peptides by RP-HPLC. The 
retention times of 99mTc-RTD-Lys-(Arg11)CCMSH and 99mTc-RVD-Lys-
(Arg11)CCMSH were 12.7 and 14.6 min. 99mTc-RTD-Lys-(Arg11)CCMSH and 
99mTc-RVD-Lys-(Arg11)CCMSH were stable in mouse serum at 37°C for 24 h 
(Figure 2.3). Cellular internalization and efflux properties of 99mTc-RTD-Lys-
(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH were examined in B16/F1 
cells. Figure 2.4 illustrates the internalization and efflux properties of 99mTc-RTD-
Lys-(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH. 99mTc-RTD-Lys-
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(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH exhibited rapid cellular 
internalization and prolonged cellular retention. Approximately 71% of 99mTc-
RTD-Lys-(Arg11)CCMSH and 72% of 99mTc-RVD-Lys-(Arg11)CCMSH activities 
were internalized in the cells after 20 min of incubation. Cellular efflux results 
indicated that 75% of 99mTc-RTD-Lys-(Arg11)CCMSH and 70% of 99mTc-RVD-Lys-
(Arg11)CCMSH activities remained inside the cells at 2 h of incubation in the 
culture medium.  
The melanoma targeting and pharmacokinetic properties of 99mTc-RTD-
Lys-(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH are shown in Tables 2.1 
and 2.2. Both 99mTc-RTD-Lys-(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH 
exhibited rapid and high tumor uptake in B16/F1 melanoma-bearing C57 mice. 
99mTc-RTD-Lys-(Arg11)CCMSH exhibited the peak tumor uptake of 18.77 ± 5.13% 
ID/g at 2 h post-injection, whereas 99mTc-RVD-Lys-(Arg11)CCMSH reached the 
peak tumor uptake of 19.63 ± 4.68% ID/g at 4 h post-injection. The tumor uptake 
values gradually decreased to 5.84 ± 0.50 and 8.81 ± 2.13% ID/g by 24 h post-
injection. The tumor blocking studies (Tables 2.1-2.2) demonstrated that co-
injection of 10 μg (6.1 nM) of non-radiolabeled NDP-MSH with 99mTc-RTD-Lys-
(Arg11)CCMSH or 99mTc-RVD-Lys-(Arg11)CCMSH decreased their tumor uptake 
values to 2.85 ± 1.43 and 1.51 ± 0.6% ID/g at 2 h post-injection, demonstrating 
that the tumor uptake was MC1 receptor-mediated. 
Renal uptake values of 99mTc-RTD-Lys-(Arg11)CCMSH and 99mTc-RVD-
Lys-(Arg11)CCMSH were 135.14 ± 23.62 and 94.01 ± 18.31% ID/g at 2 h post 
injection, respectively.  The renal uptake values of 99mTc-RTD-Lys-
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(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH decreased to 46.84 ± 14.83 
and 44.34 ± 12.11% ID/g at 24 h post-injection. The effect of L-lysine co-injection 
on renal uptake is presented in Figure 2.5.  Co-injection of 15 mg L-lysine 
significantly (p<0.05) decreased the renal uptake values of 99mTc-RTD-Lys-
(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH to 60.66 ± 12.09 and 55.74 ± 
9.14% ID/g at 2 h post-injection, respectively. The L-lysine co-injection didn't 
affect the tumor uptake of 99mTc-RTD-Lys-(Arg11)CCMSH and 99mTc-RVD-Lys-
(Arg11)CCMSH (p>0.05) at 2 h post-injection. Whole-body clearance of 99mTc-
RTD-Lys-(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH was rapid, with 
approximately 55% and 59% of the injected radioactivity clearance through the 
urinary system by 2 h post-injection (Tables 2.1-2.2).  At 24 h post-injection, 82% 
of 99mTc-RTD-Lys-(Arg11)CCMSH and 77% of 99mTc-RVD-Lys-(Arg11)CCMSH 
activity cleared out the body. Normal organ uptakes of 99mTc-RTD-Lys-
(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH was minimal (<2.1% ID/g) 
except for the kidneys after 2 h post-injection (Tables 2.1-2.2). 
Whole-body SPECT/CT images are presented in Figure 2.6.  Flank 
B16/F1 melanoma lesions were clearly visualized by SPECT using 99mTc-RTD-
Lys-(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH) peptides as imaging 
probes. The SPECT image of tumor accurately matched its anatomical location 
obtained in the CT image. The SPECT image showed high contrast of tumor to 
normal organ except for kidneys, which was consistent with the biodistribution 
results. The urinary metabolites of 99mTc-RTD-Lys-(Arg11)CCMSH and 99mTc-
RVD-Lys-(Arg11)CCMSH at 2 h post-injection are shown in Figure 2.7. 
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Approximately 70% of 99mTc-RTD-Lys-(Arg11)CCMSH or 99mTc-RVD-Lys-
(Arg11)CCMSH remained intact in the urine at 2 h post-injection, while 30% of the 
99mTc-RTD-Lys-(Arg11)CCMSH or 99mTc-RVD-Lys-(Arg11)CCMSH was 
transformed to a more hydrophobic compound.  
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Discussion 
We have been interested in developing MC1 receptor-targeting α-MSH 
peptides for melanoma imaging [11-14, 23-25].  Recently, we have found that the 
substitution of RGD with RAD resulted in nearly a 10-fold increase in MC1 
receptor binding affinity for RAD-Lys-(Arg11)CCMSH as compared to RGD-Lys-
(Arg11)CCMSH in B16/F1 melanoma cells [128].  Furthermore, 99mTc-RAD-Lys-
(Arg11)CCMSH displayed higher melanoma uptake than 99mTc-RGD-Lys-
(Arg11)CCMSH (19.91 ± 4.02 vs. 14.83 ± 2.93% ID/g at 2 h post-injection) in 
B16/F1 melanoma-bearing C57 mice [128]. Because the only structural 
difference between 99mTc-RAD-Lys-(Arg11)CCMSH and 99mTc-RGD-Lys-
(Arg11)CCMSH was the extra methyl group in Ala as compared to Gly, the 
enhanced melanoma uptake of 99mTc-RAD-Lys-(Arg11)CCMSH suggested that 
the methyl group in Ala dramatically affected the MC1 receptor binding motif 
(His-DPhe-Trp-Arg) in the (Arg11)CCMSH moiety. Thus, we were interested in 
whether and how the replacement of Gly with other amino acids could affect the 
melanoma targeting and pharmacokinetic properties of 99mTc-labeled RXD-Lys-
(Arg11)CCMSH peptides. Specifically, we substituted the Gly with Thr and Val to 
examine the effects of -CH(CH3)OH and -CH(CH3)2 groups on the biodistribution 
properties of  99mTc-labeled RTD-Lys-(Arg11)CCMSH and RVD-Lys-
(Arg11)CCMSH peptides in this study.  
The substitution of Gly with Thr and Val retained low nanomolar MC1 
receptor binding affinities of the peptides in B16/F1 melanoma cells. RTD-Lys-
(Arg11)CCMSH and RVD-Lys-(Arg11)CCMSH exhibited stronger MC1 receptor 
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binding affinities than RGD-Lys-(Arg11)CCMSH and weaker MC1 receptor 
binding affinities than RAD-Lys-(Arg11)CCMSH. The differences in MC1 receptor 
binding affinities among these peptides were attributed to the subtle structural 
differences among the amino acids (Gly, Ala, Thr and Val). We further 
radiolabeled RTD-Lys-(Arg11)CCMSH and RVD-Lys-(Arg11)CCMSH with 99mTc 
and determined their biodistribution and tumor imaging properties in B16/F1 
melanoma-bearing C57 mice. Both 99mTc-RTD-Lys-(Arg11)CCMSH and 99mTc-
RVD-Lys-(Arg11)CCMSH were stable in mouse serum for 24 h at 37 C. 99mTc-
RTD-Lys-(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH showed similar 
patterns in cellular internalization and efflux in B16/F1 melanoma cells. 99mTc-
RTD-Lys-(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH exhibited 
comparable high receptor-mediated melanoma uptake as 99mTc-RAD-Lys-
(Arg11)CCMSH. However, the tumor uptake pattern was different between 99mTc-
RTD-Lys-(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH. 99mTc-RTD-Lys-
(Arg11)CCMSH showed the highest tumor uptake of 18.77 ± 5.13% ID/g at 2 h 
post-injection, whereas 99mTc-RVD-Lys-(Arg11)CCMSH reached the highest 
tumor uptake of 19.63 ± 4.68% ID/g at 4 h post-injection. Meanwhile, 99mTc-RVD-
Lys-(Arg11)CCMSH exhibited lower renal uptake than 99mTc-RTD-Lys-
(Arg11)CCMSH at 0.5, 2, and 4 h post-injection. The renal uptake of 99mTc-RVD-
Lys-(Arg11)CCMSH was 62, 70, and 70% of the renal uptake of 99mTc-RTD-Lys-
(Arg11)CCMSH at 0.5, 2, and 4 h post-injection, respectively.  
The B16/F1 melanoma lesions could be clearly visualized by SPECT 
using 99mTc-RTD-Lys-(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH as 
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imaging probes. Moreover, switching from the diagnostic 99mTc to therapeutic 
188Re/186Re could further expand their therapeutic applications. Since 188Re/186Re 
share similar coordination chemistry with 99mTc, both RTD-Lys-(Arg11)CCMSH 
and RVD-Lys-(Arg11)CCMSH should be readily labeled with 188Re/186Re without 
structural modification of the peptides. Because the renal uptake of 99mTc-RVD-
Lys-(Arg11)CCMSH was about 30% less than that of 99mTc-RTD-Lys-
(Arg11)CCMSH, RVD-Lys-(Arg11)CCMSH could be a better candidate for 
melanoma therapy when labeled with 188Re/186Re. However, 99mTc-RVD-Lys-
(Arg11)CCMSH displayed high non-specific renal uptake in this study. Thus, it is 
desirable to reduce the renal uptake to facilitate its therapeutic application. L-
lysine co-injection dramatically decreased the renal uptake of 99mTc-RTD-Lys-
(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH by 40-50% (Figure 2.5), 
suggesting that the overall positive charges of the 99mTc-RXD-Lys-(Arg11)CCMSH 
peptides played key roles in their non-specific renal uptake. The reduction of the 
overall positive charge of 111In-DOTA-GlyGlu-CycMSH via a negatively-charged 
glutamic acid linker resulted in a decrease in renal uptake by 44% as compared 
to 111In-DOTA-GlyGlu-CycMSH [100]. Accordingly, it is likely that the reduction of 
the overall positive charges of the 99mTc-RXD-Lys-(Arg11)CCMSH peptides 
through the structural modification would decrease their non-specific renal 
uptake. It is worthwhile to note that four positively-charged amino acids, namely 
three arginines and one lysine linker, contributed to the overall positive charges 
of the 99mTc-RXD-Lys-(Arg11)CCMSH peptides. Because two arginines in the 
(Arg11)CCMSH motif are critical for MC1 receptor binding, the structural 
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modification on the arginines in the (Arg11)CCMSH motif would likely decrease 
the receptor binding affinity of the peptide. Alternatively, the replacement of 
lysine linker or arginine in the RXD motif by neutral or negatively-charged amino 
acids would likely reduce the overall positive charges of 99mTc-RXD-Lys-
(Arg11)CCMSH peptides without sacrificing their receptor binding affinities. It will 
be interesting to examine how the structural modification on the lysine linker or 
arginine in the RXD motif affects the tumor and renal uptake in future studies. 
In conclusion, the substitution of Gly with Thr and Val retained low 
nanomolar MC1 receptor binding affinities of the peptides in B16/F1 melanoma 
cells. 99mTc-RVD-Lys-(Arg11)CCMSH exhibited comparable high melanoma 
uptake as 99mTc-RTD-Lys-(Arg11)CCMSH, but 30% less renal uptake than 99mTc-
RTD-Lys-(Arg11)CCMSH. In spite of high receptor-mediated melanoma uptake, 
high non-specific renal uptake of 99mTc-RVD-Lys-(Arg11)CCMSH needs to be 
reduced to facilitate its future application. 
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Tables 
 
Table 2.1.  Biodistribution of 99mTc-RTD-Lys-(Arg11)CCMSH  
Biodistribution of 99mTc-RTD-Lys-(Arg11)CCMSH in B16/F1 melanoma-bearing 
C57 mice. The data was presented as percent injected dose/gram or as 
percent injected dose (mean  SD, n=4). 
 
Tissue 0.5 h 2 h 4 h 24 h 
2 h NDP 
Blockade 
 Percent injected dose/gram (%ID/g) 
Tumor 14.56 ± 5.31 18.77 ± 5.13 13.84 ± 3.10 5.84 ± 0.50 2.85 ± 1.43* 
Brain 0.14 ± 0.04 0.03 ± 0.01 0.02 ± 0.01 0.03 ± 0.01 0.08 ± 0.06 
Blood 15.95 ± 3.97 0.44 ± 0.13 0.55 ± 0.41 0.40 ± 0.21 0.50 ± 0.20 
Heart 1.86 ± 0.21 0.29 ± 0.08 0.19 ± 0.05 0.12 ± 0.02 0.42 ± 0.26 
Lung 4.27 ± 0.27 0.51 ± 0.37 0.39 ± 0.24 0.23 ± 0.04 1.18 ± 0.40 
Liver 2.09 ± 0.04 1.62 ± 0.14 2.01 ± 0.39 1.03 ± 0.10 2.09 ± 0.64 
Skin 3.99 ± 0.42 0.50 ± 0.19 0.27 ± 0.13 1.01 ± 0.31 1.21 ± 0.64 
Spleen 1.04 ± 0.33 0.48 ± 0.20 0.47 ± 0.18 0.19 ± 0.13 0.64 ± 0.37 
Stomach 1.87 ± 0.21 0.67 ± 0.16 0.70 ± 0.23 0.21 ± 0.04 1.11 ± 0.82 
Kidneys 144.56 ± 24.64 135.14 ± 23.62 105.54 ± 27.67 46.84 ± 14.83 96.23 ± 28.13 
Muscle 0.80 ± 0.38 0.15 ± 0.05 0.07 ± 0.02 0.52 ± 0.10 0.33 ± 0.03 
Pancreas 0.83 ± 0.40 0.11 ± 0.04 0.09 ± 0.05 0.13 ± 0.07 0.44 ± 0.34 
Bone 1.66 ± 0.10 0.46 ± 0.11 0.39 ± 0.12 0.23 ± 0.09 0.91 ± 0.59 
 Percent injected dose (%ID) 
Intestines 1.73 ± 0.17 0.84 ± 0.20 0.72 ± 0.18 0.48 ± 0.13 1.16 ± 0.61 
Urine 28.64 ± 8.85 54.76 ± 5.65 61.21 ± 5.56 82.19 ± 4.69 48.53 ± 21.62 
 Uptake ratio of tumor/normal tissue 
Tumor/Blood 0.91 42.66 25.16 14.60 5.70 
Tumor/Kidneys 0.10 0.14 0.13 0.12 0.03 
Tumor/Lung 3.41 36.80 35.49 25.39 2.42 
Tumor/Liver 6.97 11.59 6.89 5.67 1.36 
Tumor/Muscle 18.20 125.13 197.71 11.23 8.64 
 
*p<0.05 (p=0.01) for determining the significance of differences in tumor and 
kidney uptake between 99mTc-RTD-Lys-(Arg11)CCMSH with or without NDP-
MSH peptide blockade at 2 h post-injection. 
  
65 
 
Table 2.2.   Biodistribution of 99mTc-RVD-Lys-(Arg11)CCMSH 
Biodistribution of 99mTc-RVD-Lys-(Arg11)CCMSH in B16/F1 melanoma-
bearing C57 mice. The data was presented as percent injected dose/gram or 
as percent injected dose (mean  SD, n=4). 
 
Tissue 0.5 h 2 h 4 h 24 h 2 h NDP Blockade 
 Percent injected dose/gram (%ID/g) 
Tumor 16.70 ± 5.31 17.10 ± 3.82 19.63 ± 4.68 8.81 ± 2.13 1.51 ± 0.6* 
Brain 0.15 ± 0.05 0.04 ± 0.01 0.02 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 
Blood 1.50 ± 0.52 0.49 ± 0.05 0.54 ± 0.45 0.07 ± 0.02 0.55 ± 0.35 
Heart 0.74 ± 0.43 0.26 ± 0.15 0.16 ± 0.03 0.10 ± 0.07 0.26 ± 0.11 
Lung 2.01 ± 0.97 0.87 ± 0.40 0.49 ± 0.43 0.19 ± 0.10 0.83 ± 0.24 
Liver 1.86 ± 0.17 1.40 ± 0.34 1.59 ± 0.13 1.21 ± 0.26 1.32 ± 0.14 
Skin 9.59 ± 0.62 0.69 ± 0.18 0.35 ± 0.08 0.42 ± 0.27 0.65 ± 0.10 
Spleen 0.82 ± 0.43 0.40 ± 0.10 0.50 ± 0.15 0.34 ± 0.06 0.18 ± 0.14 
Stomach 1.92 ± 0.53 1.21 ± 0.61 0.96 ± 0.27 0.40 ± 0.13 1.39 ± 0.79 
Kidneys 90.19 ± 15.41 94.01 ± 18.31 73.92 ± 3.73 44.34 ± 12.11 67.24 ± 9.72 
Muscle 11.25 ± 6.02 0.17 ± 0.10 0.10 ± 0.07 0.26 ± 0.02 0.03 ± 0.02 
Pancreas 0.62 ± 0.25 0.10 ± 0.02 0.08 ± 0.08 0.18 ± 0.07 0.06 ± 0.03 
Bone 1.6 ± 0.73 0.57 ± 0.08 0.54 ± 0.28 0.47 ± 0.05 0.46 ± 0.10 
 Percent injected dose (%ID) 
Intestines 1.36 ± 0.27 1.59 ± 1.08 0.95 ± 0.30 0.44 ± 0.22 1.36 ± 0.48 
Urine 44.47 ± 3.12 59.2 ± 9.65 67.47 ± 10.00 76.85 ± 8.21 76.07 ± 3.55 
 Uptake ratio of tumor/normal tissue 
Tumor/Blood 11.13 34.89 36.35 125.86 2.75 
Tumor/Kidneys 0.19 0.18 0.27 0.20 0.02 
Tumor/Lung 8.31 19.66 40.06 46.37 1.82 
Tumor/Liver 8.98 12.21 12.35 7.28 1.14 
Tumor/Muscle 1.48 100.59 196.30 33.88 50.33 
 
*p<0.05 (p=0.002) for determining the significance of differences in tumor and 
kidney uptake between 99mTc-RVD-Lys-(Arg11)CCMSH with or without NDP-
MSH peptide blockade at 2 h post-injection. 
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Figure Legends 
 
Figure 2.1. Schematic structures of RTD-Lys-(Arg11)CCMSH and RVD-Lys-
(Arg11)CCMSH. 
 
Figure 2.2. The competitive binding curves of RTD-Lys-(Arg11)CCMSH (■) and 
RVD-Lys-(Arg11)CCMSH (▲) in B16/F1 melanoma cells. The IC50 value of RTD-
Lys-(Arg11)CCMSH and RVD-Lys-(Arg11)CCMSH was 0.7 ± 0.07 and 1.0 ± 0.3 
nM, respectively. 
 
Figure 2.3. Radioactive HPLC profiles of 99mTc-RTD-Lys-(Arg11)CCMSH (A) 
and 99mTc-RVD-Lys-(Arg11)CCMSH (B) in mouse serum after incubation at 37 °C 
for 24 h. The arrows denote the original retention times of 99mTc-RTD-Lys-
(Arg11)CCMSH (12.7 min) and 99mTc-RVD-Lys-(Arg11)CCMSH (14.6 min) prior to 
the incubation in mouse serum. 
 
Figure 2.4. Cellular internalization and efflux of 99mTc-RTD-Lys-(Arg11)CCMSH 
(A and B) and 99mTc-RVD-Lys-(Arg11)CCMSH (C and D) in B16/F1 melanoma 
cells. Total bound radioactivity (♦), internalized radioactivity (▲) and cell 
membrane radioactivity (■) were presented as counts per minute (cpm).  
 
Figure 2.5. Effect of L-lysine co-injection on the tumor and kidney uptakes of 
99mTc-RTD-Lys-(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH at 2 h post-
injection in B16/F1 melanoma-bearing C57 mice. The white ( ) and light grey     
( ) columns represented the tumor and renal uptake of 99mTc-RTD-Lys-
(Arg11)CCMSH with or without L-lysine co-injection. The heavy grey ( ) and 
black ( ) columns represented the tumor and renal uptake of 99mTc-RVD-Lys-
(Arg11)CCMSH with or without L-lysine co-injection. L-lysine co-injection 
significantly (*p<0.05) reduced the renal uptake of 99mTc-RTD-Lys-(Arg11)CCMSH 
by 55% and the renal uptake of 99mTc-RVD-Lys-(Arg11)CCMSH by 41% at 2 h 
post-injection without affecting their tumor uptake. 
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Figure 2.6. Representative whole-body SPECT/CT images of B16/F1 
melanoma- bearing C57 mice 2 h post injection of 7.4 MBq of 99mTc-RTD-Lys-
(Arg11)CCMSH (A) and 99mTc-RVD-Lys-(Arg11)CCMSH (B). Flank melanoma 
lesions (T) and kidneys (K) were highlighted with arrows on the images. 
 
Figure 2.7. Radioactive HPLC profiles of urinary metabolites at 2 h post-
injection of 99mTc-RTD-Lys-(Arg11)CCMSH (A) and 99mTc-RVD-Lys-
(Arg11)CCMSH (B). The arrows denote the original retention times of 99mTc-RTD-
Lys-(Arg11)CCMSH (12.7 min) and 99mTc-RVD-Lys-(Arg11)CCMSH (14.6 min) 
prior to tail vein injection. 
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Figure 2.1 
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Figure 2.2 
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Figure 2.3 
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Figure 2.4 
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Figure 2.5 
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Figure 2.6 
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Figure 2.7 
 
 
 
m
V
0
20
40
60
80
100
120
140
160
180
Minutes
2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32
m
V
0
2
4
6
8
10
Minutes
2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32
12
B
A
75 
 
Chapter 3 
Effects of amino acids on melanoma targeting and clearance properties of 
Tc-99m-labeled Arg-X-Asp-conjugated α-melanocyte stimulating hormone 
peptides 
 
Introduction 
Malignant melanoma is the most lethal form of skin cancer with an 
increasing incidence [3]. Unfortunately, no curative treatment exists for 
metastatic melanoma. It is of great interest to develop receptor-targeting imaging 
probes for melanoma. Both melanocortin-1 (MC1) and αvβ3 integrin receptors 
have been attractive molecular targets for developing melanoma imaging probes 
[91, 100, 103, 105, 125, 129, 130, 132-134, 136-145, 147].  Generally, the 
radiolabeled α-melanocyte stimulating hormone (α-MSH) peptides could target 
the MC1 receptors [91, 100, 103, 105, 129-137], whereas the radiolabeled Arg-
Gly-Asp (RGD) peptides could bind to the αvβ3 integrin receptors [138-145]. In 
2010, we reported a novel α-MSH hybrid peptide which could target both MC1 
and αvβ3 integrin receptors [127].  Specifically, a cyclic RGD motif {Arg-Gly-Asp-
DTyr-Asp} was attached to [Cys3,4,10, D-Phe7, Arg11]-MSH3-13 peptide via a lysine 
linker to yield RGD-Lys-(Arg11)CCMSH peptide. The dual receptor-targeting 
99mTc-RGD-Lys-(Arg11)CCMSH displayed enhanced melanoma uptake as 
compared to single receptor-targeting 99mTc-RAD-Lys-(Arg11)CCMSH or 99mTc-
RGD-Lys-(Arg11)CCMSHscramble in M21 human melanoma-xenografts [127]. 
Interestingly, the substitution of Gly in 99mTc-RGD-Lys-(Arg11)CCMSH with Ala, 
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Thr and Val improved the MC1 receptor binding affinities and enhanced the 
melanoma uptake in B16/F1 melanoma-bearing C57 mice [127, 128, 148].These 
interesting findings suggested that the single amino acid at that specific position 
generated a profound impact on the MC1 receptor binding affinity. 
The structural differences among Gly, Ala, Thr and Val were minimal. As 
compared to Gly, the Ala has one extra -CH3 group, the Thr has one extra -
CH(OH)CH3 group, whereas the Val has one extra -CH(CH3)2 group. The 
comparison in biodistribution results of 99mTc-RXD-Lys-(Arg11)CCMSH (X = Gly, 
Ala, Thr and Val) demonstrated that such subtle structural modification retained 
high melanoma uptake in B16/F1 melanoma-bearing C57 mice. Thus, we were 
interested in whether and how other amino acids could affect the melanoma 
targeting and pharmacokinetic properties of 99mTc-RXD-Lys-(Arg11)CCMSH 
peptide. For instance, whether and how a long hydrocarbon chain and a bulky 
benzene ring could affect the receptor binding and melanoma targeting 
properties of the peptides. In this study, we replaced the Gly with Ser, Nle, Phe 
and DPhe to generate four new peptides, namely RSD-Lys-(Arg11)CCMSH,  
RNleD-Lys-(Arg11)CCMSH, RFD-Lys-(Arg11)CCMSH and RfD-Lys-
(Arg11)CCMSH peptides. The MC1 receptor binding affinities of these four 
peptides were examined in B16/F1 melanoma cells. Based on the receptor 
binding affinities, we further radiolabeled RSD-Lys-(Arg11)CCMSH,  RFD-Lys-
(Arg11)CCMSH and RfD-Lys-(Arg11)CCMSH with 99mTc. Then we determined the 
cellular internalization and efflux in B16/F1 melanoma cells and biodistribion 
properties in B16/F1 melanoma-bearing C57 mice for these three 99mTc-peptides. 
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Thereafter, we determined the imaging property of 99mTc-RSD-Lys-
(Arg11)CCMSH in B16/F1 melanoma-bearing C57 mice. 
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Experimental design and methods 
 
Chemicals and Reagents 
 
Amino acids and resin were purchased from Advanced ChemTech Inc. 
(Louisville, KY) and Novabiochem (San Diego, CA). 125I-Tyr2-[Nle4, DPhe7]-α-
MSH {125I-(Tyr2)-NDP-MSH} was obtained from PerkinElmer, Inc. (Waltham, MA) 
for receptor binding assay. 99mTcO4
- was purchased from Cardinal Health 
(Albuquerque, NM). L-lysine was purchased from Sigma-Aldrich (St. Louis, MO). 
All other chemicals used in this study were purchased from Thermo Fischer 
Scientific (Waltham, MA) and used without further purification. B16/F1 murine 
melanoma cells were obtained from American Type Culture Collection 
(Manassas, VA). 
 
Peptide Synthesis and In Vitro Competitive Binding Assay 
 
The RSD-Lys-(Arg11)CCMSH,  RNleD-Lys-(Arg11)CCMSH, RFD-Lys-
(Arg11)CCMSH and RfD-Lys-(Arg11)CCMSH peptides were synthesized using 
fluorenylmethyloxycarbonyl (Fmoc) chemistry according to our previously 
published procedure [146] with slight modification on Sieber amide resin by an 
Advanced ChemTech multiple-peptide synthesizer (Louisville, KY). Briefly, 70 
µmol of Sieber amide resin and 210 µmol of Fmoc-protected amino acids were 
used for the synthesis. Fmoc-Lys(Boc) was used to generate a Lys linker in each 
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peptide. Intermediate scaffolds of H2N-Arg(Pbf)-Ser/Nle/Phe/DPhe-Asp(OtBu)-
DTyr(tBu)-Asp(O-2-phenylisopropyl)-Lys(Boc)-Cys(Trt)-Cys(Trt)-Glu(OtBu)-
His(Trt)-DPhe-Arg(Pbf)-Trp(Boc)-Cys(Trt)-Arg(Pbf)-Pro-Val were synthesized on 
Sieber amide resin. The protecting group of 2-phenylisopropyl of each scaffold 
was removed and each peptide was cleaved from the resin treating with a 
mixture of 2.5% of trifluoroacetic acid (TFA) and 5% of triisopropylsilane. After 
the precipitation with ice-cold ether and characterization by MS, each protected 
peptide was dissolved in H2O/CH3CN (50:50) and lyophilized to remove the 
reagents such as TFA and triisopropylsilane. Each protected peptide was further 
cyclized by coupling the carboxylic group from the Asp with the alpha amino 
group from the Arg at the N-terminus. The cyclization reaction was achieved by 
overnight reaction in dimethylformamide (DMF) using benzotriazole-1-yl-oxy-tris-
pyrrolidino-phosphonium-hexafluorophosphate (PyBOP) as a coupling agent in 
the presence of N,N-diisopropylethylamine (DIPEA). The protecting groups were 
totally removed by treating with a mixture of TFA, thioanisole, phenol, water, 
ethanedithiol and triisopropylsilane (87.5:2.5:2.5:2.5:2.5:2.5) for 2 h at room 
temperature (25 °C). Each peptide was precipitated and washed with ice-cold 
ether for four times, purified by RP-HPLC and characterized by MS. The 
chemical purity of each peptide was determined by Waters RP-HPLC (Milford, 
MA) on a Grace Vydac C-18 reverse phase analytic column (Deerfield, IL) using 
a 20-min gradient of 16-26% acetonitrile in 20 mM HCl aqueous solution at a flow 
rate of 1 mL/min. The purities of all four peptides were greater than 95%. 
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The IC50 values of RSD-Lys-(Arg
11)CCMSH,  RNleD-Lys-(Arg11)CCMSH, 
RFD-Lys-(Arg11)CCMSH and RfD-Lys-(Arg11)CCMSH peptides for the MC1 
receptor were determined in B16/F1 melanoma cells. The receptor binding assay 
was replicated in triplicate for each peptide. The B16/F1 cells were seeded into a 
24-well cell culture plate at a density of 2.5 × 105 cells/well and incubated at 37° 
C overnight. After being washed with binding medium {modified Eagle’s medium 
with 25 mM N-(2-hydroxyethyl)-piperazine-N′-(2-ethanesulfonic acid) (HEPES), 
pH 7.4, 0.2% bovine serum albumin (BSA), 0.3 mM 1,10-phenathroline}, the cells 
were incubated at 25 °C for 2 h with approximately 30,000 counts per minute 
(cpm) of 125I-(Tyr2)-NDP-MSH in the presence of increasing concentrations (10-13 
M to 10-6 M) of each peptide in 0.3 mL of binding medium. The reaction medium 
was aspirated after the incubation. The cells were rinsed twice with 0.5 mL of ice-
cold pH 7.4, 0.2% BSA/0.01 M phosphate buffered saline (PBS) to remove any 
unbound radioactivity and lysed in 0.5 mL of 1 M NaOH for 5 min. The activities 
associated with the cells were measured in a Wallac 2480 automated gamma 
counter (PerkinElmer, NJ). The IC50 value for each peptide was calculated using 
Prism software (GraphPad Software, La Jolla, CA). 
 
Peptide Radiolabeling 
 
Because RNleD-Lys-(Arg11)CCMSH exhibited lowest receptor binding 
affinity among four peptides, we only further evaluated the other three peptides. 
RSD-Lys-(Arg11)CCMSH,  RFD-Lys-(Arg11)CCMSH and RfD-Lys-(Arg11)CCMSH 
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peptides were labeled with 99mTc via a direct reduction reaction with SnCl2. 
Briefly, 10 μL of 1 mg/mL SnCl2 in 0.1 M HCl, 40 μL of 0.5 M NH4OAc (pH 5.2), 
100 μL of 0.2 M Na2tartate (pH 9.2), 100 μL of fresh 
99mTcO4
- solution (37-74 
MBq), and 10 μL of 1 mg/mL of each peptide in aqueous solution were added 
into a reaction vial and incubated at 25 °C for 20 min to form 99mTc-labeled 
peptide. Each 99mTc-peptide was purified to a single species by Waters RP-HPLC 
(Milford, MA) on a Grace Vydac C-18 reverse phase analytic column (Deerfield, 
IL) using a 20-min gradient of 16-26% acetonitrile in 20 mM HCl aqueous 
solution at a flow rate of 1 mL/min. Each purified peptide was purged with N2 gas 
for 20 min to remove the acetonitrile. The pH of final peptide solution was 
adjusted to 7.4 with 0.1 N NaOH and sterile normal saline for stability, 
biodistribution and imaging studies. The serum stabilities of 99mTc-RSD-Lys-
(Arg11)CCMSH,  99mTc-RFD-Lys-(Arg11)CCMSH  and 99mTc-RfD-Lys-
(Arg11)CCMSH were determined by incubation in mouse serum at 37 C for 24 h 
and monitored for degradation by RP-HPLC. Briefly, 100 µL of HPLC-purified 
peptide solution (~7.4 MBq) was added into 100 µL of mouse serum (Sigma-
Aldrich Corp, St. Louis, MO) and incubated at 37 oC for 24 h. After the 
incubation, 200 µL of a mixture of ethanol and acetonitrile (V:V = 1:1) was added 
to precipitate the serum proteins. The resulting mixture was centrifuged at 16,000 
g for 5 min to collect the supernatant. The supernatant was purged with N2 gas 
for 30 min to remove the ethanol and acetonitrile. The resulting sample was 
mixed with 500 µL of water and injected into RP-HPLC for analysis using the 
gradient described above.   
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Cellular Internalization and Efflux  
 
Cellular internalization and efflux of 99mTc-RSD-Lys-(Arg11)CCMSH,  
99mTc-RFD-Lys-(Arg11)CCMSH  and 99mTc-RfD-Lys-(Arg11)CCMSH were 
evaluated in B16/F1 melanoma cells. The B16/F1 cells were seeded into a 24-
well cell culture plate at a density of 2.5 × 105 cells/well and incubated at 37° C 
overnight. After being washed twice with binding medium [modified Eagle's 
medium with 25 mM N-(2-hydroxyethyl)-piperazine-N’-(2-ethanesulfonic acid), pH 
7.4, 0.2% bovine serum albumin (BSA), 0.3 mM 1,10-phenathroline], the B16/F1 
cells were incubated at 25C for 20, 40, 60, 90 and 120 min (n=3) in the 
presence of approximate 300,000 counts per minute (cpm) of HPLC-purified of 
99mTc-RSD-Lys-(Arg11)CCMSH,  99mTc-RFD-Lys-(Arg11)CCMSH  or 99mTc-RfD-
Lys-(Arg11)CCMSH. After incubation, the reaction medium was aspirated and the 
cells were rinsed with 2  0.5 mL of ice-cold pH 7.4, 0.2% BSA / 0.01 M PBS. 
Cellular internalization was assessed by washing the cells with acidic buffer [40 
mM sodium acetate (pH 4.5) containing 0.9% NaCl and 0.2% BSA] to remove the 
membrane-bound radioactivity. The remaining internalized radioactivity was 
obtained by lysing the cells with 0.5 mL of 1 N NaOH for 5 min. Membrane-bound 
and internalized activities were counted in a gamma counter. Cellular efflux was 
determined by incubating the B16/F1 cells with 99mTc-RSD-Lys-(Arg11)CCMSH,  
99mTc-RFD-Lys-(Arg11)CCMSH  or 99mTc-RfD-Lys-(Arg11)CCMSH for 2 h at 25C, 
removing non-specific-bound activity with 2  0.5 mL of ice-cold PBS rinse, and 
monitoring radioactivity released into cell culture medium. At time points of 20, 
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40, 60, 90 and 120 min, the radioactivities on the cell surface and inside the cells 
were separately collected and counted in a gamma counter. 
 
Biodistribution Studies  
 
All the animal studies were conducted in compliance with Institutional 
Animal Care and Use Committee approval. The biodistribution properties of 
99mTc-RSD-Lys-(Arg11)CCMSH,  99mTc-RFD-Lys-(Arg11)CCMSH  and 99mTc-RfD-
Lys-(Arg11)CCMSH were determined in B16/F1 melanoma-bearing C57 female 
mice (Harlan, Indianapolis, IN). Each C57 mouse was subcutaneously inoculated 
on the right flank with 1106 B16/F1 cells. The weight of tumors reached 
approximately 0.2 g 10 days post cell inoculation. Each melanoma-bearing 
mouse was injected with 0.037 MBq of 99mTc-RSD-Lys-(Arg11)CCMSH,  99mTc-
RFD-Lys-(Arg11)CCMSH  or 99mTc-RfD-Lys-(Arg11)CCMSH via the tail vein. 
Groups of 4 mice were sacrificed at 0.5, 2, 4 and 24 h post-injection, and tumors 
and organs of interest were harvested, weighed and counted. Blood values were 
taken as 6.5% of the body weight. The specificity of tumor uptake was 
determined by co-injecting 99mTc-RSD-Lys-(Arg11)CCMSH,  99mTc-RFD-Lys-
(Arg11)CCMSH  or 99mTc-RfD-Lys-(Arg11)CCMSH with 10 g (6.1 nmol) of 
unlabeled NDP-MSH at 2 h post-injection. 
L-lysine co-injection is effective in decreasing the renal uptake of 
radiolabeled α-MSH peptides. Because 99mTc-RSD-Lys-(Arg11)CCMSH exhibited 
the highest tumor uptake and fastest urinary clearance among three 99mTc-
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peptdes, we only examined the effect of L-lysine co-injection on the renal uptake 
of 99mTc-RSD-Lys-(Arg11)CCMSH. Briefly, a group of 4 mice were injected with a 
mixture of 0.037 MBq of 99mTc-RSD-Lys-(Arg11)CCMSH and 15 mg of L-lysine. 
The mice were sacrificed at 2 h post-injection, and tumors and organs of interest 
were harvested, weighed and counted in a gamma counter. 
 
Melanoma Imaging with 99mTc-RSD-Lys-(Arg11)CCMSH 
 
99mTc-RSD-Lys-(Arg11)CCMSH was the lead peptide due to its higher 
tumor uptake and faster urinary clearance. Thus, we further determined the 
melanoma imaging property of 99mTc-RSD-Lys-(Arg11)CCMSH. Approximately 
4.1 MBq of 99mTc-RSD-Lys-(Arg11)CCMSH was injected into a B16/F1 
melanoma-bearing C57 mouse via the tail vein. The mouse was euthanized for 
small animal SPECT/CT (Nano-SPECT/CT®, Bioscan, Washington DC) imaging 
2 h post-injection. The 9-min CT imaging was immediately followed by the 
SPECT imaging of whole-body. The SPECT scans of 24 projections were 
acquired. Reconstructed data from SPECT and CT were visualized and co-
registered using InVivoScope (Bioscan, Washington DC). 
 
Urinary Metabolites of 99mTc-RSD-Lys-(Arg11)CCMSH 
 
We also examined the urinary metabolites of 99mTc-RSD-Lys-
(Arg11)CCMSH. Approximately 3.7 MBq of 99mTc-RSD-Lys-(Arg11)CCMSH was 
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injected into a B16/F1 melanoma-bearing C57 mouse via the tail vein to 
determine the urinary metabolites. The mouse was euthanized to collect urine at 
2 h post-injection. The collected urine sample was centrifuged at 16,000 g for 5 
min before the HPLC analysis. Thereafter, an aliquot of the urine was injected 
into the HPLC. A 20-minute gradient of 16-26% acetonitrile / 20 mM HCl with a 
flow rate of 1 mL/min was used for urine analysis. 
 
Statistical Analysis 
 
Statistical analysis was performed using the Student’s t-test for unpaired 
data to determine the significance of differences in tumor and kidney uptake 
with/without peptide blockade or with/without L-lysine co-injection in 
biodistribution studies described above. Differences at the 95% confidence level 
(p<0.05) were considered significant. 
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Results 
The schematic structures of RSD-Lys-(Arg11)CCMSH,  RNleD-Lys-
(Arg11)CCMSH, RFD-Lys-(Arg11)CCMSH and RfD-Lys-(Arg11)CCMSH are 
presented in Figure 3.1. The peptides were synthesized and purified by reverse 
phase-high performance liquid chromatography (RP-HPLC). The overall 
synthetic yields were 30% for all four peptides. The chemical purities of RSD-
Lys-(Arg11)CCMSH,  RNleD-Lys-(Arg11)CCMSH, RFD-Lys-(Arg11)CCMSH and 
RfD-Lys-(Arg11)CCMSH were greater than 95% after the HPLC purification. The 
peptide identities were confirmed by electrospray mass spectrometry (MS). The 
measured molecular weight was 2180 for RSD-Lys-(Arg11)CCMSH,  2206 for 
RNleD-Lys-(Arg11)CCMSH, 2240 for RFD-Lys-(Arg11)CCMSH and RfD-Lys-
(Arg11)CCMSH (Table 3.1). The competitive binding curves of the peptides are 
shown in Figure 3.2. The IC50 value was 1.30 ± 0.36 nM for RSD-Lys-
(Arg11)CCMSH, 2.99 ± 0.26 nM for RNleD-Lys-(Arg11)CCMSH, 0.82 ± 0.06 nM 
for RFD-Lys-(Arg11)CCMSH, and 1.35 ± 0.08 nM for RfD-Lys-(Arg11)CCMSH in 
B16/F1 melanoma cells, respectively. 
Because RNleD-Lys-(Arg11)CCMSH exhibited lowest receptor binding 
affinity among four peptides, as well as lower receptor binding affinity than that of 
RGD-Lys-(Arg11)CCMSH in our previous report [146], we only further evaluated 
the other three peptides. RSD-Lys-(Arg11)CCMSH,  RFD-Lys-(Arg11)CCMSH and 
RfD-Lys-(Arg11)CCMSH were readily radiolabeled with 99mTc with greater than 
95% radiolabeling yields. All three 99mTc-peptides were separated from their 
excess non-labeled peptides by RP-HPLC. The radiochemical purities of three 
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99mTc-peptides were greater than 99% (Table 3.1). The specific activities of 
99mTc-RSD-Lys-(Arg11)CCMSH, 99mTc-RFD-Lys-(Arg11)CCMSH and 99mTc-RfD-
Lys-(Arg11)CCMSH were 8.834  109, 8.598  109 , 8.598  109 MBq/g, 
respectively. The retention times of 99mTc-RSD-Lys-(Arg11)CCMSH, 99mTc-RFD-
Lys-(Arg11)CCMSH and 99mTc-RfD-Lys-(Arg11)CCMSH were 12.5, 18.4 and 20.8 
min, respectively. 99mTc-RSD-Lys-(Arg11)CCMSH, 99mTc-RFD-Lys-(Arg11)CCMSH 
and 99mTc-RfD-Lys-(Arg11)CCMSH were stable in mouse serum at 37°C for 24 h 
(Figure 3.3). Cellular internalization and efflux properties of 99mTc-RSD-Lys-
(Arg11)CCMSH, 99mTc-RFD-Lys-(Arg11)CCMSH and 99mTc-RfD-Lys-
(Arg11)CCMSH were examined in B16/F1 cells. Figure 3.4 illustrates the 
internalization and efflux properties of 99mTc-RSD-Lys-(Arg11)CCMSH, 99mTc-
RFD-Lys-(Arg11)CCMSH and 99mTc-RfD-Lys-(Arg11)CCMSH. All three 99mTc-
peptides exhibited rapid cellular internalization and prolonged cellular retention. 
Approximately 69% of 99mTc-RSD-Lys-(Arg11)CCMSH, 87% of 99mTc-RFD-Lys-
(Arg11)CCMSH and 87% of 99mTc-RfD-Lys-(Arg11)CCMSH activities were 
internalized in the cells after 20 min of incubation. Cellular efflux results indicated 
that 76% of 99mTc-RSD-Lys-(Arg11)CCMSH, 73% of 99mTc-RFD-Lys-
(Arg11)CCMSH and 46% of 99mTc-RfD-Lys-(Arg11)CCMSH activities remained 
inside the cells after 2 h of incubation in the culture medium.  
The melanoma targeting and pharmacokinetic properties of 99mTc-RSD-
Lys-(Arg11)CCMSH, 99mTc-RFD-Lys-(Arg11)CCMSH and 99mTc-RfD-Lys-
(Arg11)CCMSH are shown in Tables 3.2-3.4. Both 99mTc-RFD-Lys-(Arg11)CCMSH 
and 99mTc-RfD-Lys-(Arg11)CCMSH exhibited similar tumor uptake pattern in 
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B16/F1 melanoma-bearing C57 mice. 99mTc-RFD-Lys-(Arg11)CCMSH exhibited 
its highest tumor uptake of 15.01 ± 4.40% ID/g at 4 h post-injection, whereas 
99mTc-RfD-Lys-(Arg11)CCMSH reached its highest tumor uptake of 13.11 ± 1.21% 
ID/g at 4 h post-injection. The tumor uptake values of 99mTc-RFD-Lys-
(Arg11)CCMSH and 99mTc-RfD-Lys-(Arg11)CCMSH decreased to 7.19 ± 1.02 and 
6.29 ± 1.39% ID/g by 24 h post-injection. The tumor blocking studies revealed 
that co-injection of 10 μg (6.1 nM) of non-radiolabeled NDP-MSH with 99mTc-
RFD-Lys-(Arg11)CCMSH or 99mTc-RfD-Lys-(Arg11)CCMSH decreased their tumor 
uptake values to 2.82 ± 0.48 and 1.57 ± 0.48% ID/g at 2 h post-injection, 
demonstrating that the tumor uptake was MC1 receptor-mediated. 99mTc-RSD-
Lys-(Arg11)CCMSH displayed a different tumor uptake pattern as compared to 
99mTc-RFD-Lys-(Arg11)CCMSH and 99mTc-RfD-Lys-(Arg11)CCMSH. 99mTc-RSD-
Lys-(Arg11)CCMSH exhibited rapid and high melanoma uptake of 18.01 ± 4.22% 
ID/g at 30 min post-injection. The tumor uptake of 99mTc-RSD-Lys-(Arg11)CCMSH 
gradually reduced to 8.04 ± 1.80% ID/g at 24 h post-injection. Furthermore, co-
injection of 10 μg (6.1 nM) of non-radiolabeled NDP-MSH with 99mTc-RSD-Lys-
(Arg11)CCMSH decreased their tumor uptake value to 2.35 ± 0.01% ID/g at 2 h 
post-injection, demonstrating that the tumor uptake was MC1 receptor-mediated.   
Kidneys were the excretion pathways for 99mTc-RSD-Lys-(Arg11)CCMSH, 
99mTc-RFD-Lys-(Arg11)CCMSH and 99mTc-RfD-Lys-(Arg11)CCMSH. The renal 
uptake values of 99mTc-RSD-Lys-(Arg11)CCMSH, 99mTc-RFD-Lys-(Arg11)CCMSH 
and 99mTc-RfD-Lys-(Arg11)CCMSH were 80.01 ± 15.67,  88.08 ± 9.31 and 111.54 
± 10.19% ID/g at 2 h post injection, respectively. At 24 h post-injection, The renal 
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uptake values of for 99mTc-RSD-Lys-(Arg11)CCMSH, 99mTc-RFD-Lys-
(Arg11)CCMSH and 99mTc-RfD-Lys-(Arg11)CCMSH decreased to 23.15 ± 2.94,  
51.01 ± 3.62 and 73.05 ± 9.87% ID/g, respectively. Liver uptake was different 
among these three 99mTc-peptides. 99mTc-RSD-Lys-(Arg11)CCMSH demonstrated 
lower liver uptake than 99mTc-RFD-Lys-(Arg11)CCMSH and 99mTc-RfD-Lys-
(Arg11)CCMSH. The liver uptake of 99mTc-RSD-Lys-(Arg11)CCMSH, 99mTc-RFD-
Lys-(Arg11)CCMSH and 99mTc-RfD-Lys-(Arg11)CCMSH were 1.22 ± 0.12,  9.87 ± 
1.26 and 5.29 ± 1.30% ID/g at 2 h post injection, respectively. 
 99mTc-RSD-Lys-(Arg11)CCMSH exhibited faster whole-body clearance 
than 99mTc-RFD-Lys-(Arg11)CCMSH and 99mTc-RfD-Lys-(Arg11)CCMSH. 
Approximately 68% of 99mTc-RSD-Lys-(Arg11)CCMSH cleared through the urinary 
system by 2 h post-injection, whereas approximately 43% of 99mTc-RFD-Lys-
(Arg11)CCMSH and 44% of 99mTc-RfD-Lys-(Arg11)CCMSH washed through the 
urinary system by 2 h post-injection. At 24 h post-injection, 84% of 99mTc-RSD-
Lys-(Arg11)CCMSH, 76% of 99mTc-RFD-Lys-(Arg11)CCMSH and 73% of 99mTc-
RfD-Lys-(Arg11)CCMSH cleared out the body. 99mTc-RSD-Lys-(Arg11)CCMSH 
also displayed lower normal organ uptake than 99mTc-RFD-Lys-(Arg11)CCMSH 
and 99mTc-RfD-Lys-(Arg11)CCMSH. Normal organ uptake of 99mTc-RSD-Lys-
(Arg11)CCMSH was minimal (<1.2% ID/g) except for the kidneys after 2 h post-
injection. 
Since 99mTc-RSD-Lys-(Arg11)CCMSH showed higher tumor uptake and 
faster urinary clearance than 99mTc-RFD-Lys-(Arg11)CCMSH and 99mTc-RfD-Lys-
(Arg11)CCMSH, the effect of L-lysine co-injection on the tumor and renal uptake 
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of 99mTc-RSD-Lys-(Arg11)CCMSH was examined in B16/F1 melanoma-bearing 
C57 mice. L-lysine co-injection significantly (*p<0.05) reduced the renal uptake of 
99mTc-RSD-Lys-(Arg11)CCMSH by 37% at 2 h post-injection without affecting the 
tumor uptake (Figure 3.5). Whole-body single photon emission computed 
tomography (SPECT)/CT image at 2 h post-injection are presented in Figure 3.6.  
Flank B16/F1 melanoma lesions were clearly visualized by SPECT using 99mTc-
RSD-Lys-(Arg11)CCMSH peptide as an imaging probe. The SPECT image of 
tumor accurately matched its anatomical location obtained in the CT image. The 
SPECT image showed high contrast of tumor to normal organ except for kidneys, 
which was consistent with the biodistribution results. The urinary metabolites of 
99mTc-RSD-Lys-(Arg11)CCMSH at 2 h post-injection are shown in Figure 3.7. 
Approximately 70% of 99mTc-RSD-Lys-(Arg11)CCMSH remained intact in the 
urine at 2 h post-injection, while 30% of the 99mTc-RSD-Lys-(Arg11)CCMSH was 
transformed to a more hydrophobic compound.  
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Discussion 
In our previous reports [24-26] we have found the important role of Gly in 
the tumor targeting property of 99mTc-RGD-Lys-(Arg11)CCMSH in B16/F1 
melanoma-bearing C57 mice. Despite the minimal structural differences among 
Gly, Ala, Thr and Val amino acids, the replacement of Gly in RGD-Lys-
(Arg11)CCMSH with Ala, Thr and Val enhanced the MC1 receptor binding 
affinities and B16/F1 melanoma uptake of the peptides [24-26]. In this study, we 
further investigated whether the substitution of Gly with a longer hydrocarbon 
chain (Nle) and a bulky benzene ring (Phe or DPhe) could affect the receptor 
binding and melanoma targeting properties of the peptides. On the other hand, 
we hypothesized that the replacement of Gly with Ser would facilitate the urinary 
clearance of the peptide as compared to hydrophobic Nle, Phe and DPhe. Thus, 
we synthesized and evaluated RSD-Lys-(Arg11)CCMSH,  RNleD-Lys-
(Arg11)CCMSH, RFD-Lys-(Arg11)CCMSH and RfD-Lys-(Arg11)CCMSH peptides 
in this study. 
The introduction of Ser, Nle, Phe and DPhe generated different impact on 
the MC1 receptor binding affinities of the peptides. The linear long hydrocarbon 
chain from Nle decreased the MC1 receptor binding affinity of the peptide, 
whereas the short CH2OH group from Ser and the bulky benzene ring from Phe 
and DPhe increased the MC1 receptor binding affinity of the peptides. Among 
these four new peptides, RNleD-Lys-(Arg11)CCMSH displayed the weakest MC1 
receptor binding affinity of 2.99 ± 0.26 nM, whereas RSD-Lys-(Arg11)CCMSH and 
RfD-Lys-(Arg11)CCMSH exhibited similar strong MC1 receptor binding affinities of 
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1.30 ± 0.36 and 1.35 ± 0.08 nM. Overall, RfD-Lys-(Arg11)CCMSH showed the 
strongest MC1 receptor binding affinity of 0.82 ± 0.06 nM. Despite that the -His-
DPhe-Arg-Trp- motif is the binding moiety to MC1 receptor, the difference in 
receptor binding affinity indicated that the Ser, Nle, Phe and DPhe interacted with 
the receptor binding moiety. Such subtle interactions were likely related to the 
flexibility of lactam bonds among amino acid residues in the peptides. In our 
previous report [25,26], the MC1 receptor binding affinities were 2.1, 0.3, 0.7 and 
1.0 nm for RGD-Lys-(Arg11)CCMSH, RAD-Lys-(Arg11)CCMSH, RTD-Lys-
(Arg11)CCMSH and RVD-Lys-(Arg11)CCMSH in B16/F1 cells, respectively. 
Clearly, RNleD-Lys-(Arg11)CCMSH displayed the weakest MC1 receptor binding 
affinity among all RXD-Lys-(Arg11)CCMSH peptides. Thus, we further 
radiolabeled RSD-Lys-(Arg11)CCMSH,  RFD-Lys-(Arg11)CCMSH and RfD-Lys-
(Arg11)CCMSH with 99mTc and evaluated their cellular internalization and efflux 
properties, as well as their in vivo biodistribution and clearance properties. It is 
worthwhile to note that three cysteine residues in each peptide provide a NS3 
chelating system for 99mTc. It was reported that non-radioactive rhenium-
conjugated (Arg11)CCMSH retained comparable nanomolar MC1 receptor 
binding affinity as (Arg11)CCMSH peptide (1.9 vs. 1.7 nM) [149]. Accordingly, the 
radiolabeling of three RXD-Lys-(Arg11)CCMSH peptides with 99mTc should retain 
their nanomolar binding affinities. 
99mTc-RSD-Lys-(Arg11)CCMSH, 99mTc-RFD-Lys-(Arg11)CCMSH and 99mTc-
RfD-Lys-(Arg11)CCMSH exhibited similar rapid internalization and prolonged 
efflux properties in B16/F1 melanoma cells. Despite the similar pattern in cellular 
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internalization and efflux properties, 99mTc-RSD-Lys-(Arg11)CCMSH displayed a 
different tumor uptake pattern as compared to 99mTc-RFD-Lys-(Arg11)CCMSH 
and 99mTc-RfD-Lys-(Arg11)CCMSH. 99mTc-RSD-Lys-(Arg11)CCMSH exhibited 
rapid and high melanoma uptake of 18.01 ± 4.22% ID/g at 30 min post-injection. 
Meanwhile, 99mTc-RSD-Lys-(Arg11)CCMSH displayed lower renal uptake than 
99mTc-RFD-Lys-(Arg11)CCMSH and 99mTc-RfD-Lys-(Arg11)CCMSH. The renal 
uptake of 99mTc-RSD-Lys-(Arg11)CCMSH was 45% of the renal uptake of 99mTc-
RFD-Lys-(Arg11)CCMSH, and 32% of the renal uptake of 99mTc-RfD-Lys-
(Arg11)CCMSH at 24 h post-injection. Not surprisingly, 99mTc-RSD-Lys-
(Arg11)CCMSH also showed lower liver uptake than 99mTc-RFD-Lys-
(Arg11)CCMSH and 99mTc-RfD-Lys-(Arg11)CCMSH. The liver uptake of 99mTc-
RSD-Lys-(Arg11)CCMSH was 12% of the liver uptake of 99mTc-RFD-Lys-
(Arg11)CCMSH, and 23% of the liver uptake of 99mTc-RfD-Lys-(Arg11)CCMSH at 2 
h post-injection. Furthermore, 99mTc-RSD-Lys-(Arg11)CCMSH exhibited faster 
urinary clearance than 99mTc-RFD-Lys-(Arg11)CCMSH and 99mTc-RfD-Lys-
(Arg11)CCMSH. Interestingly, the stereochemistry of Phe and DPhe affected the 
renal and liver uptake. 99mTc-RFD-Lys-(Arg11)CCMSH displayed higher liver 
uptake than that of 99mTc-RfD-Lys-(Arg11)CCMSH, whereas 99mTc-RfD-Lys-
(Arg11)CCMSH displayed higher renal uptake than that of 99mTc-RFD-Lys-
(Arg11)CCMSH. Clearly, the tumor targeting and clearance properties of 99mTc-
RSD-Lys-(Arg11)CCMSH were more favorable than those of 99mTc-RFD-Lys-
(Arg11)CCMSH and 99mTc-RfD-Lys-(Arg11)CCMSH. 
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The B16/F1 melanoma lesions could be clearly visualized by SPECT/CT 
using 99mTc-RSD-Lys-(Arg11)CCMSH as an imaging probe. However, the image 
also indicated very high renal uptake. In fact, extremely high renal uptake (67-
135% ID/g at 2 h post-injection) appears to be a common issue for all reported 
99mTc-RXD-Lys-(Arg11)CCMSH peptides [128, 146, 148]. Despite that 99mTc-
RSD-Lys-(Arg11)CCMSH exhibited the second lowest renal uptake (80.01 ± 
15.67% ID/g at 2 h post-injection) among all reported 99mTc-RXD-Lys-
(Arg11)CCMSH peptides, it is desirable to reduce the non-specific renal uptake in 
future studies to facilitate its potential therapeutic application. In this study, L-
lysine co-injection significantly (*p<0.05) reduced the renal uptake of 99mTc-RSD-
Lys-(Arg11)CCMSH by 37% at 2 h post-injection without affecting its tumor 
uptake. Obviously, L-lysine co-injection can be utilized to decrease the renal 
uptake of 99mTc-RSD-Lys-(Arg11)CCMSH in future studies. The effect of L-lysine 
co-injection also highlighted the contribution of the overall positive charge of 
99mTc-RSD-Lys-(Arg11)CCMSH to its renal uptake. Clearly, the substitution of the 
positively-charged Lys linker with a neutral or negatively-charged amino acid (i.e. 
Gly or Glu) can decrease the overall charge of 99mTc-RSD-Lys-(Arg11)CCMSH. 
According to the effect of L-lysine co-injection in this study, it is very likely that 
the substitution of Lys with a neutral or negatively-charged amino acid will 
decrease the renal uptake. 
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Conclusions 
In summary, the substitution of Gly with Ser, Phe and DPhe increased the 
MC1 receptor binding affinities of the peptides, whereas the substitution of Gly 
with Nle decreased the MC1 receptor binding affinity of the peptide in B16/F1 
melanoma cells. 99mTc-RSD-Lys-(Arg11)CCMSH exhibited higher melanoma 
uptake and lower kidney and liver uptake than those of 99mTc-RFD-Lys-
(Arg11)CCMSH and 99mTc-RfD-Lys-(Arg11)CCMSH. The B16/F1 melanoma 
lesions could be clearly visualized by SPECT/CT using 99mTc-RSD-Lys-
(Arg11)CCMSH as an imaging probe. It is desirable to reduce the non-specific 
renal uptake of 99mTc-RSD-Lys-(Arg11)CCMSH to facilitate its potential 
therapeutic application. 
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Tables 
 
Table 3.1. Peptide properties  
Capacity factors, chemical/radiochemical purities and measured molecular 
weights of RXD-Lys-(Arg11)CCMSH peptides and their 99mTc-conjugates. 
 
Peptide 
Capacity 
factor (k’) 
Chemical/Radiochemical 
Purity (%) 
Measured 
Molecular Weight 
(Da) 
RSD-Lys-(Arg11)CCMSH 2.19 97.01 2180 
RNleD-Lys-(Arg11)CCMSH 4.36 95.83 2206 
RFD-Lys-(Arg11)CCMSH 3.77 98.25 2240 
RfD-Lys-(Arg11)CCMSH 3.86 95.75 2240 
99mTc-RSD-Lys-(Arg11)CCMSH 3.18 99.75 ND 
99mTc-RFD-Lys-(Arg11)CCMSH 4.93 99.27 ND 
99mTc-RfD-Lys-(Arg11)CCMSH 5.13 99.78 ND 
 
ND = not determined. 
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Table 3.2.  Biodistribution of 99mTc-RSD-Lys-(Arg11)CCMSH  
Biodistribution of 99mTc-RSD-Lys-(Arg11)CCMSH in B16/F1 melanoma-bearing 
C57 mice. The data was presented as percent injected dose/gram or as percent 
injected dose (mean  SD, n=4). 
 
Tissue 0.5 h 2 h 4 h 24 h 2 h NDP Blockade 
Percent injected dose/gram (%ID/g) 
Tumor 18.01 ± 4.22 17.42 ± 1.52 10.12 ± 1.72 8.04 ± 1.80 2.35 ± 0.01* 
Brain 0.25 ± 0.12 0.02 ± 0.01 0.01 ± 0.01 0.06 ± 0.01 0.05 ± 0.01 
Blood 13.59 ± 1.25 0.19 ± 0.11 0.06 ± 0.04 2.01 ± 1.52 0.69 ± 0.42 
Heart 2.14 ± 0.49 0.14 ± 0.05 0.09 ± 0.04 0.14 ± 0.05 0.46 ± 0.30 
Lung 3.69 ± 1.18 0.33 ± 0.13 0.22 ± 0.06 0.27 ± 0.13 0.65 ± 0.16 
Liver 2.25 ± 0.20 1.22 ± 0.12 1.57 ± 0.81 0.70 ± 0.14 1.54 ± 0.11 
Skin 5.31 ± 0.63 0.33 ± 0.10 0.27 ± 0.05 2.19 ± 0.58 0.75 ± 0.02 
Spleen 1.73 ± 0.17 0.18 ± 0.10 0.38 ± 0.15 0.22 ± 0.07 0.28 ± 0.10 
Stomach 2.31 ± 0.31 0.73 ± 0.08 0.61 ± 0.18 0.30 ± 0.17 1.19 ± 0.04 
Kidneys 98.25 ± 13.78 80.01 ± 15.67 69.23 ± 17.41 23.15 ± 2.94 90.41 ± 19.21 
Muscle 1.42 ± 0.57 0.09 ± 0.04 0.07 ± 0.04 1.01 ± 0.50 0.09 ± 0.06 
Pancreas 0.68 ± 0.27 0.04 ± 0.04 0.09 ± 0.06 0.17 ± 0.07 0.15 ± 0.03 
Bone 2.11 ± 0.67 0.44 ± 0.18 0.32 ± 0.19 0.59 ± 0.09 0.47 ± 0.13 
Percent injected dose (%ID) 
Intestines 2.02 ± 0.17 0.63 ± 0.08 1.48 ± 0.22 0.66 ± 0.27 1.06 ± 0.79 
Urine 36.01 ± 2.73 68.19 ± 9.80 74.72 ± 6.63 84.03 ± 2.67 69.99 ± 4.72 
Uptake ratio of tumor/normal tissue 
Tumor/Blood 1.33 91.68 168.67 4.02 3.41 
Tumor/Kidneys 0.18 0.22 0.15 0.35 0.03 
Tumor/Lung 4.88 52.79 46.00 29.78 3.62 
Tumor/Liver 8.00 14.28 6.45 11.49 1.53 
Tumor/Muscle 12.68 193.56 144.57 8.04 26.11 
 
*p<0.05 (p=0.002) for determining the significance of differences in tumor and 
kidney uptake between 99mTc-RSD-Lys-(Arg11)CCMSH with or without NDP-MSH 
peptide blockade at 2 h post-injection. 
  
98 
 
Table 3.3.  Biodistribution of 99mTc-RFD-Lys-(Arg11)CCMSH  
Biodistribution of 99mTc-RFD-Lys-(Arg11)CCMSH in B16/F1 melanoma-bearing 
C57 mice. The data was presented as percent injected dose/gram or as percent 
injected dose (mean  SD, n=4). 
 
Tissue 0.5 h 2 h 4 h 24 h 2 h NDP Blockade 
 Percent injected dose/gram (%ID/g) 
Tumor 7.42 ± 3.56 11.22 ± 1.53 13.11 ± 1.21 6.29 ± 1.39 1.57 ± 0.48* 
Brain 0.21 ± 0.01 0.07 ± 0.01 0.04 ± 0.01 0.01 ± 0.01 0.08 ± 0.01 
Blood 6.78 ± 3.79 1.99 ± 0.24 0.91 ± 0.38 0.23 ± 0.01 1.61 ± 0.01 
Heart 2.63 ± 1.13 0.94 ± 0.11 0.88 ± 0.35 0.14 ± 0.02 0.76 ± 0.17 
Lung 7.51 ± 1.60 3.38 ± 0.48 2.11 ± 0.51 0.38 ± 0.17 2.10 ± 0.29 
Liver 6.75 ± 2.44 9.87 ± 1.26 12.11 ± 1.86 4.73 ± 1.53 6.34 ± 2.19 
Skin 4.27 ± 1.16 1.54 ± 0.20 0.87 ± 0.17 0.46 ± 0.05 1.48 ± 0.44 
Spleen 4.82 ± 1.31 4.40 ± 0.72 4.85 ± 1.33 2.56 ± 0.45 2.40 ± 1.11 
Stomach 6.21 ± 0.37 4.40 ± 3.33 3.80 ± 1.14 0.92 ± 0.44 10.65 ± 2.76 
Kidneys 56.86 ± 16.58 88.08 ± 9.31 81.89 ± 23.37 51.01 ± 3.62 72.29 ± 6.08 
Muscle 1.27 ± 0.42 0.31 ± 0.19 0.21 ± 0.01 0.01 ± 0.01 0.33 ± 0.15 
Pancreas 1.17 ± 0.23 0.38 ± 0.17 0.45 ± 0.01 0.20 ± 0.08 0.19 ± 0.08 
Bone 1.97 ± 0.32 1.11 ± 0.07 0.44 ± 0.25 0.41 ± 0.25 0.05 ± 0.01 
 Percent injected dose (%ID) 
Intestines 3.23 ± 1.73 4.69 ± 1.24 7.02 ± 2.79 1.50 ± 0.50 13.77 ± 11.25 
Urine 30.19 ± 11.73 42.61 ± 2.89 61.42 ± 0.29 75.8 ± 5.02 39.05 ± 10.35 
 Uptake ratio of tumor/normal tissue 
Tumor/Blood 1.09 5.64 14.41 27.35 0.98 
Tumor/Kidneys 0.13 0.13 0.16 0.12 0.02 
Tumor/Lung 0.99 3.38 6.21 16.55 0.75 
Tumor/Liver 1.10 1.14 1.08 1.33 0.25 
Tumor/Muscle 5.84 36.19 62.43 629.00 4.76 
 
*p<0.05 (p=0.001) for determining the significance of differences in tumor and 
kidney uptake between 99mTc-RFD-Lys-(Arg11)CCMSH with or without NDP-MSH 
peptide blockade at 2 h post-injection. 
  
99 
 
Table 3.4.  Biodistribution of 99mTc-RfD-Lys-(Arg11)CCMSH  
Biodistribution of 99mTc-RfD-Lys-(Arg11)CCMSH in B16/F1 melanoma-bearing 
C57 mice. The data was presented as percent injected dose/gram or as percent 
injected dose (mean  SD, n=4). 
 
Tissue 0.5 h 2 h 4 h 24 h 2 h NDP Blockade 
 Percent injected dose/gram (%ID/g) 
Tumor 9.56 ± 2.36 12.68 ± 2.39 15.01 ± 4.40 7.19 ± 1.02 2.82 ± 0.48* 
Brain 0.16 ± 0.01 0.04 ± 0.01 0.03 ± 0.02 0.01 ± 0.01 0.04 ± 0.01 
Blood 7.85 ± 2.12 1.01 ± 0.11 0.45 ± 0.12 0.06 ± 0.01 0.74 ± 0.01 
Heart 2.67 ± 0.89 0.50 ± 0.17 0.45 ± 0.12 0.21 ± 0.08 0.60 ± 0.09 
Lung 6.44 ± 1.81 2.73 ± 1.08 1.19 ± 0.44 0.47 ± 0.22 1.83 ± 0.35 
Liver 6.59 ± 0.61 5.29 ± 1.30 4.47 ± 1.63 4.57 ± 0.45 3.77 ± 1.53 
Skin 4.87 ± 0.41 1.25 ± 0.29 0.85 ± 0.11 0.34 ± 0.08 1.30 ± 0.43 
Spleen 2.98 ± 1.23 1.26 ± 0.45 0.86 ± 0.19 0.76 ± 0.08 0.93 ± 0.36 
Stomach 3.37 ± 1.40 2.71 ± 0.75 1.86 ± 0.46 0.51 ± 0.11 4.49 ± 0.85 
Kidneys 103.75 ± 11.26 111.54 ± 10.19 104.95 ± 8.06 73.05 ± 9.87 111.34 ± 12.41 
Muscle 0.45 ± 0.12 0.04 ± 0.03 0.02 ± 0.01 0.04 ± 0.03 0.03 ± 0.01 
Pancreas 0.48 ± 0.16 0.38 ± 0.15 0.18 ± 0.03 0.05 ± 0.01 0.31 ± 0.11 
Bone 0.07 ± 0.06 0.43 ± 0.07 0.15 ± 0.03 0.19 ± 0.14 0.38 ± 0.30 
 Percent injected dose (%ID) 
Intestines 2.49 ± 0.60 2.58 ± 1.38 3.18 ± 1.08 0.82 ± 0.14 2.65 ± 1.53 
Urine 22.56 ± 12.86 44.49 ± 12.39 50.50 ± 8.66 72.74 ± 7.36 54.88 ± 2.72 
 Uptake ratio of tumor/normal tissue 
Tumor/Blood 1.22 12.55 33.36 119.83 3.81 
Tumor/Kidneys 0.09 0.11 0.14 0.10 0.03 
Tumor/Lung 1.48 4.64 12.61 15.30 1.54 
Tumor/Liver 1.45 2.40 3.36 1.57 0.75 
Tumor/Muscle 21.24 317.00 750.50 179.75 94.00 
 
*p<0.05 (p=0.002) for determining the significance of differences in tumor and 
kidney uptake between 99mTc-RfD-Lys-(Arg11)CCMSH with or without NDP-MSH 
peptide blockade at 2 h post-injection. 
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Figure Legends 
 
Figure 3.1. Schematic structures of RXD-Lys-(Arg11)CCMSH peptides. 
 
Figure 3.2. The competitive binding curves of RSD-Lys-(Arg11)CCMSH (●), 
RNleD-Lys-(Arg11)CCMSH (▲), RFD-Lys-(Arg11)CCMSH (■), and RfD-Lys-
(Arg11)CCMSH (♦) in B16/F1 murine melanoma cells.  The IC50 value was 1.30 ± 
0.36 nM for RSD-Lys-(Arg11)CCMSH, 2.99 ± 0.26 nM for RNleD-Lys-
(Arg11)CCMSH, 0.82 ± 0.06 nM for RFD-Lys-(Arg11)CCMSH, and 1.35 ± 0.08 nM 
for RfD-Lys-(Arg11)CCMSH, respectively. 
 
Figure 3.3. Radioactive HPLC profiles of 99mTc-RSD-Lys-(Arg11)CCMSH (A),  
99mTc-RFD-Lys-(Arg11)CCMSH (B) and 99mTc-RfD-Lys-(Arg11)CCMSH (C) in 
mouse serum after incubation at 37 °C for 24 h. The arrows denote the original 
retention times of 99mTc-RSD-Lys-(Arg11)CCMSH (12.5 min), 99mTc-RFD-Lys-
(Arg11)CCMSH (18.4 min) and 99mTc-RfD-Lys-(Arg11)CCMSH (20.8 min) prior to 
the incubation in mouse serum.  
 
Figure 3.4. Cellular internalization and efflux of 99mTc-RSD-Lys-(Arg11)CCMSH 
(A and B), 99mTc-RFD-Lys-(Arg11)CCMSH (C and D) and 99mTc-RfD-Lys-
(Arg11)CCMSH (E and F) in B16/F1 melanoma cells. Total bound radioactivity 
(♦), internalized radioactivity (■) and cell membrane radioactivity (▲) were 
presented as counts per minute (cpm). 
 
Figure 3.5. Effect of L-lysine co-injection on the tumor and kidney uptakes of 
99mTc-RSD-Lys-(Arg11)CCMSH at 2 h post-injection in B16/F1 melanoma-bearing 
C57 mice. The white ( ) and black ( ) columns represent the tumor and renal 
uptake of 99mTc-RSD-Lys-(Arg11)CCMSH with or without L-lysine co-injection. L-
lysine co-injection significantly (*p<0.05) reduced the renal uptake of 99mTc-RSD-
Lys-(Arg11)CCMSH by 37% at 2 h post-injection without affecting the tumor 
uptake. 
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Figure 3.6. Representative whole-body SPECT/CT image of B16/F1 
melanoma- bearing C57 mice 2 h post injection of 7.4 MBq of 99mTc-RSD-Lys-
(Arg11)CCMSH. Flank melanoma lesions (T) are highlighted with an arrow on the 
image. 
 
Figure 3.7. Radioactive HPLC profiles of urinary metabolites at 2 h post-
injection of 99mTc-RSD-Lys-(Arg11)CCMSH. The arrow denotes the original 
retention time of 99mTc-RSD-Lys-(Arg11)CCMSH (12.5 min) prior to tail vein 
injection. 
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Figure 3.1 
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Figure 3.2 
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Figure 3.3 
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Figure 3.4 
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Figure 3.5 
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Figure 3.6 
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Figure 3.7 
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Chapter 4 
Substitution of the Lys linker with the β-Ala linker dramatically decreased 
the renal uptake of Tc-99m-labeled Arg-X-Asp-conjugated and X-Ala-Asp-
conjugated α-MSH peptides 
 
Introduction 
Melanocortin-1 (MC1) receptor is an attractive molecular target for 
melanoma imaging due to its over-expression on both murine and human 
melanoma cells [90, 91, 95, 100, 101, 105, 127, 129-137]. Recently, we have 
identified a class of 99mTc-labeled α-melanocyte stimulating hormone (α-MSH) 
peptides to target MC1 receptors for melanoma imaging. Specifically, the cyclic 
RXD motifs {Arg-X-Asp-DTyr-Asp, X = Gly, Ala, Val, Thr, Ser, Nle, Phe and DPhe} 
were attached to [Cys3,4,10, DPhe7, Arg11]-MSH3-13 via a lysine linker to yield 
RXD-Lys-(Arg11)CCMSH peptides. Interestingly, single amino acid substitutions 
at the X position yielded a profound impact on the melanoma targeting and 
clearance properties of 99mTc-RXD-Lys-(Arg11)CCMSH peptides. For instance, 
the substitution of Gly in 99mTc-RGD-Lys-(Arg11)CCMSH with Ala, Thr, Val and 
Ser improved the MC1 receptor binding affinities and enhanced the melanoma 
uptake in B16/F1 melanoma-bearing C57 mice [128, 150, 151]. On the other 
hand, the substitution of Gly in 99mTc-RGD-Lys-(Arg11)CCMSH with Nle 
decreased the MC1 receptor binding affinity. Although the substitution of Gly in 
99mTc-RGD-Lys-(Arg11)CCMSH with Phe and DPhe increased the MC1 receptor 
binding affinities, both 99mTc-RFD-Lys-(Arg11)CCMSH and 99mTc-RfD-Lys-
110 
 
(Arg11)CCMSH exhibited much higher liver uptake as compared to 99mTc-RGD-
Lys-(Arg11)CCMSH [151]. 
Despite the promising melanoma targeting results, extremely high renal 
uptake (67-135% ID/g at 2 h post-injection) is a common issue associated with all 
99mTc-RXD-Lys-(Arg11)CCMSH peptides [128, 150, 151]. Thus, it is desirable to 
reduce the non-specific renal uptake of 99mTc-RXD-Lys-(Arg11)CCMSH peptides 
to facilitate their potential therapeutic applications. In our previous reports, L-
lysine co-injection significantly reduced the renal uptake of 99mTc-RXD-Lys-
(Arg11)CCMSH peptides by 37%-51% at 2 h post-injection without affecting their 
tumor uptake [128, 150, 151]. L-lysine is a positively-charged amino acid. The 
effect of L-lysine co-injection in reducing the renal uptake indicated that the 
overall positive charge of the 99mTc-RXD-Lys-(Arg11)CCMSH peptides contributed 
their non-specific renal uptake. Obviously, the substitution of the positively-
charged Lys linker with a neutral amino acid can decrease the overall charges of 
99mTc-RXD-Lys-(Arg11)CCMSH peptides. According to the effect of L-lysine co-
injection in decreasing the renal uptake, we hypothesized that the substitution of 
the Lys linker with a neutral β-Ala linker would decrease the renal uptake of the 
99mTc-RXD-Lys-(Arg11)CCMSH peptides. To examine our hypothesis, we 
synthesized six peptides with β-Ala linkers, namely RSD-β-Ala-(Arg11)CCMSH, 
RTD-β-Ala-(Arg11)CCMSH, RVD-β-Ala-(Arg11)CCMSH, RAD-β-Ala-
(Arg11)CCMSH, NAD-β-Ala-(Arg11)CCMSH and EAD-β-Ala-(Arg11)CCMSH. The 
MC1 receptor binding affinities of these six peptides were examined in B16/F1 
melanoma cells. The peptides were readily radiolabeled with 99mTc using SnCl2 
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as a reducing agent. We further determined the cellular internalization and efflux 
in B16/F1 melanoma cells and biodistribution properties in B16/F1 melanoma-
bearing C57 mice for these six 99mTc-peptides. Thereafter, we determined the 
imaging properties of 99mTc-RAD-β-Ala-(Arg11)CCMSH in B16/F1 melanoma-
bearing C57 mice. 
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Experimental Design and Methods 
 
Chemicals and Reagents 
 
Amino acids and resin were purchased from Advanced ChemTech Inc. 
(Louisville, KY) and Novabiochem (San Diego, CA). 125I-Tyr2-[Nle4, DPhe7]-α-
MSH {125I-(Tyr2)-NDP-MSH} was obtained from PerkinElmer, Inc. (Waltham, MA) 
for receptor binding assay. 99mTcO4
- was purchased from Cardinal Health 
(Albuquerque, NM). All other chemicals used in this study were purchased from 
Thermo Fischer Scientific (Waltham, MA) and used without further purification. 
B16/F1 murine melanoma cells were obtained from American Type Culture 
Collection (Manassas, VA). 
 
Peptide Synthesis and In Vitro Competitive Binding Assay 
 
RSD-β-Ala-(Arg11)CCMSH, RTD-β-Ala-(Arg11)CCMSH, RVD-β-Ala-
(Arg11)CCMSH, RAD-β-Ala-(Arg11)CCMSH, NAD-β-Ala-(Arg11)CCMSH and EAD-
β-Ala-(Arg11)CCMSH were synthesized using fluorenylmethyloxycarbonyl (Fmoc) 
chemistry according to our previously published procedures17-19 with slight 
modification on Sieber amide resin by an Advanced ChemTech multiple-peptide 
synthesizer (Louisville, KY). Briefly, 70 µmol of Sieber amide resin and 210 µmol 
of Fmoc-protected amino acids were used for the synthesis. Fmoc-β-Ala was 
used to generate a β-Ala linker in the hybrid peptide. Each peptide was purified 
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by RP-HPLC and characterized by liquid chromatography-mass spectroscopy 
(LC-MS). 
The IC50 values of RSD-β-Ala-(Arg
11)CCMSH, RTD-β-Ala-(Arg11)CCMSH, 
RVD-β-Ala-(Arg11)CCMSH, RAD-β-Ala-(Arg11)CCMSH, NAD-β-Ala-
(Arg11)CCMSH and EAD-β-Ala-(Arg11)CCMSH for the MC1 receptor were 
determined in B16/F1 melanoma cells. The receptor binding assay was 
replicated in triplicate for each peptide. The B16/F1 cells were seeded into a 24-
well cell culture plate at a density of 2.5 × 105 cells/well and incubated at 37° C 
overnight. After being washed with binding medium {modified Eagle’s medium 
with 25 mM N-(2-hydroxyethyl)-piperazine-N′-(2-ethanesulfonic acid) (HEPES), 
pH 7.4, 0.2% bovine serum albumin (BSA), 0.3 mM 1,10-phenathroline}, the cells 
were incubated at 25 °C for 2 h with approximately 30,000 counts per minute 
(cpm) of 125I-(Tyr2)-NDP-MSH in the presence of increasing concentrations (10-13 
M to 10-6 M) of each peptide in 0.3 mL of binding medium. The reaction medium 
was aspirated after the incubation. The cells were rinsed twice with 0.5 mL of ice-
cold pH 7.4, 0.2% BSA/0.01 M phosphate buffered saline (PBS) to remove any 
unbound radioactivity and lysed in 0.5 mL of 1 M NaOH for 5 min. The activities 
associated with the cells were measured in a Wallac 2480 automated gamma 
counter (PerkinElmer, NJ). The IC50 value for each peptide was calculated using 
Prism software (GraphPad Software, La Jolla, CA). 
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Peptide Radiolabeling 
 
RSD-β-Ala-(Arg11)CCMSH, RTD-β-Ala-(Arg11)CCMSH, RVD-β-Ala-
(Arg11)CCMSH, RAD-β-Ala-(Arg11)CCMSH, NAD-β-Ala-(Arg11)CCMSH and EAD-
β-Ala-(Arg11)CCMSH were labeled with 99mTc via a direct reduction reaction 
using SnCl2 as a reducing agent. Briefly, 10 μL of 1 mg/mL SnCl2 in 0.1 M HCl, 
40 μL of 0.5 M NH4OAc (pH 5.2), 100 μL of 0.2 M Na2tartate (pH 9.2), 100 μL of 
fresh 99mTcO4
- solution (37-74 MBq), and 10 μL of 1 mg/mL of each peptide in 
aqueous solution were added into a reaction vial and incubated at 25 °C for 20 
min to form the 99mTc-labeled peptide. Each 99mTc-peptide was purified to a 
single species by Waters RP-HPLC (Milford, MA) on a Grace Vydac C-18 
reverse phase analytic column (Deerfield, IL) using a 20-min gradient of 18-28% 
acetonitrile in 20 mM HCl aqueous solution at a flow rate of 1 mL/min. Each 
purified peptide was purged with N2 gas for 20 min to remove the acetonitrile. 
The pH of final peptide solution was adjusted to 7.4 with 0.1 N NaOH and sterile 
normal saline for stability, biodistribution and imaging studies. The serum 
stabilities of 99mTc-RSD-β-Ala-(Arg11)CCMSH, 99mTc-RTD-β-Ala-(Arg11)CCMSH, 
99mTc-RVD-β-Ala-(Arg11)CCMSH, 99mTc-RAD-β-Ala-(Arg11)CCMSH, 99mTc-NAD-
β-Ala-(Arg11)CCMSH and 99mTc-EAD-β-Ala-(Arg11)CCMSH were determined by 
incubation in mouse serum at 37C for 24 h and monitored for degradation by 
RP-HPLC. Briefly, 100 µL of each HPLC-purified peptide solution (~7.4 MBq) 
was added into 100 µL of mouse serum (Sigma-Aldrich Corp, St. Louis, MO) and 
incubated at 37 oC for 24 h. After the incubation, 200 µL of a mixture of ethanol 
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and acetonitrile (V:V = 1:1) was added to precipitate the serum proteins. The 
resulting mixture was centrifuged at 16,000 g for 5 min to collect the supernatant. 
The supernatant was purged with N2 gas for 30 min to remove the ethanol and 
acetonitrile. The resulting sample was mixed with 500 µL of water and injected 
into RP-HPLC for analysis using the gradient described above.   
 
Biodistribution Studies  
 
All the animal studies were conducted in compliance with Institutional 
Animal Care and Use Committee approval. The biodistribution properties of 
99mTc-RSD-β-Ala-(Arg11)CCMSH, 99mTc-RTD-β-Ala-(Arg11)CCMSH, 99mTc-RVD-
β-Ala-(Arg11)CCMSH, 99mTc-RAD-β-Ala-(Arg11)CCMSH, 99mTc-NAD-β-Ala-
(Arg11)CCMSH and 99mTc-EAD-β-Ala-(Arg11)CCMSH were determined in B16/F1 
melanoma-bearing C57 female mice (Harlan, Indianapolis, IN). Each C57 mouse 
was subcutaneously inoculated on the right flank with 1106 B16/F1 cells. The 
weight of tumors reached approximately 0.2 g 10 days post cell inoculation. Each 
melanoma-bearing mouse was injected with 0.037 MBq of 99mTc-RSD-β-Ala-
(Arg11)CCMSH, 99mTc-RTD-β-Ala-(Arg11)CCMSH, 99mTc-RVD-β-Ala-
(Arg11)CCMSH, 99mTc-RAD-β-Ala-(Arg11)CCMSH, 99mTc-NAD-β-Ala-
(Arg11)CCMSH or 99mTc-EAD-β-Ala-(Arg11)CCMSH via the tail vein. Groups of 4 
mice were sacrificed at 0.5, 2, 4 and 24 h post-injection, and tumors and organs 
of interest were harvested, weighed and counted. Blood values were taken as 
6.5% of the body weight. The specificity of tumor uptake was determined by co-
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injecting each 99mTc-peptide with 10 g (6.1 nmol) of unlabeled NDP-MSH at 2 h 
post-injection. 
 
Melanoma Imaging with 99mTc-RAD-β-Ala-(Arg11)CCMSH 
 
99mTc-RAD-β-Ala-(Arg11)CCMSH was the lead peptide due to its highest 
tumor uptake and the lowest renal uptake. Thus, we further determined the 
melanoma imaging property of 99mTc-RAD-β-Ala-(Arg11)CCMSH. Approximately 
4.1 MBq of 99mTc-RAD-β-Ala-(Arg11)CCMSH was injected into a B16/F1 
melanoma-bearing C57 mouse via the tail vein. The mouse was euthanized for 
small animal SPECT/CT (Nano-SPECT/CT®, Bioscan, Washington DC) imaging 
2 h post-injection. The 9-min CT imaging was immediately followed by the 
SPECT imaging of whole-body. The SPECT scans of 24 projections were 
acquired. Reconstructed data from SPECT and CT were visualized and co-
registered using InVivoScope (Bioscan, Washington DC). 
 
Urinary Metabolites of 99mTc-RAD-β-Ala-(Arg11)CCMSH 
 
We also examined the urinary metabolites of 99mTc-RAD-β-Ala-
(Arg11)CCMSH. Approximately 3.7 MBq of 99mTc-RAD-β-Ala-(Arg11)CCMSH was 
injected into a B16/F1 melanoma-bearing C57 mouse via the tail vein to 
determine the urinary metabolites. The mouse was euthanized to collect urine at 
2 h post-injection. The collected urine sample was centrifuged at 16,000 g for 5 
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min before the HPLC analysis. Thereafter, an aliquot of the urine was injected 
into the HPLC. A 20-minute gradient of 16-26% acetonitrile / 20 mM HCl with a 
flow rate of 1 mL/min was used for urine analysis. 
 
Statistical Analysis 
 
Statistical analysis was performed using the Student’s t-test for unpaired 
data to determine the significance of differences in tumor and kidney uptake 
with/without peptide blockade in biodistribution studies described above. 
Differences at the 95% confidence level (p<0.05) were considered significant. 
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Results 
The schematic structures of RSD-β-Ala-(Arg11)CCMSH, RTD-β-Ala-
(Arg11)CCMSH, RVD-β-Ala-(Arg11)CCMSH, RAD-β-Ala-(Arg11)CCMSH, NAD-β-
Ala-(Arg11)CCMSH and EAD-β-Ala-(Arg11)CCMSH are presented in Figure 4.1. 
The peptides were synthesized and purified by reverse phase-high performance 
liquid chromatography (RP-HPLC) according to our previously published 
procedures [150, 151]. The overall synthetic yields were 30% for all six peptides. 
The chemical purities of RSD-β-Ala-(Arg11)CCMSH, RTD-β-Ala-(Arg11)CCMSH, 
RVD-β-Ala-(Arg11)CCMSH, RAD-β-Ala-(Arg11)CCMSH, NAD-β-Ala-
(Arg11)CCMSH and EAD-β-Ala-(Arg11)CCMSH were greater than 95% after the 
HPLC purification. The peptide identities were confirmed by electrospray mass 
spectrometry. The measured molecular weight was 2123 Da for RSD-β-Ala-
(Arg11)CCMSH,  2137 Da for RTD-β-Ala-(Arg11)CCMSH, 2135 Da for RVD-β-Ala-
(Arg11)CCMSH, 2107 Da for RAD-β-Ala-(Arg11)CCMSH, 2064 Da for NAD-β-Ala-
(Arg11)CCMSH and 2080 Da for EAD-β-Ala-(Arg11)CCMSH (Table 4.1). The 
competitive binding curves of the peptides are shown in Figure 4.2. The IC50 
value was 2.76 ± 0.51 nM for RSD-β-Ala-(Arg11)CCMSH,  1.56 ± 0.63 nM for 
RTD-β-Ala-(Arg11)CCMSH, 1.99 ± 0.16 nM for RVD-β-Ala-(Arg11)CCMSH, 0.35 ± 
0.01 nM for RAD-β-Ala-(Arg11)CCMSH, 3.34 ± 0.28 nM for NAD-β-Ala-
(Arg11)CCMSH and 3.83 ± 0.71 nM for EAD-β-Ala-(Arg11)CCMSH in B16/F1 
melanoma cells, respectively. 
RSD-β-Ala-(Arg11)CCMSH, RTD-β-Ala-(Arg11)CCMSH, RVD-β-Ala-
(Arg11)CCMSH, RAD-β-Ala-(Arg11)CCMSH, NAD-β-Ala-(Arg11)CCMSH and EAD-
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β-Ala-(Arg11)CCMSH were readily radiolabeled with 99mTc with greater than 95% 
radiolabeling yields (Table 4.1). All six 99mTc-peptides were separated from their 
excess non-labeled peptides by RP-HPLC. The retention times of 99mTc-RSD-β-
Ala-(Arg11)CCMSH, 99mTc-RTD-β-Ala-(Arg11)CCMSH, 99mTc-RVD-β-Ala-
(Arg11)CCMSH, 99mTc-RAD-β-Ala-(Arg11)CCMSH, 99mTc-NAD-β-Ala-
(Arg11)CCMSH and 99mTc-EAD-β-Ala-(Arg11)CCMSH were 13.1, 13.0, 14.1, 13.7, 
17.0 and 14.2 min, respectively. All six 99mTc-peptides were stable in mouse 
serum at 37°C for 24 h (Figure 4.3).  
Cellular internalization and efflux properties of 99mTc-RSD-β-Ala-
(Arg11)CCMSH, 99mTc-RTD-β-Ala-(Arg11)CCMSH, 99mTc-RVD-β-Ala-
(Arg11)CCMSH, 99mTc-RAD-β-Ala-(Arg11)CCMSH, 99mTc-NAD-β-Ala-
(Arg11)CCMSH, and 99mTc-EAD-β-Ala-(Arg11)CCMSH were examined in B16/F1 
cells. Figure 4.4-4.5 illustrates the internalization and efflux properties of 99mTc-
RSD-β-Ala-(Arg11)CCMSH, 99mTc-RTD-β-Ala-(Arg11)CCMSH, 99mTc-RVD-β-Ala-
(Arg11)CCMSH, 99mTc-RAD-β-Ala-(Arg11)CCMSH, 99mTc-NAD-β-Ala-
(Arg11)CCMSH, and 99mTc-EAD-β-Ala-(Arg11)CCMSH. All six 99mTc-peptides 
exhibited rapid cellular internalization and prolonged cellular retention. 
Approximately 64% of 99mTc-RSD-β-Ala-(Arg11)CCMSH, 66% of 99mTc-RTD-β-
Ala-(Arg11)CCMSH, 70% of 99mTc-RVD-β-Ala-(Arg11)CCMSH, 77% of 99mTc-RAD-
β-Ala-(Arg11)CCMSH, 70% of 99mTc-NAD-β-Ala-(Arg11)CCMSH and 67% of 
99mTc-EAD-β-Ala-(Arg11)CCMSH activities were internalized in the cells after 20 
min of incubation. Cellular efflux results indicated that 76% of 99mTc-RSD-β-Ala-
(Arg11)CCMSH, 56% of 99mTc-RTD-β-Ala-(Arg11)CCMSH, 70% of 99mTc-RVD-β-
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Ala-(Arg11)CCMSH, 66% of 99mTc-RAD-β-Ala-(Arg11)CCMSH, 70% of 99mTc-NAD-
β-Ala-(Arg11)CCMSH and 54% of 99mTc-EAD-β-Ala-(Arg11)CCMSH activities 
remained inside the cells after 2 h of incubation in the culture medium.     
The melanoma targeting and pharmacokinetic properties of 99mTc-RSD-β-
Ala-(Arg11)CCMSH, 99mTc-RTD-β-Ala-(Arg11)CCMSH, 99mTc-RVD-β-Ala-
(Arg11)CCMSH, 99mTc-RAD-β-Ala-(Arg11)CCMSH, 99mTc-NAD-β-Ala-
(Arg11)CCMSH and 99mTc-EAD-β-Ala-(Arg11)CCMSH are shown in Tables 4.2-
4.7. All six 99mTc-peptides exhibited similar tumor uptake pattern in B16/F1 
melanoma-bearing C57 mice. The highest tumor uptake appeared either at 2 or 4 
h post-injection. Among these six 99mTc-peptides, 99mTc-RAD-β-Ala-
(Arg11)CCMSH showed the highest tumor uptake of  15.66 ± 6.19% ID/g at 2 h 
post-injection. The tumor uptake of 99mTc-RAD-β-Ala-(Arg11)CCMSH gradually 
decreased to 14.67 ± 3.81 and 7.79 ± 2.68% ID/g at 4 and 24 h post-injection. 
Co-injection of 10 μg (6.1 nM) of non-radiolabeled NDP-MSH with 99mTc-RAD-β-
Ala-(Arg11)CCMSH decreased the tumor uptake to 2.43 ± 0.53% ID/g at 2 h post-
injection, demonstrating that the tumor uptake was MC1 receptor-mediated.   
Kidneys were the excretion routes for all six 99mTc-peptides. Among these 
six 99mTc-peptides, 99mTc-RAD-β-Ala-(Arg11)CCMSH showed the lowest renal 
uptake of  20.18 ± 3.86% ID/g at 2 h post-injection. The renal uptake of 99mTc-
RAD-β-Ala-(Arg11)CCMSH gradually decreased to 19.83 ± 6.34 and 3.92 ± 
0.99% ID/g at 4 and 24 h post-injection. Co-injection of 10 μg (6.1 nM) of non-
radiolabeled NDP-MSH with 99mTc-RAD-β-Ala-(Arg11)CCMSH didn't significantly 
reduce the renal uptake (p>0.05) at 2 h post-injection, indicating that the renal 
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uptake was non-specific. The substitution of the positively-charged Lys linker with 
the neutral β-Ala dramatically decreased the renal uptake of 99mTc-RXD-β-Ala-
(Arg11)CCMSH peptides. Interestingly, further reduction of the overall positive 
charge of 99mTc-NAD-β-Ala-(Arg11)CCMSH and 99mTc-EAD-β-Ala-(Arg11)CCMSH 
peptides did not further decrease the renal uptake as compared to 99mTc-RAD-β-
Ala-(Arg11)CCMSH. All six 99mTc-peptides displayed fast urinary clearance. 
Approximately 68-78% of 99mTc-peptides cleared through the urinary system by 2 
h post-injection, whereas approximately 77-86% of 99mTc-peptides washed out 
through the urinary system by 4 h post-injection. Normal organ uptake of all 
99mTc-peptides was minimal (<3.1 % ID/g) except for kidneys after 2 h post-
injection. 
Because 99mTc-RAD-β-Ala-(Arg11)CCMSH showed the highest tumor 
uptake and the lowest renal uptake than the other five 99mTc-peptides at 2 h post-
injection, we further determined the imaging property and urinary metabolites of 
99mTc-RAD-β-Ala-(Arg11)CCMSH in B16/F1 melanoma-bearing C57 mice. Whole-
body single photon emission computed tomography (SPECT)/CT image at 2 h 
post-injection is presented in Figure 4.6.  Flank B16/F1 melanoma lesions were 
clearly visualized by SPECT using 99mTc-RAD-β-Ala-(Arg11)CCMSH peptide as 
an imaging probe. The SPECT image of tumor accurately matched its anatomical 
location obtained in the CT image. The SPECT image showed high contrast of 
tumor to normal organ except for kidneys, which was consistent with the 
biodistribution results. The urinary metabolites of 99mTc-RAD-β-Ala-
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(Arg11)CCMSH at 2 h post-injection are shown in Figure 4.7. 99mTc-RAD-β-Ala-
(Arg11)CCMSH remained intact in the urine at 2 h post-injection. 
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Discussion 
In our previous reports [128, 150, 151], we have found the importance of 
single amino acid at the X position in the tumor targeting properties of 99mTc-
RXD-Lys-(Arg11)CCMSH peptides in B16/F1 melanoma-bearing C57 mice. 
Specifically, the substitution of Gly in 99mTc-RGD-Lys-(Arg11)CCMSH with Ala, 
Thr, Val and Ser improved the MC1 receptor binding affinities and enhanced the 
melanoma uptake in B16/F1 melanoma-bearing C57 mice [128, 150, 151]. 
Despite the promising melanoma targeting results associated with 99mTc-RXD-
Lys-(Arg11)CCMSH peptides, it is desirable to reduce the non-specific renal 
uptake (67-135% ID/g at 2 h post-injection) of 99mTc-RXD-Lys-(Arg11)CCMSH 
peptides to facilitate their potential therapeutic applications. In this study, we 
substituted the positively-charged Lys linker with the neutral β-Ala linker to 
determine whether such linker change could reduce the renal uptake of  99mTc-
RXD-β-Ala-(Arg11)CCMSH peptides. Furthermore, we replaced the RAD moiety 
with NAD and EAD moieties to examine whether the further reduction of the 
overall positive changes of 99mTc-NAD-β-Ala-(Arg11)CCMSH and 99mTc-EAD-β-
Ala-(Arg11)CCMSH could decrease their renal uptake further. 
The substitution of Lys linker with β-Ala linker slightly affected the receptor 
binding affinities of RXD-β-Ala-(Arg11)CCMSH peptides. The receptor binding 
affinities of RXD-β-Ala-(Arg11)CCMSH peptides were approximately 2-fold 
weaker than RXD-Lys-(Arg11)CCMSH peptides, respectively. Despite the fact the 
-His-DPhe-Arg-Trp- motif is the binding moiety to the MC1 receptor, the decrease 
in receptor binding affinity with the β-Ala linker substitution indicated that the 
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linker might somehow interact with the receptor binding moiety. Such interaction 
might be related to the side chain of the Lys linker. The decrease in receptor 
binding affinities of RXD-β-Ala-(Arg11)CCMSH peptides also resulted in the 
reduction in tumor uptake of  99mTc-RXD-β-Ala-(Arg11)CCMSH peptides by 21-
45% in B16/F1 melanoma-bearing C57 mice. Specifically, the tumor uptake of 
99mTc-RAD-β-Ala-(Arg11)CCMSH was 79% of the tumor uptake of 99mTc-RAD-
Lys-(Arg11)CCMSH at 2 h post-injection [128]. 
The substitution of Lys linker with β-Ala linker dramatically decreased the 
renal uptake of 99mTc-RXD-β-Ala-(Arg11)CCMSH peptides by 64-79% in B16/F1 
melanoma-bearing C57 mice. For instance, the renal uptake of 99mTc-RAD-β-Ala-
(Arg11)CCMSH was only 22% of the renal uptake of 99mTc-RAD-Lys-
(Arg11)CCMSH at 2 h post-injection [128]. It is worthwhile to note that there is a 
positively-charged Arg residue in the RAD moiety of 99mTc-RAD-Lys-
(Arg11)CCMSH. Thus, we were interested whether the replacement of Arg with 
Nle (neutral) and Glu (negatively-charged) could further decrease the renal 
uptake of 99mTc-NAD-β-Ala-(Arg11)CCMSH and 99mTc-EAD-β-Ala-(Arg11)CCMSH 
as compared to 99mTc-RAD-β-Ala-(Arg11)CCMSH. Interestingly, the replacement 
of Arg with Nle and Glu did not further decrease the renal uptake of 99mTc-NAD-
β-Ala-(Arg11)CCMSH and 99mTc-EAD-β-Ala-(Arg11)CCMSH as compared to 
99mTc-RAD-β-Ala-(Arg11)CCMSH. Clearly, the tumor targeting and clearance 
properties of 99mTc-RAD-β-Ala-(Arg11)CCMSH were more favorable than the 
other 99mTc-peptides investigated in this study. Thus, we further examined its 
melanoma imaging property and urinary metabolites. The B16/F1 melanoma 
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lesions could be clearly visualized by SPECT/CT using 99mTc-RAD-β-Ala-
(Arg11)CCMSH as an imaging probe.  
The dramatic reduction in renal uptake with the substitution of the neutral 
β-Ala linker demonstrates the importance of the electrostatic interactions of the 
positive charges on the peptides in renal handling and non-specific uptake in-
vivo.  It is imperative to maintain high contrast of tumor uptake to normal organ 
tissues for enhanced diagnostic imaging and potential therapeutic applications 
utilizing radiolabeled peptide conjugates as targeting molecules.  99mTc-labeled 
radiopharmaceuticals can be readily translated to therapeutic 
radiopharmaceuticals through the replacement of 99mTc with 186Re/ 188Re [152, 
153].  Both 99mTc and 186Re/ 188Re have similar coordination chemistry.  The 
same biomolecule can be labeled with 186Re/ 188Re without structural 
modification.  The combined use of 99mTc- and 186Re/ 188Re-labeled 
radiopharmaceuticals for imaging and therapy will enhance the success of 
targeted radionuclide treatment for individual patients. 
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Conclusions  
The substitution of the Lys linker with the β-Ala linker dramatically 
decreased the renal uptake of 99mTc-RXD-β-Ala-(Arg11)CCMSH peptides. Among 
these four 99mTc-RXD-β-Ala-(Arg11)CCMSH peptides, 99mTc-RAD-β-Ala-
(Arg11)CCMSH exhibited the highest tumor uptake and the lowest renal uptake at 
2 h post-injection. The replacement of Arg with Nle and Glu didn't further 
decrease the renal uptake of 99mTc-NAD-β-Ala-(Arg11)CCMSH and 99mTc-EAD-β-
Ala-(Arg11)CCMSH as compared to 99mTc-RAD-β-Ala-(Arg11)CCMSH. The tumor 
targeting and clearance properties of 99mTc-RAD-β-Ala-(Arg11)CCMSH 
highlighted it as a lead peptide for future studies.  
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Tables 
 
Table 4.1.  Peptide properties 
Capacity factors, chemical/ radiochemical purities, measured molecular weights, 
and IC50 values of RXD-β-Ala-(Arg
11)CCMSH and XAD-β-Ala-(Arg11)CCMSH 
peptides and their 99mTc-conjugates.   
 
Peptide 
Capacity 
factor (k') 
Chemical/Radiochemical 
Purity (%) 
Measured Molecular 
Weight (Da) 
RSD-β-Ala-(Arg11)CCMSH 1.35 95.32 2123 
RTD-β-Ala-(Arg11)CCMSH 0.98 95.36 2137 
RVD-β-Ala-(Arg11)CCMSH 1.94 95.89 2135 
RAD-β-Ala-(Arg11)CCMSH 3.32 96.51 2107 
NAD-β-Ala-(Arg11)CCMSH 3.17 95.62 2064 
EAD-β-Ala-(Arg11)CCMSH 2.28 95.59 2080 
99mTc-RSD-β-Ala-(Arg11)CCMSH 3.34 99.91 ND 
99mTc-RTD-β-Ala-(Arg11)CCMSH 3.29 98.12 ND 
99mTc-RVD-β-Ala-(Arg11)CCMSH 3.40 99.98 ND 
99mTc-RAD-β-Ala-(Arg11)CCMSH 4.18 98.40 ND 
99mTc-NAD-β-Ala-(Arg11)CCMSH 4.63 98.29 ND 
99mTc-EAD-β-Ala-(Arg11)CCMSH 3.47 98.11 ND 
 
ND= Not Determined  
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Table 4.2.  Biodistribution of 99mTc-RSD-β-Ala-(Arg11)CCMSH  
Biodistribution of 99mTc-RSD-β-Ala-(Arg11)CCMSH in B16/F1 melanoma-bearing 
C57 mice. The data was presented as percent injected dose/gram or as percent 
injected dose (mean  SD, n=4). 
 
Tissue 0.5 h 2h 4h 24 h 
2h NDP-
Block 
Percentage Injected Dose/Gram (%ID/g) 
Tumor 9.64 ± 1.52 9.62 ± 1.53 12.15 ± 2.36 3.62 ± 1.10 1.12 ± 0.01* 
Brain 0.15 ± 0.01 0.02 ± 0.01 0.02 ± 0.02 0.02 ± 0.01 0.02 ± 0.01 
Blood 2.66 ± 0.84 0.50 ± 0.14 0.06 ± 0.02 0.61 ± 0.46 0.03 ± 0.01 
Heart 1.56 ± 0.13 0.23 ± 0.04 0.10 ± 0.06 0.07 ± 0.03 0.17 ± 0.01 
Lung 3.85 ± 0.40 0.64 ± 0.15 0.34 ± 0.11 0.29 ± 0.12 0.48 ± 0.06 
Liver 1.41 ± 0.13 0.74 ± 0.08 0.86 ± 0.08 0.31 ± 0.08 0.57 ± 0.05 
Skin 3.07 ± 1.85 0.52 ± 0.40 0.32 ± 0.13 0.48 ± 0.24 0.29 ± 0.18 
Spleen 1.34 ± 0.15 0.32 ± 0.05 0.35 ± 0.05 0.18 ± 0.06 0.22 ± 0.06 
Stomach 1.83 ± 0.20 0.62 ± 0.17 0.77 ± 0.21 0.32 ± 0.16 0.62 ± 0.23 
Kidneys 30.5 ± 5.18 28.73 ± 3.40 28.70 ± 5.22 8.12 ± 2.34 13.67 ± 2.54 
Muscle 0.25 ± 0.02 0.04 ± 0.03 0.02 ± 0.01 0.05 ± 0.02 0.05 ± 0.07 
Pancreas 0.68 ± 0.28 0.11 ± 0.01 0.04 ± 0.02 0.04 ± 0.01 0.08 ± 0.01 
Bone 0.93 ± 0.45 0.19 ± 0.06 0.05 ± 0.01 0.42 ± 0.28 0.16 ± 0.09 
Percentage Injected Dose (%ID) 
Intestines 1.71 ± 0.21 1.11 ± 0.60 1.59 ± 0.41 0.63 ± 0.19 0.76 ± 0.23 
Urine 53.37 ± 4.23 68.46 ± 9.28 83.96 ± 0.88 84.33 ± 3.37 90.95 ± 0.59 
Uptake Ratio of Tumor/Normal Tissue 
Tumor/Blood 3.62 19.24 202.50 5.93 37.33 
Tumor/Kidneys 0.32 0.33 0.42 0.45 0.08 
Tumor/Lung 2.50 15.03 35.74 12.48 2.33 
Tumor/Liver 6.84 13.00 14.13 11.68 1.96 
Tumor/Muscle 38.56 240.50 607.50 72.40 22.40 
 
*p<0.05 (*p=0.001,) for determining the significance of differences in 
tumor and kidney uptake between 99mTc-RSD-β-Ala-(Arg11)CCMSH with 
or without NDP-MSH peptide blockade at 2 h post-injection. 
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Table 4.3.  Biodistribution of 99mTc-RTD-β-Ala-(Arg11)CCMSH    
Biodistribution of 99mTc-RTD-β-Ala-(Arg11)CCMSH in B16/F1 melanoma-bearing 
C57 mice. The data was presented as percent injected dose/gram or as percent 
injected dose (mean  SD, n=4). 
 
Tissue 0.5 h 2h 4h 24 h 2h NDP-Block 
Percentage Injected Dose/Gram (%ID/g) 
Tumor 13.29 ± 2.36 13.85 ± 1.43 9.40 ± 2.86 5.23 ± 1.81 1.19 ± 0.30* 
Brain 0.20 ± 0.01 0.02 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 
Blood 7.53 ± 0.99 1.48 ± 0.02 0.27 ± 0.17 0.06 ± 0.05 3.69 ± 0.01 
Heart 2.38 ± 1.75 0.27 ± 0.07 0.14 ± 0.05 0.09 ± 0.02 0.22 ± 0.01 
Lung 4.61 ± 3.16 0.53 ± 0.13 0.30 ± 0.01 0.16 ± 0.03 0.39 ± 0.14 
Liver 1.36 ± 0.10 0.78 ± 0.02 0.73 ± 0.07 0.43 ± 0.11 0.61 ± 0.08 
Skin 6.44 ± 2.64 1.33 ± 0.59 0.22 ± 0.15 0.22 ± 0.04 0.38 ± 0.08 
Spleen 1.19 ± 0.58 0.31 ± 0.15 0.27 ± 0.14 0.23 ± 0.06 0.21 ± 0.07 
Stomach 2.01 ± 0.72 0.83 ± 0.23 0.66 ± 0.20 0.37 ± 0.26 0.92 ± 0.37 
Kidneys 35.79 ± 2.11 28.60 ± 5.14 26.17 ± 4.83 11.50 ± 2.81 18.09 ± 1.89^ 
Muscle 0.46 ± 0.19 0.06 ± 0.05 0.02 ± 0.01 0.03 ± 0.03 0.04 ± 0.01 
Pancreas 1.25 ± 1.00 0.11 ± 0.09 0.02 ± 0.02 0.05 ± 0.03 0.07 ± 0.03 
Bone 0.90 ± 0.90 0.29 ± 0.20 0.09 ± 0.07 0.11 ± 0.06 0.11 ± 0.04 
Percentage Injected Dose (%ID) 
Intestines 2.28 ± 1.24 0.93 ± 0.21 1.29 ± 0.47 2.03 ± 1.42 0.84 ± 0.22 
Urine 53.46 ± 7.42 77.83 ± 2.83 84.94 ± 2.10 90.45 ± 3.66 
90.63 ± 
2.07** 
Uptake Ratio of Tumor/Normal Tissue 
Tumor/Blood 1.76 9.36 34.81 87.17 0.32 
Tumor/Kidneys 0.37 0.48 0.36 0.45 0.07 
Tumor/Lung 2.88 26.13 31.33 32.69 3.05 
Tumor/Liver 9.77 17.76 12.88 12.16 1.95 
Tumor/Muscle 28.89 230.83 470.00 174.33 29.75 
 
*p<0.05 (*p=0.003, ^p=.015, **p=0.01) for determining the significance of 
differences in tumor and kidney uptake between 99mTc-RTD-β-Ala-
(Arg11)CCMSH with or without NDP-MSH peptide blockade at 2 h post-
injection. 
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Table 4.4.  Biodistribution of 99mTc-RVD-β-Ala-(Arg11)CCMSH  
Biodistribution of 99mTc-RVD-β-Ala-(Arg11)CCMSH in B16/F1 melanoma-bearing 
C57 mice. The data was presented as percent injected dose/gram or as percent 
injected dose (mean  SD, n=4). 
 
Tissue 0.5 h 2h 4h 24 h 
2h NDP-
Block 
Percentage Injected Dose/Gram (%ID/g) 
Tumor 12.49 ± 2.10 13.11 ± 4.78 11.18 ± 2.76 4.66 ± 1.92 1.30 ± 0.46* 
Brain 0.14 ± 0.01 0.03 ± 0.01 0.01 ± 0.01 0.03 ± 0.02 0.02 ± 0.01 
Blood 6.11 ± 0.56 0.78 ± 0.06 0.14 ± 0.08 0.06 ± 0.01 0.43 ± 0.01 
Heart 1.99 ± 0.11 0.35 ± 0.07 0.15 ± 0.02 0.08 ± 0.02 0.32 ± 0.06 
Lung 2.61 ± 0.26 1.13 ± 0.09 0.41 ± 0.13 0.11 ± 0.02 0.64 ± 0.12 
Liver 2.22 ± 0.05 1.36 ± 0.33 1.62 ± 0.34 0.50 ± 0.06 1.34 ± 0.23 
Skin 4.86 ± 2.81 0.98 ± 0.44 0.16 ± 0.07 0.34 ± 0.05 0.82 ± 0.18 
Spleen 1.36 ± 0.38 0.27 ± 0.14 0.31 ± 0.09 0.08 ± 0.02 0.34 ± 0.08 
Stomach 2.82 ± 0.60 1.02 ± 0.48 0.85 ± 0.29 0.39 ± 0.15 1.74 ± 0.27 
Kidneys 30.77 ± 2.40 30.37 ± 6.04 27.03 ± 0.71 7.58 ± 1.78 17.96 ± 5.92 
Muscle 0.44 ± 0.11 0.17 ± 0.05 0.02 ± 0.02 0.14 ± 0.04 0.12 ± 0.07 
Pancreas 0.76 ± 0.36 0.14 ± 0.01 0.10 ± 0.06 0.08 ± 0.06 0.10 ± 0.11 
Bone 0.46 ± 0.12 0.60 ± 0.38 0.09 ± 0.09 0.17 ± 0.15 0.10 ± 0.05 
Percentage Injected Dose (%ID) 
Intestines 1.89 ± 0.32 0.87 ± 0.22 1.33 ± 0.47 1.00 ± 0.59 0.90 ± 0.17 
Urine 49.29 ± 2.66 74.19 ± 7.90 84.10 ± 4.44 84.47 ± 6.30 86.59 ± 4.94 
Uptake Ratio of Tumor/Normal Tissue 
Tumor/Blood 2.04 16.81 79.86 77.67 3.02 
Tumor/Kidneys 0.41 0.43 0.41 0.61 0.07 
Tumor/Lung 4.79 11.60 27.27 42.36 2.03 
Tumor/Liver 5.63 9.64 6.90 9.32 0.97 
Tumor/Muscle 28.39 77.12 559.00 33.29 10.83 
 
*p<0.05 (*p=0.001) for determining the significance of differences in tumor 
and kidney uptake between 99mTc-RVD-β-Ala-(Arg11)CCMSH with or 
without NDP-MSH peptide blockade at 2 h post-injection. 
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Table 4.5.  Biodistribution of 99mTc-RAD-β-Ala-(Arg11)CCMSH 
Biodistribution of 99mTc-RAD-β-Ala-(Arg11)CCMSH in B16/F1 melanoma-
bearing C57 mice. The data was presented as percent injected dose/gram 
or as percent injected dose (mean  SD, n=4). 
 
Tissue 0.5 h 2h 4h 24 h 
2h NDP-
Block 
Percentage Injected Dose/Gram (%ID/g) 
Tumor 12.55 ± 3.37 15.66 ± 6.19 14.67 ± 3.81 7.79 ± 2.68 2.43 ± 0.53* 
Brain 0.19 ± 0.04 0.05 ± 0.01 0.03 ± 0.01 0.05 ± 0.05 0.02 ± 0.02 
Blood 3.82 ± 0.62 1.01 ± 0.42 0.60 ± 0.29 0.46 ± 0.44 0.51 ± 0.10 
Heart 2.28 ± 0.29 0.90 ± 0.34 0.69 ± 0.33 0.31 ± 0.21 0.73 ± 0.23 
Lung 7.22 ± 1.60 3.15 ± 0.79 2.34 ± 1.19 1.01 ± 0.48 3.12 ± 1.13 
Liver 2.39 ± 0.62 1.09 ± 0.13 1.05 ± 0.26 0.56 ± 0.23 1.17 ± 0.33 
Skin 5.50 ± 0.60 1.38 ± 0.41 0.70 ± 0.13 0.42 ± 0.24 1.29 ± 0.42 
Spleen 1.39 ± 0.51 0.80 ± 0.31 0.55 ± 0.34 0.60 ± 0.38 0.64 ± 0.43 
Stomach 7.11 ± 2.20 2.61 ± 1.04 1.88 ± 0.63 0.44 ± 0.20 2.88 ± 0.65 
Kidneys 25.64 ± 4.06 20.18 ± 3.86 19.83 ± 6.34 3.92 ± 0.99 19.82 ± 9.39 
Muscle 0.90 ± 0.48 0.23 ± 0.14 0.18 ± 0.11 0.34 ± 0.32 0.17 ± 0.08 
Pancreas 0.84 ± 0.35 0.29 ± 0.09 0.12 ± 0.08 0.20 ± 0.14 0.14 ± 0.05 
Bone 1.60 ± 0.27 0.59 ± 0.16 0.24 ± 0.20 0.50 ± 0.42 0.33 ± 0.20 
Percentage Injected Dose (%ID) 
Intestines 2.93 ± 0.44 2.58 ± 1.25 1.90 ± 0.39 0.89 ± 1.10 1.46 ± 0.26 
Urine 49.54 ± 2.65 78.28 ± 2.36 83.80 ± 3.67 94.25 ± 1.90 83.61 ± 5.94 
Uptake Ratio of Tumor/Normal Tissue 
Tumor/Blood 3.29 15.50 24.45 16.93 4.76 
Tumor/Kidneys 0.49 0.78 0.74 1.99 0.12 
Tumor/Lung 1.74 4.97 6.27 7.71 0.78 
Tumor/Liver 5.25 14.37 13.97 13.91 2.08 
Tumor/Muscle 13.94 68.09 81.50 22.91 14.29 
 
*p<0.05 (p=0.002) for determining the significance of differences in tumor 
and kidney uptake between 99mTc-RAD-β-Ala-(Arg11)CCMSH with or 
without NDP-MSH peptide blockade at 2 h post-injection. 
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Table 4.6.  Biodistribution of 99mTc-NAD-β-Ala-(Arg11)CCMSH  
Biodistribution of 99mTc-NAD-β-Ala-(Arg11)CCMSH in B16/F1 melanoma-bearing 
C57 mice. The data was presented as percent injected dose/gram or as percent 
injected dose (mean  SD, n=4). 
 
Tissue 0.5 h 2h 4h 24 h 
2h NDP-
Block 
Percentage Injected Dose/Gram (%ID/g) 
Tumor 3.43 ± 1.75 11.38 ± 1.29 10.81 ± 5.48 4.17 ± 1.14 2.06 ± 0.85* 
Brain 0.17 ± 0.01 0.01 ± 0.01 0.02 ± 0.01 0.01 ± 0.01 0.05 ± 0.01 
Blood 10.13 ± 1.66 1.02 ± 0.48 0.87 ± 0.43 0.14 ± 0.02 1.22 ± 0.01 
Heart 1.85 ± 0.56 0.62 ± 0.03 0.56 ± 0.31 0.11 ± 0.03 0.48 ± 0.25 
Lung 5.68 ± 1.37 2.31 ± 0.55 1.28 ± 0.27 0.74 ± 0.30 1.92 ± 0.41 
Liver 2.03 ± 0.41 1.67 ± 0.39 1.37 ± 0.45 0.50 ± 0.08 1.93 ± 0.77 
Skin 3.71 ± 1.95 1.14 ± 0.23 0.62 ± 0.10 0.16 ± 0.04 1.47 ± 0.68 
Spleen 1.71 ± 0.74 0.76 ± 0.21 0.55 ± 0.08 0.20 ± 0.13 0.33 ± 0.20 
Stomach 2.45 ± 1.72 1.14 ± 0.37 0.75 ± 0.06 0.25 ± 0.09 2.11 ± 0.84 
Kidneys 32.37 ± 5.90 37.23 ± 9.69 32.68 ± 6.55 8.39 ± 2.56 22.48 ± 9.23 
Muscle 0.33 ± 0.10 0.06 ± 0.06 0.15 ± 0.04 0.05 ± 0.01 0.39 ± 0.29 
Pancreas 0.37 ± 0.23 0.22 ± 0.08 0.01 ± 0.01 0.01 ± 0.01 0.25 ± 0.14 
Bone 0.75 ± 0.40 0.35 ± 0.29 0.03 ± 0.01 0.09 ± 0.07 0.19 ± 0.08 
Percentage Injected Dose (%ID) 
Intestines 1.29 ± 0.67 2.84 ± 1.98 4.77 ± 3.46 0.59 ± 0.18 2.28 ± 0.78 
Urine 53.93 ± 19.61 73.27 ± 5.41 77.67 ± 5.88 93.77 ± 1.03 74.78 ± 10.44 
Uptake Ratio of Tumor/Normal Tissue 
Tumor/Blood 0.34 11.16 12.43 29.79 1.69 
Tumor/Kidneys 0.11 0.31 0.33 0.50 0.09 
Tumor/Lung 0.60 4.93 8.45 5.64 1.07 
Tumor/Liver 1.69 6.81 7.89 8.34 1.07 
Tumor/Muscle 10.39 189.67 72.07 83.40 5.28 
 
*p<0.05 (*p=0.003) for determining the significance of differences in tumor 
and kidney uptake between 99mTc-NAD-β-Ala-(Arg11)CCMSH with or 
without NDP-MSH peptide blockade at 2 h post-injection. 
  
133 
 
Table 4.7.  Biodistribution of 99mTc-EAD-β-Ala-(Arg11)CCMSH  
Biodistribution of 99mTc-EAD-β-Ala-(Arg11)CCMSH in B16/F1 melanoma-bearing 
C57 mice. The data was presented as percent injected dose/gram or as percent 
injected dose (mean  SD, n=4). 
 
Tissue 0.5 h 2h 4h 24 h 
2h NDP-
Block 
Percentage Injected Dose/Gram (%ID/g) 
Tumor 12.25 ± 1.86 10.13 ± 3.60 13.36 ± 4.12 3.71 ± 1.59 1.20 ± 0.25* 
Brain 0.15 ± 0.01 0.02 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 
Blood 5.94 ± 1.42 0.86 ± 0.04 0.38 ± 0.12 0.08 ± 0.01 0.47 ± 0.01 
Heart 1.73 ± 0.35 0.44 ± 0.08 0.35 ± 0.03 0.14 ± 0.08 0.29 ± 0.15 
Lung 3.50 ± 1.96 2.57 ± 1.00 1.35 ± 0.51 0.35 ± 0.08 1.73 ± 0.74 
Liver 2.06 ± 0.73 1.08 ± 0.41 0.93 ± 0.16 0.26 ± 0.08 0.86 ± 0.03 
Skin 5.92 ± 0.76 0.55 ± 0.03 0.64 ± 0.05 0.24 ± 0.02 0.86 ± 0.15 
Spleen 1.95 ± 1.15 0.59 ± 0.25 0.49 ± 0.18 0.14 ± 0.11 0.26 ± 0.05 
Stomach 2.91 ± 1.36 0.70 ± 0.12 0.89 ± 0.06 0.12 ± 0.02 1.16 ± 0.30 
Kidneys 25.65 ± 8.27 25.25 ± 9.26 24.37 ± 7.66 4.12 ± 1.14 25.93 ± 1.62 
Muscle 0.85 ± 0.26 0.05 ± 0.03 0.03 ± 0.01 0.10 ± 0.08 0.04 ± 0.04 
Pancreas 0.72 ± 0.39 0.14 ± 0.07 0.06 ± 0.04 0.02 ± 0.01 0.07 ± 0.02 
Bone 1.43 ± 0.32 0.27 ± 0.12 0.07 ± 0.03 0.14 ± 0.06 0.10 ± 0.05 
Percentage Injected Dose (%ID) 
Intestines 2.19 ± 0.72 1.38 ± 0.92 2.29 ± 0.66 0.55 ± 0.16 2.51 ± 0.34 
Urine 42.67 ± 21.25 75.09 ± 11.87 86.51 ± 3.43 92.30 ± 1.33 85.18 ± 0.53 
Uptake Ratio of Tumor/Normal Tissue 
Tumor/Blood 2.06 11.78 35.16 46.38 2.55 
Tumor/Kidneys 0.48 0.40 0.55 0.90 0.05 
Tumor/Lung 3.50 3.94 9.90 10.60 0.69 
Tumor/Liver 5.95 9.38 14.37 14.27 1.40 
Tumor/Muscle 14.41 202.60 445.33 37.10 30.00 
 
*p<0.05 (*p=0.003) for determining the significance of differences in tumor 
and kidney uptake between 99mTc-EAD-β-Ala-(Arg11)CCMSH with or 
without NDP-MSH peptide blockade at 2 h post-injection. 
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Figure Legends 
 
Figure 4.1. Schematic structures of RXD-β-Ala-(Arg11)CCMSH & XAD-β-
Ala-(Arg11)CCMSH peptides. 
 
Figure 4.2. The competitive binding curves of RSD-β-Ala-(Arg11)CCMSH 
(●), RTD-β-Ala-(Arg11)CCMSH (■), RVD-β-Ala-(Arg11)CCMSH (▲), RAD-β-
Ala-(Arg11)CCMSH (□), NAD-β-Ala-(Arg11)CCMSH (  )  and EAD-β-Ala-
(Arg11)CCMSH (   ), and in B16/F1 murine melanoma cells.  The IC50 value 
was 2.76 ± 0.51 nM for RSD-β-Ala-(Arg11)CCMSH, 1.56 ± 0.63 nM for RTD-β-
Ala-(Arg11)CCMSH,  1.99 ± 0.16 nM for RVD-β-Ala-(Arg11)CCMSH, 0.35 ± 
0.01 nM for RAD-β-Ala-(Arg11)CCMSH, 3.34 ± 0.28 nM for NAD-β-Ala-
(Arg11)CCMSH and 3.84 ± 0.71 nM for EAD-β-Ala-(Arg11)CCMSH 
respectively. 
 
Figure 4.3. Radioactive HPLC profiles of 99mTc-RSD-β-Ala-(Arg11)CCMSH 
(A), 99mTc-RTD-β-Ala-(Arg11)CCMSH (B),  99mTc-RVD-β-Ala-(Arg11)CCMSH 
(C),  99mTc-RAD-β-Ala-(Arg11)CCMSH (D),  99mTc-NAD-β-Ala-(Arg11)CCMSH 
(E), and 99mTc-EAD-β-Ala-(Arg11)CCMSH (F) in mouse serum after incubation 
at 37 °C for 24 h. The arrows denote the original peak retention times of 
99mTc-RSD-β-Ala-(Arg11)CCMSH (13.1 min), 99mTc-RTD-β-Ala-(Arg11)CCMSH 
(13.0 min), 99mTc-RVD-β-Ala-(Arg11)CCMSH (14.1 min), 99mTc-RAD-β-Ala-
(Arg11)CCMSH (13.7 min), 99mTc-NAD-β-Ala-(Arg11)CCMSH (17.0 min), and 
99mTc-EAD-β-Ala-(Arg11)CCMSH (14.2 min), prior to the incubation in mouse 
serum.  
 
Figure 4.4. Cellular internalization and efflux of 99mTc-RSD-β-Ala-
(Arg11)CCMSH (A and B), 99mTc-RTD-β-Ala-(Arg11)CCMSH (C and D) and 
99mTc-RVD-β-Ala-(Arg11)CCMSH (E and F) in B16/F1 melanoma cells. Total 
bound radioactivity (♦), internalized radioactivity (■) and cell membrane 
radioactivity (▲) were presented as counts per minute (cpm). 
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Figure 4.5. Cellular internalization and efflux of 99mTc-RAD-β-Ala-
(Arg11)CCMSH (G and H), 99mTc-NAD-β-Ala-(Arg11)CCMSH (I and J) and 
99mTc-EAD-β-Ala-(Arg11)CCMSH (K and L) in B16/F1 melanoma cells. Total 
bound radioactivity (♦), internalized radioactivity (■) and cell membrane 
radioactivity (▲) were presented as counts per minute (cpm). 
 
Figure 4.6. Representative whole-body SPECT/CT image of B16/F1 
melanoma- bearing C57 mice 2 h post injection of 7.4 MBq of 99mTc-RAD-β-
Ala-(Arg11)CCMSH. Flank melanoma lesions (T) are highlighted with an arrow 
on the image. 
 
Figure 4.7. Radioactive HPLC profiles of urinary metabolites at 2 h post-
injection of 99mTc-RAD-β-Ala-(Arg11)CCMSH. The arrow denotes the original 
retention time of 99mTc-RAD-β-Ala-(Arg11)CCMSH (15.98 min) prior to tail vein 
injection. 
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Figure 4.1 
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Figure 4.2 
 
 
  
 
10 - 1 3 10 - 1 2 10 - 1 1 10 - 1 0 10 - 9 10 - 8 10 - 7 10 - 6 10 - 5
0
20
40
60
80
100
 Molar Concentration of Displacing Peptide
%
 R
a
d
io
a
c
ti
v
e
ty
 B
o
u
n
d
138 
 
Figure 4.3 
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Figure 4.4 
 
 
  
 
 
 
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
0 20 40 60 80 100 120
R
a
d
io
a
c
ti
v
it
y
  
B
o
u
n
d
 (
c
p
m
)
Time (min)
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
0 20 40 60 80 100 120
R
a
d
io
a
c
ti
v
it
y
  
B
o
u
n
d
 (
c
p
m
)
Time (min)
A B
0
1000
2000
3000
4000
5000
6000
0 20 40 60 80 100 120
R
a
d
io
a
c
ti
v
it
y
  
B
o
u
n
d
 (
c
p
m
)
Time (min)
0
500
1000
1500
2000
2500
3000
3500
0 20 40 60 80 100 120
R
a
d
io
a
c
ti
v
it
y
  
B
o
u
n
d
 (
c
p
m
)
Time (min)
C D
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
0 20 40 60 80 100 120
R
a
d
io
a
c
ti
v
it
y
  
B
o
u
n
d
 (
c
p
m
)
Time (min)
0
500
1000
1500
2000
2500
3000
3500
0 20 40 60 80 100 120
R
a
d
io
a
c
ti
v
it
y
  
B
o
u
n
d
 (
c
p
m
)
Time (min)
E F
140 
 
Figure 4.5 
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Figure 4.6 
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Figure 4.7 
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Chapter 5 
Project Summary 
The development of receptor-targeting diagnostic or therapeutic 
radiopharmaceuticals, has taken a near herculean effort; understanding the 
coordination chemistry involved within the metal complexes, determining optimal 
radiolabeling procedures, and designing the structures of the targeting 
biomolecules.  At the present time, many 99mTc-labeled radiopharmaceuticals 
have been widely used as diagnostic imaging agents in various disease states 
such as cancer, thrombosis, infection, and inflammation.  Administration of site-
specific targeted radiopharmaceuticals provides the prospect of treating widely 
disseminated diseases, such as metastatic cancer.  Ideally, the targeted 
radiopharmaceutical is designed to locate with high specificity to cancerous foci 
at locations undetected and unknown within the human body [152].  The use of 
small peptides in targeting of radiopharmaceuticals provides a mechanism of 
targeting specific overexpressed receptors on the cancerous cell surface, 
enabling high specificity targeting of the cancer cell while minimizing radiation to 
healthy tissues.   
In this project, we developed novel iterations of α-melanocyte stimulating 
hormone peptides capable of binding the melanoma specific, melanocortin-1 
receptor, in order to characterize and determine the most effective small peptides 
for melanoma targeting.  Through previous research, it was determined that a 
single amino acid substitution of Gly to Ala in the RXD motif of the RGD-Lys-
(Arg11)CCMSH peptide greatly improved MC1R binding affinity in B16/F1 murine 
144 
 
melanoma cells (2.0 nM vs 0.3 nM, respectively) [127].  In this study, we 
developed novel α-MSH peptides with further modifications to this same residue 
in order to examine the influence of the amino acid on in-vivo melanoma 
targeting of the α-MSH peptides. Initially the substitutions of the Gly residue with 
Thr and Val amino acids were performed to examine the effects of the –
CH(CH3)OH and –CH(CH3)2 groups on the biodistribution properties of the 
99mTc-
labeled RTD-Lys-(Arg11)CCMSH and RVD-Lys-(Arg11)CCMSH peptides. The 
RTD-Lys-(Arg11)CCMSH and RVD-Lys-(Arg11)CCMSH peptides were 
synthesized via fluorenylmethyloxycarbonyl (Fmoc) chemistry and purified 
through RP-HPLC, with chemical purities >95%.  Cellular binding studies on 
B16/F1 murine melanoma cells demonstrated increased affinity for the MC1R as 
compared to the original RGD-Lys-(Arg11)CCMSH peptide, but weaker affinity 
than the RAD-Lys-(Arg11)CCMSH peptide with IC50 values of 0.70 ± 0.07 nM for 
RTD-Lys-(Arg11)CCMSH and 1.00 ± 0.30 nM for RVD-Lys-(Arg11)CCMSH.   
RTD-Lys-(Arg11)CCMSH and RVD-Lys-(Arg11)CCMSH peptides were 
radiolabeled with 99mTc and purified via RP-HPLC with radiochemical purities 
>95%.  Both compounds demonstrated to be stable in mouse serum for 24 h at 
37°C. In-vivo biodistribution studies in B16/F1 bearing female C57BL/6 mice 
revealed high receptor-mediated melanoma uptake as compared with 99mTc-
RAD-Lys-(Arg11)CCMSH but with different uptake patterns.  99mTc-RTD-Lys-
(Arg11)CCMSH showed the highest tumor uptake of 18.77 ± 5.13% ID/g at 2 h 
post-injection, whereas 99mTc-RVD-Lys-(Arg11)CCMSH showed the highest tumor 
uptake of 19.63 ± 4.68% ID/g at 4 h post-injection.  Both the 99mTc-RTD-Lys-
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(Arg11)CCMSH and 99mTc-RVD-Lys-(Arg11)CCMSH exhibited extremely high 
renal uptake at 0.5, 2, and 4 h post-injection with values ranging from 105.54 ± 
27.67- 144.56 ± 24.64% ID/g for 99mTc-RTD-Lys-(Arg11)CCMSH and 73.92 ± 
3.73- 94.01 ± 18.31% ID/g for 99mTc-RVD-Lys-(Arg11)CCMSH.  SPECT/CT 
imaging studies utilizing 99mTc-RTD-Lys-(Arg11)CCMSH and 99mTc-RVD-Lys-
(Arg11)CCMSH as imaging probes demonstrated that B16/F1 lesions could be 
clearly visualized by SPECT/CT imaging.  
Further evaluation of the targeting and pharmacokinetic properties 
associated with the substitution of the Gly residue in the RXD motif was 
performed in the second study in which the Gly residue was substituted with Ser, 
Nle, Phe, and DPhe amino acids. The substitutions were designed to evaluate the 
effects of the long hydrocarbon chain (Nle), and the bulky benzene rings (Phe 
and DPhe) on MC1R binding affinity and melanoma targeting properties of the 
peptides.  In addition, the –CH2OH group (Ser) was substituted in an attempt to 
facilitate urinary clearance of the peptides compared to the hydrophobic Nle, 
Phe, and DPhe compounds.  The four peptides were synthesized utilizing a 
similar Fmoc chemistry approach as the previously described RTD-Lys-
(Arg11)CCMSH and RVD-Lys-(Arg11)CCMSH peptides and purified to >95% 
chemical purity via RP-HPLC.  Cellular binding studies on B16/F1 murine 
melanoma cells demonstrated varying impacts on the MC1R binding affinities of 
the peptides.  The long hydrocarbon chain from the Nle amino acid on RNleD-
Lys-(Arg11)CCMSH peptide exhibited decreased MC1R binding affinity, whereas 
the CH2OH group from the Ser amino acid and the bulky benzene rings from the 
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Phe and DPhe amino acids increased MC1R binding affinity.  IC50 values of RSD-
Lys-(Arg11)CCMSH, RNleD-Lys-(Arg11)CCMSH, RFD-Lys-(Arg11)CCMSH, and 
RfD-Lys-(Arg11)CCMSH were 1.30 ± 0.36, 2.99 ± 0.26, 0.82 ± 0.06, and 1.35 ± 
0.08 nM respectively.  The differences in receptor binding affinities of these 
peptides indicate the Ser, Nle, Phe, and DPhe residues interact with the MC1R 
binding moiety differently.  The subtle differences may be explained by the 
flexibility of the lactam bonds among the amino acid residues in the peptides. 
In order to determine the in-vivo melanoma targeting, pharmacokinetic, 
and imaging properties of the RSD-Lys-(Arg11)CCMSH, RFD-Lys-(Arg11)CCMSH, 
and RfD-Lys-(Arg11)CCMSH  peptides, all peptides were radiolabeled with 99mTc 
and purified through RP-HPLC to a radiochemical purity >95%.  Due to the poor 
binding affinity of the RNleD-Lys-(Arg11)CCMSH peptide, further evaluation of the 
in-vivo tumor targeting properties was not warranted nor determined.  Despite the 
similar pattern in B16/F1 cellular internalization and efflux, 99mTc-RSD-Lys-
(Arg11)CCMSH exhibited a contrast in tumor uptake as compared to the 99mTc-
RFD-Lys-(Arg11)CCMSH and 99mTc-RfD-Lys-(Arg11)CCMSH peptides.  99mTc-
RSD-Lys-(Arg11)CCMSH exhibited rapid and high receptor-specific melanoma 
uptake of 18.01 ± 4.22% ID/g at 30 min post-injection, whereas 99mTc-RFD-Lys-
(Arg11)CCMSH and 99mTc-RfD-Lys-(Arg11)CCMSH exhibited their peak 
melanoma uptake values of 13.11 ± 1.21 and 15.01 ± 4.40% ID/g at 4 h post-
injection, respectively.  In addition, 99mTc-RSD-Lys-(Arg11)CCMSH displayed 45% 
and 32% lower renal uptake values at 24 h than 99mTc-RFD-Lys-(Arg11)CCMSH 
and 99mTc-RfD-Lys-(Arg11)CCMSH respectively. Renal uptake values were still 
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extremely high ranging from 69.23 ± 17.41% ID/g at 4 h post-injection to 80.01 ± 
15.67% ID/g at 2 h post-injection.  Not surprisingly, however, 99mTc-RSD-Lys-
(Arg11)CCMSH showed 12% and 23% lower liver uptake than 99mTc-RFD-Lys-
(Arg11)CCMSH and 99mTc-RfD-Lys-(Arg11)CCMSH, due to the absence of the 
bulky benzene ring.  Furthermore, 99mTc-RSD-Lys-(Arg11)CCMSH exhibited 
faster urinary clearance over all time points as compared to both 99mTc-RFD-Lys-
(Arg11)CCMSH and 99mTc-RfD-Lys-(Arg11)CCMSH.  SPECT/CT imaging studies 
utilizing 99mTc-RSD-Lys-(Arg11)CCMSH as an imaging probe demonstrated that 
B16/F1 lesions could be clearly visualized in B16/F1 bearing female C57BL/6 
mice.    
The extremely high renal uptake (67-135% ID/g at 2 h post-injection) has 
become a common implication for all the reported 99mTc-RXD-Lys-(Arg11)CCMSH 
peptides [128, 146, 150].  In order to facilitate further therapeutic applications of 
these peptides, non-specific renal uptake must be reduced.  In clinical cases 
today, renal toxicity is the dose limiting factor in peptide-receptor radionuclide 
therapy (PRRT), as acute nephrotoxicity and acute renal failure seen in patients 
occurs due to accumulation of radiation dosage in the kidneys [154, 155].    It is 
hypothesized that renal handling of these radiopharmaceuticals and peptides is 
facilitated by the charge distribution throughout targeting molecule.  In the 
nephron, evidence has indicated that cationic and neutral molecules are filtered 
through the glomerulus more efficiently than anionic molecules possibly due to 
the negatively charged basement membrane of the glomerulus [154, 156].  In 
addition, the proximal tubule contains negatively charged organic cation transfer 
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(OCT) cell surface receptors that can interact with positively charged molecules 
[154].   
With the overall positive charge and strong positive charge of the Lys 
linker in the 99mTc-RXD-Lys-(Arg11)CCMSH peptides, it stands to reason that high 
renal uptake of these peptides is due to their potential electrostatic interactions 
with multiple constituents of renal physiology.  As a proof-of-concept study, co-
injection of purified positively charged L-Lys amino acid with the 99mTc-RXD-Lys-
(Arg11)CCMSH peptides was performed.  Co-injection of the L-Lys amino acid 
dramatically decreased non-specific renal uptake of the 99mTc-RXD-Lys-
(Arg11)CCMSH peptides 37-50%, without affecting the tumor targeting properties 
of those peptides.  This reduction elucidated the necessity to mitigate the overall 
positive charge of the 99mTc-RXD-Lys-(Arg11)CCMSH peptides in order to 
facilitate reduced non-specific renal uptake.  Clearly, the substitution of the 
positively charged Lys linker in the 99mTc-RXD-Lys-(Arg11)CCMSH to a neutral or 
negatively charged linker (i.e. Gly or Glu) can decrease the overall charge of the 
99mTc-RXD-Lys-(Arg11)CCMSH peptides.  In previous studies, reducing the 
overall positive charge of 111In-DOTA-GlyGlu-CycMSH via a negatively charged 
glutamic acid linker coincided with a 44% reduction in renal uptake as compared 
to 111In-DOTA-CycMSH [100].  According to the effect seen in the L-Lys co-
injection studies and with the introduction of the glutamic acid linker in previous 
studies, it was likely that such a substitution will provide a significant reduction in 
non-specific renal uptake of the 99mTc-RXD-Lys-(Arg11)CCMSH peptides. 
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In the final study of this project we designed a multitude of novel α-MSH 
peptides with reduced overall net charge.  The positively charged Lys linker in 
the RXD-Lys-(Arg11)CCMSH peptides was replaced with a neutral β-Ala linker to 
yield the novel RAD-β-Ala-(Arg11)CCMSH, RSD-β-Ala-(Arg11)CCMSH, RTD-β-
Ala-(Arg11)CCMSH, and RVD-β-Ala-(Arg11)CCMSH peptides.  In addition, we 
designed the novel XAD-β-Ala-(Arg11)CCMSH peptides containing substitutions 
of the positively charged Arg residue in the RXD motif with a neutral Nle amino 
acid and negatively charged Glu residue to create the NAD-β-Ala-(Arg11)CCMSH 
EAD-β-Ala-(Arg11)CCMSH peptides, respectively.  The substitutions of these 
amino acids were performed to eliminate as many charge dipoles on the peptide 
backbone as possible to facilitate reduction in the non-specific renal uptake seen 
with the RXD-Lys-(Arg11)CCMSH peptides.  
All peptides were synthesized utilizing a similar Fmoc chemistry approach 
as described for the RXD-Lys-(Arg11)CCMSH peptides and purified via RP-HPLC 
to a chemical purity >95%.  Cellular binding studies performed in B16/F1 cells 
demonstrated continued low nanomolar binding affinity for the RXD-β-Ala-
(Arg11)CCMSH and XAD-β-Ala-(Arg11)CCMSH peptides.  IC50 values for the 
RAD-β-Ala-(Arg11)CCMSH, RSD-β-Ala-(Arg11)CCMSH, RTD-β-Ala-
(Arg11)CCMSH, and RVD-β-Ala-(Arg11)CCMSH peptides were 0.35 ± 0.01, 2.76 
± 0.51, 1.56 ± 0.63, and 1.99 ± 0.16 nM respectively.  These values were 
comparable to their Lys linker counterparts demonstrating no significant loss in 
binding affinity for the MC1R.  The binding affinity of the XAD-β-Ala-
(Arg11)CCMSH peptides for the MC1R was slightly lower with IC50 values of 3.84 
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± 0.71 and 3.34 ± 0.28 nM for EAD-β-Ala-(Arg11)CCMSH and NAD-β-Ala-
(Arg11)CCMSH respectively. 
In order to determine the in-vivo melanoma targeting, pharmacokinetic, 
and imaging properties of the RXD-β-Ala-(Arg11)CCMSH and XAD-β-Ala-
(Arg11)CCMSH peptides, all peptides were radiolabeled with 99mTc and purified 
through RP-HPLC to a radiochemical purity >95%.  All RXD-β-Ala-
(Arg11)CCMSH peptides exhibited rapid and high receptor-specific melanoma 
uptake similar to their Lys linker counterparts with the exception of RSD-β-Ala-
(Arg11)CCMSH.  RAD-β-Ala-(Arg11)CCMSH exhibited peak melanoma uptake of 
15.66 ± 6.19% ID/g at 2 h post-injection, not significantly different to RAD-Lys-
(Arg11)CCMSH with a peak melanoma uptake of 19.91 ± 4.02% ID/g.  RTD-β-
Ala-(Arg11)CCMSH exhibited peak melanoma uptake of 13.85 ± 1.43% ID/g at 2 
h post-injection, not significantly different to RTD-Lys-(Arg11)CCMSH with a peak 
melanoma uptake of 18.77 ± 5.13% ID/g.  RVD-β-Ala-(Arg11)CCMSH exhibited 
peak melanoma uptake of 13.11 ± 4.78% ID/g at 2 h post-injection, not 
significantly different to RVD-Lys-(Arg11)CCMSH with a peak melanoma uptake 
of 17.10 ± 3.82% ID/g.  As previously stated, RSD-β-Ala-(Arg11)CCMSH 
exhibited peak melanoma uptake of 12.15 ± 2.36% ID/g at 4 h post-injection, 
which was significantly different to RSD-Lys-(Arg11)CCMSH with a peak 
melanoma uptake of 17.42 ± 1.52% ID/g at 2 h post-injection.  EAD-β-Ala-
(Arg11)CCMSH exhibited peak melanoma uptake of 13.36 ± 4.12% ID/g at 4 h 
post-injection and NAD-β-Ala-(Arg11)CCMSH exhibited peak melanoma uptake of 
11.38 ± 1.29% ID/g at 2 h post-injection. 
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Importantly in this study, we wanted to determine the renal effects of the 
charge substitutions made to the peptides.  Non-specific renal uptake was 
dramatically reduced in the RXD-β-Ala-(Arg11)CCMSH peptides.  Non-specific 
renal uptake of RAD-β-Ala-(Arg11)CCMSH, RSD-β-Ala-(Arg11)CCMSH, RTD-β-
Ala-(Arg11)CCMSH, and RVD-β-Ala-(Arg11)CCMSH was reduced 79%, 65%, 
79%, and 68% at 2 h post-injection as compared to their Lys linker counterparts.  
All RXD-β-Ala-(Arg11)CCMSH exhibited non-specific renal uptake of less than 
30% ID/g.  The renal uptake of EAD-β-Ala-(Arg11)CCMSH and NAD-β-Ala-
(Arg11)CCMSH was not further reduced as compared to the RXD-β-Ala-
(Arg11)CCMSH with uptake values of 25.25 ± 9.26% and 37.23 ± 9.69% ID/g 2 h 
post-injection.   
The dramatic reduction in renal uptake with the substitution of the neutral 
β-Ala linker demonstrates the importance of the electrostatic interactions of the 
positive charges on the peptides in renal handling and non-specific uptake in-
vivo.  It is imperative to maintain high contrast of tumor uptake to normal organ 
tissues for enhanced diagnostic imaging and potential therapeutic applications 
utilizing radiolabeled peptide conjugates as targeting molecules.  99mTc-labeled 
radiopharmaceuticals can be readily translated to therapeutic 
radiopharmaceuticals through the replacement of 99mTc with 186Re/ 188Re [152, 
153].  Both 99mTc and 186Re/ 188Re have similar coordination chemistry.  The 
same biomolecule can be labeled with 186Re/ 188Re without structural 
modification.  The combined use of 99mTc- and 186Re/ 188Re-labeled 
radiopharmaceuticals for imaging and therapy will enhance the success of 
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targeted radionuclide treatment for individual patients.  Imaging patients with 
99mTc-labled radiopharmaceuticals can aid physicians in determining patient-
specific dosimetries for safe and efficacious treatment with the 186Re/ 188Re 
therapeutic radiopharmaceuticals.  Furthermore, imaging during the treatment of 
disease can monitor a patients response to treatment giving critical information to 
the physician and allow for modification of treatment protocols, should they be 
warranted, to further aid in therapeutic regimens [157].   
Throughout this study, one α-MSH peptide conjugate has been elucidated 
as a lead compound for further development of both imaging and therapeutic 
applications.  RAD-β-Ala-(Arg11)CCMSH has demonstrated high MC1R specific 
melanoma uptake (15.66 ± 6.19% ID/g at 2 h post-injection) with limited non-
specific renal uptake (20.18 ± 3.86% ID/g at 2 h post-injection).  This high 
melanoma uptake and low kidney uptake correlates to a very favorable tumor to 
kidney uptake ratio of 0.78 at 2 h post injection.  The tumor (target) to kidney 
uptake ratio is important in determining the total accumulation and potential dose 
limiting exposure of a patient.  The higher the ratio, the better the chance of 
reducing or eliminating the deleterious effects of radiation within the nephron, 
and allowing for stronger, more aggressive PRRT therapy to proceed [154, 155].  
 
Future Directions 
 The use of α-MSH peptide analogs for diagnosis and treatment of 
melanoma in clinical practice today is non-existent.  The utilization of these 
targeting molecules has been confined to the pre-clinical experimental phase.  
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Further development and characterization on the use of these peptide conjugates 
in human cell lines and human tissues should be extrapolated in order to 
facilitate their potential use in patients seeking clinical aide for treatment of this 
deadly disease.  In order to begin the process of moving these novel α-MSH 
peptides into a more clinical research venture, targeting and pharmacokinetic 
properties of the lead compounds in human melanoma will need to be 
established.  
1) Defining the 3-D structure of the α-MSH peptides. 
To date, it has been extremely difficult to determine the 3-D structure of the α-
MSH peptide derivatives.  Characterizing the 3-D structure will further allow 
investigators to understand the interactions of each part of the α-MSH peptide 
conjugates with the melanocortin-1 receptor.  Understanding the interactions will 
allow for manipulation of the peptides to further enhance MC1R binding affinity 
and ultimately increase in-vivo melanoma uptake.  The increased melanoma 
uptake will facilitate higher quality imaging characteristics and potential 
therapeutic treatment with PRRT treatment.        
2) Utilizing human melanoma cell lines such as TXM13 
This entire study was developed around the utilization of the murine B16/F1 
melanoma cell line which overexpresses the MC1R at densities around 7,000 
receptor sites/cell [158].  Further experimentation into the use of these peptide 
conjugates in human melanoma cells is imperative due to differences in behavior 
of both tumors and peptide uptake previously seen.  Human TXM13 melanoma 
cell lines specifically overexpress the MC1R at densities slightly lower than 
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B16/F1 around 5,500 receptor sites/cell [158].  In addition to lower MC1R 
density, histopathological analysis of both B16/F1 murine and TXM13 human 
melanoma tumors revealed striking differences.  The B16/F1 murine tumors are 
highly vascularized gelatinous masses, whereas TXM13 human tumors form 
solid masses with viable tumor cells surrounding a necrotic core containing few 
identifiable melanoma cells.  Characterizing the targeting and pharmacokinetic 
properties of our lead α-MSH compounds in human cell lines will enhance our 
efforts for utilization in human patients. 
3) Therapeutic treatment with 186Re/ 188Re. 
In order to facilitate the potential of our lead α-MSH peptide conjugate as a 
viable targeting therapeutic molecule, it is necessary to define the efficacy of 
treatment of both B16/F1 and TXM13 tumors in-vivo, utilizing 186Re/ 188Re as the 
radionuclide for radiation treatment.  As stated before, 99mTc and 186Re/ 188Re 
share similar coordination chemistry and our α-MSH peptides have been 
successfully integrated with 186Re/ 188Re in previous studies [158].  A longitudinal 
study to determine how well treatment with 186Re/ 188Re -labeled α-MSH peptide 
can decrease overall tumor volume and increase survival time of mice that have 
been implanted with both B16/F1 and TXM13 melanoma cells is imperative for 
moving this research into the clinical realm. 
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